{
  "3": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antiinflammatory and antirheumatic products, non-steroids": {
    "gene": "NQO1, PTGS2, SOD2, PTGS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "imatinib": {
    "gene": "NQO1, POR, ABCC4, KIT, SLC22A1, KDR, ABCB1, EGFR, CYP2B6, FIP1L1, CYP1A1, GSTT1, ATIC, MAPK1, SLCO1B3, FLT3, CXCL14, BCR, SLC22A4, PDGFRB, VEGFA, PDGFRA, ULK3, ABCC2, NR1I2, CCL5, ABCA3, SLC19A1, ABCG2, RUNDC3B, GSTM1, CYP3A4, SLCO1A2, FLT4, CYP2C8, CYP2F1, UGT2A1, FLT1, SHC1, CYP3A5, BCL2L11, SLC22A5, CHST1, RET, ABL1, ABCB4, ARID5B, CYP1A2, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "corticosteroids": {
    "gene": "NQO1, ST13, ZNF432, HDAC1, DTNBP1, CTLA4, NR3C1, LHX2, DCAF4, ITPA, TRDN, GSTT1, KCNN1, STIP1, APOBEC3B, LHFPL3, FCER2, FKBP5, ADORA2A, ACP1, ANKS1B, GLCCI1, SERPINE1, ABCC2, FAM240C, NR1I2, GGH, GSTM1, ZNF37A, ADRB2, POGK, ADAM33, NEU3, CYP2C8, ME3, SUMF1, IL10, CYP3A5, NRP2, KANSL1, BCL2L11, TAAR6, MAPT, ACOT7, TBX21, ABCC1, ANKRD30B, KL, CRHR1, GSTP1, WNT7B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluorouracil": {
    "gene": "NQO1, ABCC4, PARD3B, ERCC1, LGR5, HNF4A, NT5C1A, PSMB3P, RAB27A, RRM2B, IL6, RBX1, HLA-DQA1, KDR, ABCB1, REV3L, MIR24-2, KLC3, ENOSF1, HMMR, MECP2, KHDRBS3, TOP2A, PPARA, EGFR, ERCC4, MTHFR, OR10AE3P, CSPG4, WNT5B, PON1, GSTT1, MTHFD1, VENTXP7, APEX1, ALDH1A1, CYP2C19, NOS1, WDR7, TNFSF13B, COLEC10, KRAS, OGG1, HLA-DQB1, PERP, SPARC, GALNT14, STAT3, DPYD, MSH6, IMPDH2, CYP4X1, ATM, ALDH3A1, TYMP, ERCC2, PPARD, SHMT1, TWIST1, TPMT, PIK3R2, CBR1, PPP2R5D, FGFR4, XRCC1, FOXO1, PDGFRB, VEGFA, SELE, SOD2, TK1, COL6A3, UGT2B7, GCKR, CDA, WRN, ABCC2, NR1I2, SLC19A1, ABCG2, PTEN, WWOX, ABCG1, FEN1, CCND1, TP53, ERCC5, IRS1, NFKB1, TP53AIP1, UMPS, GSTM1, IGF2BP2, ABCC5, MTR, RAD51, CCL2, CYP19A1, ABCC11, KLC1, VDR, CYP3A4, C18orf56, RXRG, XPC, SCN1A, RGS5, XRCC3, NLGN1, HLA-DRB1, FLT4, RALBP1, TNF, MUTYH, IL8, CYP2C8, OSGEP, SOD3, CYP1B1, FLT1, TMEM167A, UGT1A1, CHN2, MSH2, PIGB, SLCO1B1, IGFBP3, CYP2A6, DPYS, XRCC4, ETFRF1, NEIL1, SLC22A16, PROM1, CCNK, SMAD7, IFNG, DLG5, ABCA2, INSR, AGXT, MIR27A, KCNQ1, UPB1, GNAS, MSH3, ABCC1, EXO1, TYMS, ZNF215, MEGF11, NR1I3, PPARG, GSTP1, NOS3, CBR3, HLA-G, MIR23A, GNL3",
    "advice": "An Italian working group comprising the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) has published recommendations for the use of DPYD genotype when prescribing fluoropyrimidines (5-fluorouracil, capecitabine and tegafur).\n",
    "source": "AIOM"
  },
  "anthracyclines and related substances": {
    "gene": "NQO1, SLC28A1, CAT, UGT1A10, SLC28A3, HPR, ABCB1, ADCY2, CYP2D6, EGLN3, FMO2, SLC22A2, CYP4F2, SPG7, CYP4X1, HNMT, UGT1A9, SLC22A17, CBR1, UGT1A8, GPR35, FMO3, SLC10A2, VEGFA, SOD2, ABCC2, ADH7, GSTM1, RARG, HAS3, FLT1, CELF4, SULT2B1, CYP3A5, UGT1A6, ABCB4, UGT1A7, ABCC1, HCG22, ECT2L, EPAS1, GSTP1, NOS3, CBR3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "oxaliplatin": {
    "gene": "NQO1, PARD3B, ERCC1, MT1A, KCNE1, KDR, ABCB1, KLC3, ENOSF1, KCNE2, MTHFR, PON1, GSTT1, PTGS2, KRAS, DPYD, MSH6, FARS2, TAC1, CAMK2N1, TYMP, ERCC2, APOBEC2, XRCC1, VEGFA, SELE, SOD2, GCKR, CDA, ABCC2, ARHGEF4, ABCG2, TP53, GSTM1, IGF2BP2, ABCC5, CYP3A4, CCNH, XRCC3, CSMD1, HLA-DRB1, FLT4, FOXC1, SOD3, FLT1, UGT1A1, GNA13, CYP3A5, PIN1, ITGA1, UGT1A6, MGAT4A, CYP2A6, PROM1, SMAD7, AGXT, UGT1A7, KCNQ1, ABCC1, TYMS, ACYP2, BTG4, GSTP1, NOS3, DLEU7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antiepileptics": {
    "gene": "NQO1, ALDH5A1, CYP2C9, ABCB1, NR3C1, DDX12P, OPRD1, CYP1A1, OPRM1, CPS1, HLA-A, SOD2, CACNA1C, ABCC2, CACNA1H, ABCG2, SCN2A, ABCC5, HLA-B, SCN1A, NANOGP6, NIPAL2, ACE, KCNT1, CACNA1A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "analgesics and anesthetics": {
    "gene": "NQO1, SOD2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antibiotics": {
    "gene": "NQO1, KCNE1, ABCB1, LGALS3, SOD2, CACNA1C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antifungals for systemic use": {
    "gene": "NQO1, SOD2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antimycobacterials": {
    "gene": "NQO1, SOD2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antithyroid preparations": {
    "gene": "NQO1, HLA-DQA1, HLA-DQB1, FOXF2, KLRC4, SOD2, HLA-B, HLA-DRB1, EHMT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "drugs for treatment of tuberculosis": {
    "gene": "NQO1, ABCC3, ABCC4, HLA-DQA1, CFTR, ABCB1, HPX, CYP2B6, GSTT1, HLA-DQB1, ABCC8, HLA-A, XPO1, SOD2, RIPOR2, UGT2B7, ABCC2, ABCC9, GSTM1, ABCC5, CYP2E1, METTL3, ABCC6, HLA-C, UGT1A1, SLCO1B1, NAT2, METTL14, ABCC10, HMOX1, ABCC13, ABCC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "platinum compounds": {
    "gene": "NQO1, ABCC3, ERCC1, ABCB1, KLC3, MLH1, ERCC4, ATP7A, ERCC3, MTHFR, WNT5B, CYP1A1, GSTT1, WIF1, APEX1, YAP1, CDKN2B-AS1, OGG1, SLC22A2, EIF3A, DPYD, POLR1G, PPP1R13L, IGF2, APLF, ERCC2, XPA, XRCC1, DYNC2H1, H19, CDA, WRN, ABCC2, SLC19A1, ABCG2, INS-IGF2, FEN1, CCND1, TP53, HOTTIP, ERCC5, NUP107, HMGB1, GSTM1, AXIN2, HMGB2, MTR, RAD51, XBP1, HLA-DOB, XPC, MALAT1, XRCC3, MDM2, ATP7B, HSPA5, TMEM167A, IL16, HOTAIR, MSH2, IL1B, FASLG, NAT2, CCN4, IGF2-AS, XRCC4, NEIL1, SLC31A1, SLC47A1, MEG3, FAS, RETN, CXXC4, CASP7, MSH3, RRM1, GSTP1, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fec100": {
    "gene": "NQO1, ALDH1A1, DPYD, PPCDC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cisplatin": {
    "gene": "NQO1, ABCC3, ABCC4, ERCC1, REV1, CSNK2A3, GSTA1, SLC22A1, IL6, KDR, ABCB1, REV3L, WFS1, KLC3, ENOSF1, SYNE3, MECP2, ACSS2, CYBA, NRAS, LARP1B, MTHFR, GSTT1, MTHFD1, MAP3K1, APEX1, PIK3CA, OGG1, SEMA6A, SLC22A2, SPTAN1, EIF3A, GALNT14, DPYD, POLR1G, PPP1R13L, BLMH, DCBLD1, RARS1, NHLH1, UGT1A9, EPO, TYMP, ERCC2, PPARD, GALNT18, TPMT, CERS6, DDX25, AQP1, XRCC1, LIG3, ABCB5, EPHX1, VEGFA, SOD2, UGT2B7, DUX1, TRPA1, RAF1, CDA, ABCC2, CLCN6, SLC19A1, PTEN, WWOX, AKT1, CCND1, TP53, ERCC5, GSTM1, ABCC5, MTR, MYO1H, CCL2, GSTM3, CYP2E1, CYP3A4, C18orf56, XPC, TLR4, MIR335, XRCC3, LRP2, CYP24A1, FLT4, TNF, CD274, MUTYH, CDH13, HIF1A, TRAF3IP2-AS1, CYP2C8, OSGEP, OTOS, SLC16A5, CYP1B1, FLT1, CASP3, TMEM43, UGT1A1, MSH2, CMPK1, CYP3A5, AKT2, FASLG, NAT2, GSTM4, UBE2I, SLC31A1, GPX5, MTOR, TRAF3IP2, GNAS, MLLT3, RRM1, TYMS, GGT1, NFE2L2, COMT, ACYP2, RAD52, ADH1C, ALDH2, GSTP1, ESR1",
    "advice": "The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for TPMT gene variants when prescribing cisplatin in pediatric cancer patients. They recommend testing for the TPMT alleles *2, *3A, *3B or *3C in all pediatric cancer patients due to the association of these alleles with an increased risk of cisplatin-induced ototoxicity.\n",
    "source": "CPNDS"
  },
  "clozapine": {
    "gene": "NQO1, INSIG2, POR, LEPR, CYP3A43, ITIH3, DRD2, DTNBP1, ABCB1, HTR1A, HTR2C, ELAVL2, SH2B1, PPARA, PRKAB2, AOC1, CYP2D6, MTHFR, DRD1, CYP1A1, MIR1912, GSTT1, MC4R, CYP2C19, C3, HLA-DQB1, CYP2C18, UGT1A4, PRKAA2, SLC6A3, HNMT, GRIN2B, FKBP5, HLA-DRB5, TRAT1, SLC6A4, GPX1, EPM2A, CHRM1, HTR2A, GLP1R, SOD2, UGT2B7, TRAC, APOE, CNR1, ABCG2, GRIN1, MIR1264, GCG, AGT, ANKK1, TACR1, GSTM1, LEP, FAAH, NFIB, CYP3A4, ACKR1, DRD4, CCKBR, HLA-B, OXT, LEPROT, HRH1, HLA-DRB1, TNF, HLA-DPB1, HLA-DRB3, HTR3A, ERBB4, GFRA2, HLA-C, UGT1A1, CYP3A5, NTRK2, DRD3, NQO2, ACE, CYP1A2, ABCC1, COMT, MPO, SLC1A1, RABEP1, UGT2B10, PPARG, GSTP1, TBC1D1",
    "advice": "There is no gene-drug interaction between CYP1A2 and clozapine.\n",
    "source": "DPWG"
  },
  "cyclophosphamide": {
    "gene": "NQO1, FBXO21, ABCC3, ABCC4, ERCC1, TUBB2A, SLC28A3, CYP2C9, GSTA1, RAB27A, RRM2B, RBX1, HLA-DQA1, MIR146A, ABCB1, KLC3, HMMR, CYBA, GATA3, TOP2A, CYP2B6, MCPH1, MTHFR, EGLN3, CYP1A1, GSTT1, ALDH1A1, CYP2C19, NOS1, TNRC6B, TNFSF13B, HLA-DQB1, PERP, FCGR3A, DOP1B, DPYD, BMP7, CYP4X1, MIR423, MIR577, ATM, ALDH3A1, ERCC2, CXCL12, TPMT, PIK3R2, CBR1, PPP2R5D, PNPLA3, FGFR4, MIR449B, XRCC1, FOXO1, LIG3, GEMIN4, EPHX1, VEGFA, SOD2, UGT2B7, DUX1, MIR2053, ABCC2, NR1I2, XPO5, ABCG2, TP53, ERCC5, CXCR2, IRS1, TP53AIP1, GSTM1, MTR, CYP2A7P1, GSTM3, ATF5, CYP2E1, CYP3A4, C18orf56, MIR1206, MIR1307, CPT1A, HLA-DRB1, METTL3, MIR3117, EPHA6, SPIDR, TNRC6A, MIR4268, RAC2, MUTYH, MISP, IL8, MIR604, FCGR2A, AGO1, CYP2C8, CTH, DOK5, IKZF3, CYP1B1, FLT1, IL10, LINC00251, MIR492, UGT1A1, MIR300, CYP3A5, C5orf22, PIGB, SLCO1B1, NAT2, CYP2A6, DDX20, SLC22A16, CCNK, MIR618, INSR, CTNNB1, NQO2, ABCC1, TYMS, IGHMBP2, CNOT1, ZNF215, RAD52, ADH1C, EPAS1, GSTP1, DROSHA, NOS3, CBR3, GNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cytarabine": {
    "gene": "NQO1, ABCC3, ABCC4, SLC28A3, RRM2B, CTPS1, MIR146A, ABCB1, GATA3, CYP1A1, GSTT1, TNRC6B, DCK, RRM2, BMP7, MIR423, MIR577, P2RY12, NT5C2, RAD50, GLI1, TPMT, PNPLA3, MIR449B, XRCC1, GEMIN4, MIR2053, CDA, XPO5, NME4, GSTM1, ATF5, ARHGAP9, CYP2E1, C18orf56, MIR1206, MIR1307, CPT1A, MIR3117, TNRC6A, MIR4268, NT5C3A, MIR604, AGO1, DOK5, IL10, LINC00251, SULT2B1, MIR492, UGT1A1, MIR300, CMPK1, C5orf22, SLCO1B1, MED12L, DDX20, MIR618, SLC22A12, NQO2, ADH1A, RRM1, TYMS, IGHMBP2, CNOT1, GSTP1, DROSHA, NOS3, CBR3, SLC29A1, BRD10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "doxorubicin": {
    "gene": "NQO1, FBXO21, ERBB2, ABCC3, ABCC4, ERCC1, CYP2J2, SLC28A1, SETD4, SLC28A3, GPX3, GSTA1, AKR7A2, ABCB1, KLC3, CYBA, GATA3, TOP2A, CYP2B6, MTHFR, CYP1A1, GSTT1, MTHFD1, ALDH1A1, CYP2C19, SLC22A2, FCGR3A, ETFB, GALNT14, DOP1B, DPYD, G6PD, BMP7, POLR1G, CYP4F2, PPP1R13L, SPG7, COL1A2, HNMT, ATM, ALDH3A1, SLC22A17, AKR1C3, ERCC2, TPMT, CBR1, PNPLA3, GPR35, XRCC1, SLCO6A1, FMO3, SLC10A2, HFE, SOD2, ABCC2, ABCC9, NR1I2, CLCN6, ADH7, ABCG2, CCND1, TP53, SERPINA6, GSTM1, GSTA2, ABCB11, ABCC5, MTR, XDH, GSTM3, CYP3A4, C18orf56, XPC, CPT1A, RARG, SLC13A3, RAC2, FCGR2A, HAS3, CYP2C8, DOK5, CYP1B1, LINC00251, CASP3, TMEM43, SULT2B1, UGT1A1, MSH2, ABCA1, FASLG, SLCO1B1, UGT1A6, ABCC10, SLC22A16, SLC22A7, ABCB4, NQO2, NCF4, ABCC1, TYMS, IGHMBP2, TOP2B, GSTP1, SLCO4C1, NOS3, CBR3, SLC15A1",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "epirubicin": {
    "gene": "NQO1, ERCC1, TUBB2A, SLC28A3, RAB27A, RRM2B, RBX1, HLA-DQA1, ABCB1, ENOSF1, HMMR, TOP2A, MCPH1, MTHFR, EGLN3, PON1, GSTT1, MDM4, NOS1, TNFSF13B, HLA-DQB1, PERP, DPYD, TYMP, ERCC2, PIK3R2, PPP2R5D, XRCC1, FOXO1, VEGFA, SOD2, UGT2B7, GCKR, CDA, ABCC2, ABCG2, TP53, IRS1, TP53AIP1, GSTM1, IGF2BP2, CYP3A4, C18orf56, HLA-DRB1, RARG, EPHA6, SPIDR, MISP, CYP2C8, SOD3, CYP1B1, FLT1, UGT1A1, CYP3A5, PIGB, SLCO1B1, UGT1A6, CCNK, INSR, KCNQ1, ABCC1, RRM1, TYMS, ZNF215, EPAS1, GSTP1, NOS3, CBR3, GNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "etoposide": {
    "gene": "NQO1, ABCC3, ERCC1, ABCB1, YAP1, BLMH, SLIT1, ERCC2, DYNC2H1, ABCG2, GSTM1, CYP3A4, C18orf56, METTL3, PLA2G6, UGT1A1, SLCO1B1, TYMS, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "idarubicin": {
    "gene": "NQO1, ABCB1, CYBA, DCK, CYP2E1, RAC2, NT5C3A, SULT2B1, SLCO1B1, SLC22A12, NQO2, NCF4, ADH1A, CBR3, BRD10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methotrexate": {
    "gene": "NQO1, ABCC3, ABCC4, BIRC5, UGT1A10, SLC28A3, AMPD1, MIR146A, CNOT4, ABCB1, UGT1A3, KLC3, ENOSF1, GATA3, ADA, FGF14, ENG, C1orf167, CYP2B6, SLC16A7, RFC1, ITPA, MTHFR, GSTT1, MTHFD1, ATIC, TNRC6B, HLA-E, IL12B, HLA-DQB1, FOXP3, TNFAIP3, UGT1A4, FOLH1, RBMS3, DPYD, BMP7, RAVER2, FASTKD3, IMPDH2, KLRC1, GSK3B, MIR423, MIR577, SPECC1L, UGT1A9, SLC22A8, ADORA2A, ERCC2, MTRR, SHMT1, SLCO1B3, TPMT, ADORA3, PNPLA3, UGT1A8, NALCN, FTCDNL1, FGFR4, MIR449B, UGT1A5, PTPRM, NFATC1, GEMIN4, MROH2A, PKD1L2, SOD2, PTPN22, MIR2053, ABCC2, NR1I2, CLCN6, XPO5, SLC19A1, ABCG2, PFDN4, KLRD1, SLC22A11, ATP5F1E, COL18A1, CCND1, FOLR1, GGH, MTR, AHRR, ATF5, FPGS, CYP3A4, C18orf56, UGT1A, DHFR, SLCO1A2, TLR4, SLC22A6, MIR1206, ADORA2A-AS1, MIR1307, CPT1A, SPATA9, HLA-DRB1, NFATC2, METTL3, MIR3117, MIR5189, TNRC6A, MIR4268, HTR3A, MIR604, DDRGK1, SLC46A1, AGO1, SLC22A9, PACSIN2, KIR2DS4, DOK5, HLA-C, IL10, LINC00251, BCOR, MIR492, UGT1A1, MIR300, IMPDH1, C5orf22, CDH2, SLCO1B1, MIR595, POLG, UGT1A6, PYGL, DDX20, JAK1, MIR618, SLC28A2, UGT1A7, HTR3B, ARID5B, MSH3, ABCC1, TYMS, IGHMBP2, CNOT1, PLCG2, GSTP1, DROSHA, NOS3, HLA-G, SLC29A1, CDK9",
    "advice": "There are currently no recommendations for methotrexate dosing based on MTHFR rs1801133 genotypes.\n",
    "source": "DPWG"
  },
  "valproic acid": {
    "gene": "NQO1, ALDH5A1, ABAT, LEPR, UGT1A10, CYP2C9, ACOT1, GABRB2, HDAC1, DRD2, FABP2, ABCB1, UGT1A3, HTR2C, GABPA, SH2B1, PPARA, CYP2B6, CYP2D6, CYP1A1, GSTT1, CYP2C19, UGT1A4, PRKAA2, GRIN2B, UGT1A9, GABRG2, CPS1, SLC6A4, UGT1A8, MOBP, HLA-A, UGT1A5, HTR2A, APEH, SOD2, CACNA1C, UGT2B7, OTC, CACNA1H, SLC16A1, COL1A1, OGDH, SCN2A, CACNA1F, ANKK1, GSTM1, XBP1, CYP3A4, HLA-B, SCN1A, UNC13A, CACNA1D, HDAC9, GABRA1, GABRA3, HLA-C, CYP3A5, POLG, UGT1A6, CYP2A6, GABRA6, NTRK2, HDAC11, UGT1A7, CYP1A2, RABEP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "warfarin": {
    "gene": "NQO1, POR, CYP2C9, HNF4A, ABCB1, DNMT3A, ORM2, STX4, FRAS1, CYP1A1, F5, CYP2C19, NEDD4, CYP2C18, CYP4F2, MIR133B, PROCR, APOB, FGFBP2, SLCO1B3, SLC15A2, ORM1, MPZ, EPHX1, VEGFA, CRP, FAM201A, CACNA1C, VKORC1, APOE, NR1I2, PRSS53, GATA4, STX1B, APOC1, FPGS, VDR, CYP3A4, LRP1, CALU, F13A1, NKX2-6, F2, F11, PROC, OPN1SW, ASPH, MYC, EPHA7, UGT1A1, CYP4F11, SLCO1B1, DDHD1, CYP2A6, PROS1, F7, THBD, CYP1A2, NR1I3, VKORC1L1, GGCX",
    "advice": "Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.\n",
    "source": "RNPGx"
  },
  "benzene": {
    "gene": "NQO1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antineoplastic agents": {
    "gene": "NQO1, ABCC4, SLC28A3, CTPS1, ABCB1, NR3C1, CYP2B6, ZNF100, CYP2D6, ITPA, MTHFR, GSTT1, CYP2C19, SPARC, DPYD, AKR1C3, ADORA2A, ANKS1B, SERPINE1, ABCC2, CLCN6, ABCG2, WWOX, TP53, SERPINA3, GGH, GSTM1, FPGS, CYP3A4, UGT1A, RBFOX1, UGT2B15, DCTD, NEU3, GSTM5, CTH, IL10, CYP3A5, NRP2, BCL2L11, HTR3B, ABCC1, TYMS, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "muraglitazar": {
    "gene": "REN, EDN1, ADRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydrochlorothiazide": {
    "gene": "REN, ADO, NELFCD, SLC22A1, CSK, ADRB1, ABCB1, HMGCS2, NEDD4L, STK39, GNB3, HS3ST4, ERCC6L2, BEST3, PDE3A, YEATS4, CYP11B2, TXNDC11, TET2, ACE2, CAMK1D, SLIT1, FBXL17, PLCE1, NELL1, KCNJ1, WNK1, CSMD3, VASP, ANKFN1, USP5, CDCA3, NUCB2, TCF7L2, C5orf56, LRRC15, AGT, ADD1, GPR83, SH2B3, EBF1, AGTR1, ADRB2, PRKCA, CSMD1, GRK5, SCNN1G, ALDH1A2, DIAPH3, PRKAG2, LUC7L2, FTO, CNTNAP2, ILKAP, TTC6, ACE, UGGT2, HSD3B1, DOT1L, RAD52, SLC25A31, NOS3, FGF5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin d and analogues": {
    "gene": "REN, UGT1A3, UGT1A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amisulpride": {
    "gene": "INSIG2, DRD2, ABCB1, HTR1A, HTR2C, SH2B1, CYP2D6, MC4R, ANKS1B, ANKK1, LEP, SNAP25, RABEP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "olanzapine": {
    "gene": "INSIG2, ADRB3, LEPR, APOC3, CYP3A43, CYP2C9, SLC22A1, DRD2, ABCB1, HTR1A, HTR2C, RGS4, AHR, SH2B1, GNB3, PMCH, PRKAB2, CYP2B6, CYP2D6, MTHFR, CYP1A1, MIR1912, MC4R, CYP2C19, UGT1A4, BDNF, CYP4F2, PRKAA2, PLAGL1, SV2C, SLC6A4, ATP1A2, CHAT, TPMT, RELN, EPM2A, HLA-A, FMO3, FMO1, HTR2A, GLP1R, CACNA1C, IL1A, ABCC2, GIPR, APOE, SPOPL, CNR1, MIR1264, GCG, AGT, ANKK1, LEP, FAAH, GSTM3, CYP3A4, CCKBR, HLA-B, LEPROT, HRH1, CSMD1, EIF2AK4, SLC26A9, CYP2C8, HTR3C, PTPRN2, UGT1A1, CYP3A5, POLG, DRD3, HTR3B, ACE, CYP1A2, COMT, SLC1A1, RABEP1, UGT2B10, PPARG, GSTP1, TBC1D1",
    "advice": "There are currently no recommendations for olanzapine dosing based on CYP1A2 genotypes.\n",
    "source": "DPWG"
  },
  "quetiapine": {
    "gene": "INSIG2, LEPR, CYP3A43, CYP2C9, DRD2, ABCB1, HTR1A, RIMS1, HTR2C, RGS4, SH2B1, CYP2B6, CYP2D6, MTHFR, MIR1912, MC4R, CYP2C19, UGT1A4, MIR582, GRIN2B, KCNMA1, SV2C, SLC6A4, RELN, EPM2A, HLA-A, HTR2A, CACNA1C, APOE, CNR1, MIR1264, AGT, ANKK1, LEP, FAAH, CYP3A4, HLA-B, LEPROT, EIF2AK4, CYP3A5, POLG, DRD3, ACE, PDE4D, CYP1A2, COMT, RABEP1",
    "advice": "Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers.\nClinPGx uses CYP3A4 allele nomenclature as defined by PharmVar, while the current version of this guideline issued by the DPWG uses retired allele names. Further details are given on the DPWG curation page.\n",
    "source": "DPWG"
  },
  "risperidone": {
    "gene": "INSIG2, POR, LEPR, CYP3A43, UGT1A10, CYP2C9, DRD2, ABCB1, HTR1A, UGT1A3, HTR2C, RGS4, GRM3, SH2B1, GNB3, PPARA, CYP2B6, CYP2D6, MTHFR, DRD1, MIR1912, MC4R, CYP2C19, MSANTD1, UGT1A4, BDNF, GRIN2B, UGT1A9, SLC22A8, TMEFF2, SV2C, SLC6A4, UGT1A8, RELN, EPM2A, HLA-A, UGT1A5, GRID2, HTR2A, PPA2, GRM7, CACNA1C, TNFRSF11A, PSMD14, APOE, NR1I2, CNR1, ABCG2, MIR1264, AKT1, AGT, TNIK, ANKK1, HRH3, LEP, FAAH, SLC44A3, CCL2, NFIB, CYP2E1, HTR6, CYP3A4, HLA-B, LEPROT, ADRB2, EIF2AK4, LRP1B, HTR3A, CYP1B1, UGT1A1, CYP3A5, HRH4, FTO, POLG, UGT1A6, AGAP1, WBP2NL, DRD3, HTT, NPAS3, UGT1A7, ACE, CYP1A2, TYMS, COMT, SLC1A1, CYP3A7, RABEP1, TJP1",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for risperidone recommends decreasing the dose for CYP2D6 poor metabolizers and using an alternative drug or titrate the dose according to the maximum dose for the active metabolite for CYP2D6 ultrarapid metabolizers.\n",
    "source": "DPWG"
  },
  "antipsychotics": {
    "gene": "INSIG2, LEPR, CYP3A43, KCNE1, DRD2, ABCB1, HTR1A, HTR2C, RGS4, SMYD3, GRM3, SLC1A3, GNB3, PRKAB2, ADCY2, CYP2D6, ADRA2A, CACNG3, MTHFR, DRD1, SLC25A14, CACNA1E, MC4R, OPRM1, CYP2C19, UCP3, NRG1, PI4KA, BDNF, PRKAA2, SLC6A4, NEFM, HTR2A, BDNF-AS, CACNA1C, GABRB1, CLCN6, CNR1, ZNF804A, DNAJB13, GCG, ANKK1, LEP, NRXN1, FAAH, CCL2, CACNA2D3, GRIK3, SNAP25, CYP3A4, CACNB2, UCP2, CACNA1B, DGKB, TDRD6, CHRM4, HSPG2, IL1B, SLC1A4, SLC18A2, ADIPOQ, FTO, SLC25A27, RGS2, CYP39A1, DRD3, CACNB4, CYP1A2, ANGPTL4, COMT, IBA57, PPARG, NOS3, TBC1D1, GABRG3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pemetrexed": {
    "gene": "CAMKK2, ERCC1, EGFR, MTHFR, MTHFD1, ATIC, FOLR3, SLC22A8, ALK, VEGFA, ABCC2, SLC19A1, CCND1, GGH, C18orf56, DHFR, CD274, HIF1A, EXO1, TYMS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "drugs used in nicotine dependence": {
    "gene": "CHRNA3, OPRM1, ANKK1, CYP2A6, CHRNA5, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "opium alkaloids and derivatives": {
    "gene": "CHRNA3, CHRNA5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eculizumab": {
    "gene": "CHRNA3, C3, CHRNB1, AQP4, CHRNA1, CHRNA6, CHRNE, CHRNA4, CR1, CFH, CHRNA7, C5, CHRNA5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "varenicline": {
    "gene": "CHRNA3, PPARGC1A, CHRFAM7A, CYP2B6, ICAM5, SLC22A2, ZBTB4, CHRNB1, HYKK, NR1H4, HNF1A, NR1I2, CHRNA4, CHRNB3, CHRNB2, RXRA, CYP2A6, CHRNA5, CHRNA2, NR1I3, PPARG, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cotinine": {
    "gene": "CHRNA3, CYP2B6, NAT1, OPRM1, EGLN2, FMO3, PSMA4, CHRNB4, CYP2A6, CHRNA5, UGT2B10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "3-hydroxycotinine": {
    "gene": "CHRNA3, EGLN2, CYP2A6, CHRNA5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "efgartigimod alfa": {
    "gene": "CHRNA3, CHRNB1, CHRNA1, CHRNA6, CHRNE, CHRNA4, CHRNA7, CHRNA5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ravulizumab": {
    "gene": "CHRNA3, CHRNB1, AQP4, CHRNA1, CHRNA6, CHRNE, CHRNA4, CHRNA7, CHRNA5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rozanolixizumab": {
    "gene": "CHRNA3, CHRNB1, CHRNA1, CHRNA6, CHRNE, MUSK, CHRNA4, CHRNA7, CHRNA5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zilucoplan": {
    "gene": "CHRNA3, CHRNB1, CHRNA1, CHRNA6, CHRNE, CHRNA4, CHRNA7, CHRNA5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ethanol": {
    "gene": "CHRNA3, CAT, DRD2, FUT2, MED19, CARTPT, ACSS2, GHSR, CYP2D6, SRPRB, OPRD1, DRD1, PDYN, SLC39A8, POMC, TMX2, OPRM1, GRIK1, SLC4A8, MBOAT7, SUGP1, ADH1B, BDNF, SLC6A3, TAS2R16, OPRK1, PDE4B, ANKS1B, SLC6A4, PNPLA3, DPP6, CACNA1C, GCKR, CRHBP, ADH7, CHRNA4, GATA4, ANKK1, CYP2E1, DRD4, CHRNB3, PGM1, PIP5K1C, DBH, TNRC6A, THSD7B, CADM2, ARID4A, FTO, KLB, DRD3, HTR3B, MAP2K4, CHRNA5, ADH1A, CYP1A2, ADH1C, TM6SF2, RABGAP1L, ALDH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bupropion": {
    "gene": "CHRNA3, POR, CYP2C9, DRD2, HTR2C, AKR7A3, CYP2B6, CYP2D6, DRD1, SACM1L, CYP2C19, UGT1A4, SLC6A3, FKBP5, SLC6A4, HLA-A, HTR2A, APOE, CHRNA4, ANKK1, CYP3A4, CHRNB3, HLA-B, DBH, CHRNB2, CYP3A5, SLC18A2, POLG, CYP2A6, CHRNA5, ACE, CHRNA2, CYP1A2, EPB41, COMT, GALR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cocaine": {
    "gene": "CHRNA3, DRD2, OPRD1, OPRM1, SLC6A3, OPRK1, ARRB2, CNR1, KAT2B, ANKK1, BCHE, SYT1, GABRA2, HTR3B, CHRNA5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nicotine": {
    "gene": "CHRNA3, POR, DRD2, CARTPT, CYP2B6, CYP2D6, DRD1, PON1, MAOB, OPRM1, CHRNA10, ADGRL3, BDNF, SLC6A3, MAOA, ARRB2, CHAT, DDC, CHRNA6, EGLN2, FMO3, FMO1, HTR2A, ZNF536, APOE, CNR1, CHRNA4, ANKK1, NRXN1, DRD4, CHRNB3, TH, DBH, CHRNB2, CHRM2, HINT1, CYP2A13, GRIN3A, CYP3A5, CHRNB4, CYP2A6, CHRNA7, HTR3B, CHRNA5, CHRNA2, CYP1A2, EPB41, COMT, GALR1, UGT2B10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "interferon beta-1a": {
    "gene": "IRF6, HLA-DQA1, FHIT, CD58, GAPVD1, RORA, HLA-B, HLA-DRB1, ZNF697, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "interferon beta-1b": {
    "gene": "IRF6, HLA-DQA1, FHIT, CD58, GAPVD1, ZNF697",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "gefitinib": {
    "gene": "ERBB2, CYP2C9, ABCB1, REL, UHRF1, EGFR, CYP2D6, IKBKE, ARF1, NR1H2, MAP3K1, TAGAP, TNFAIP3, TAB2, SIRT2, USP36, NUP62, DVL2, NFKB2, RELA, ERBB3, DPT, NFKBIA, ABCG2, AKT1, NFKB1, CYP3A4, HLA-DRB1, SUMO4, ERBB4, CYP3A5, NFKBIB, IKBKB, ARFGEF3",
    "advice": "There are currently no dosing recommendations for gefitinib based on CYP2D6 genotype.\n",
    "source": "DPWG"
  },
  "erlotinib": {
    "gene": "ERBB2, ABCB1, UHRF1, EGFR, MET, CYP2D6, ARF1, MAP3K1, USP36, NUP62, DVL2, ERBB3, ABCG2, AKT1, CYP3A4, HLA-DRB1, ERBB4, UGT1A1, CYP3A5, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lapatinib": {
    "gene": "ERBB2, HLA-DQA1, EGFR, PIK3CA, ESR2, HLA-A, ERBB3, CCND1, ABCB11, HLA-B, PGR, HLA-DRB1, ERBB4, HLA-C, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "everolimus": {
    "gene": "ERBB2, ABCB1, RPTOR, ESR2, FGFR4, CYP3A4, HLA-DRB1, PIK3R1, CYP2C8, CYP3A5, MTOR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fulvestrant": {
    "gene": "ERBB2, CYP2C9, ESR2, PGR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "olaparib": {
    "gene": "ERBB2, BRCA1, PPP2R2A, ESR2, PGR, BRCA2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ixabepilone": {
    "gene": "ERBB2, ESR2, PGR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pertuzumab": {
    "gene": "ERBB2, ESR2, PGR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "neratinib": {
    "gene": "ERBB2, ESR2, PGR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trastuzumab emtansine": {
    "gene": "ERBB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pembrolizumab": {
    "gene": "ERBB2, EGFR, IL7, SMAD3, KRAS, SEMA5A, HLA-A, ALK, GABRP, BRAF, HLA-DRB1, CD274, HLA-DPB1, SLCO1B1, EDIL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nivolumab": {
    "gene": "ERBB2, EGFR, IL7, SMAD3, KRAS, G6PD, SEMA5A, HLA-A, ALK, GABRP, BRAF, CD274, SLCO1B1, EDIL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "palbociclib": {
    "gene": "ERBB2, ABCB1, SULT2A1, ESR2, CDKN2A, ABCG2, CYP3A4, PGR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ribociclib": {
    "gene": "ERBB2, ABCB1, ESR2, CYP3A4, PGR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "abemaciclib": {
    "gene": "ERBB2, ABCB1, ESR2, CYP3A4, PGR, MKI67, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eribulin": {
    "gene": "ERBB2, ESR2, PGR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "talazoparib": {
    "gene": "ERBB2, ATR, MLH1, BRCA1, RAD51C, CHEK2, ATM, CDK12, MRE11, PALB2, FANCA, NBN, BRCA2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alpelisib": {
    "gene": "ERBB2, PIK3CA, ESR2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tipiracil / trifluridine": {
    "gene": "ERBB2, KRAS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trastuzumab deruxtecan": {
    "gene": "ERBB2, ESR2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sacituzumab govitecan": {
    "gene": "ERBB2, BRCA1, ESR2, UGT1A1, BRCA2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tucatinib": {
    "gene": "ERBB2, NRAS, HRAS, KRAS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "margetuximab": {
    "gene": "ERBB2, FCGR2B, FCGR3A, FCGR2A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "elacestrant": {
    "gene": "ERBB2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "capivasertib": {
    "gene": "ERBB2, PIK3CA, PIK3CD, ESR2, PTEN, AKT1, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zolbetuximab": {
    "gene": "ERBB2, CLDN18",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "inavolisib": {
    "gene": "ERBB2, PIK3CA, ESR2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zanidatamab": {
    "gene": "ERBB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "capecitabine": {
    "gene": "ERBB2, ERCC1, SLC28A1, PHC1, SMARCAD1, ABCB1, REV3L, VPS13D, MIR24-2, ENOSF1, KHDRBS3, AREG, ADCY2, ADGRG7, MTHFR, CDX2, CYP1A1, GSTT1, MTHFD1, VENTXP7, PTGS2, WDR7, KRAS, SPARC, CES1P1, DPYD, LMNTD1, SIRPA, MIR2054, TYMP, ZMIZ1, ERCC2, PPARD, MTRR, SHMT1, APOBEC2, XRCC1, VEGFA, SELE, TK1, COL6A3, CES1, CDA, SLC19A1, ARHGEF4, ABCG2, PTEN, TP53, CD96, UMPS, GSTM1, MTR, CYP19A1, ABCC11, CYP3A4, C18orf56, SPRY2, CES2, SSU72, NSUN3, MAN1A1, TENM4, ANK3, CYP1B1, UGT1A1, CCDC70, CYP3A5, TMEM131L, SLCO1B1, MGAT4A, DPYS, FAT1, SMAD7, SLC22A7, DLG5, MIR27A, CCDC77, UPB1, RRM1, EXO1, TYMS, GSTP1, NCOA7, HLA-G, MIR23A",
    "advice": "An Italian working group comprising the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) has published recommendations for the use of DPYD genotype when prescribing fluoropyrimidines (5-fluorouracil, capecitabine and tegafur).\n",
    "source": "AIOM"
  },
  "carboplatin": {
    "gene": "ERBB2, ERCC1, ATAT1, ABCB1, ACSS2, OR4D6, NRAS, DDX53, EGFR, MTHFR, GSTT1, MAP3K1, BARD1, OPRM1, ALDH1A1, PIK3CA, EIF3A, DPYD, SCN10A, GSR, DSCAM, EIF4E2, NRG3, C6orf15, TRIM5, ALDH3A1, DOCK8, MSH5, ERCC2, SLCO1B3, PSORS1C1, BCL2, XYLT2, XRCC1, LIG3, ERBB3, VEGFA, RNF8, RAF1, MAD1L1, NR1I2, SLC19A1, ABCG2, PTEN, AKT1, MUCL3, TP53, GSTM1, MTR, FNTB, C18orf56, HCP5, CDSN, HLA-DRB1, METTL3, TNF, PPP1R18, CD274, ATP7B, PRRC2A, CYP2C8, HLA-C, TIGD1, UGT1A1, CYP3A5, AKT2, ETS2, SERPINC1, SLC31A1, GPX5, MTOR, RRM1, TYMS, SERPINA5, GSTP1, SOX10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "docetaxel": {
    "gene": "ERBB2, ERCC1, HNF4A, RAB27A, RRM2B, IL6, HLA-DQA1, RPL13, ABCB1, ORM2, ENOSF1, ACSS2, ATP7A, MTHFR, EGLN3, CYP1A1, GSTT1, MAP3K1, MDM4, BARD1, OPRM1, PIK3CA, TNFSF13B, HLA-DQB1, DPYD, SPG7, ESR2, VAC14, SNORD68, AKR1C3, TYMP, PPCDC, ERCC2, PPARD, SLCO1B3, BCL2, FGFR4, XRCC1, SULT1C4, ERBB3, SLC10A2, EPHX1, VEGFA, SOD2, RNF8, RAF1, CDA, CHST3, ABCC2, NR1I2, ABCG2, TP53, CYP4B1, GSTM1, MTR, CCL2, CYP3A4, PGR, XRCC3, CYP24A1, HLA-DRB1, TNF, CYP2C8, ABCC6, CYP1B1, FLT1, TANC1, CYP3A5, PIGB, PRDX4, SLCO1B1, NAT2, RXRA, CYP2A6, ABCC10, XRCC4, CASP7, ABCC1, RRM1, TYMS, EPAS1, NR1I3, ALDH2, GSTP1, ESR1, SOX10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "paclitaxel": {
    "gene": "ERBB2, POR, ERCC1, TUBB2A, SLC28A3, FGD4, ABCB1, ACSS2, EGFR, CYP2D6, MTHFR, CYP1A1, DAPK1, GSTT1, MAP3K1, OPRM1, DCK, POLR1G, DSCAM, EIF4E2, PPP1R13L, NRG3, TRIM5, CYP17A1, PDE4B, ERCC2, FZD3, SLCO1B3, IL17F, BCL2, AFG2A, FGFR4, LIG3, VEGFA, SOD2, RAF1, MAD1L1, CDA, ABCC2, NR1I2, EPHA5, ABCG2, EPHA8, ABCG1, TP53, GSTM1, MTR, CYP2E1, FNTB, CYP3A4, HLA-DRB1, RARG, EPHA6, SPIDR, RAC2, MISP, ARHGEF10, FCGR2A, CYP2C8, CYP1B1, TIGD1, TANC1, CMPK1, CYP3A5, SLCO1B1, NAT2, UGT1A6, ETS2, NCF4, CASP7, ABCC1, RRM1, TYMS, GGT1, GSTP1, CBR3, SLC29A1, SOX10",
    "advice": "There are currently no recommendations for paclitaxel dosing based on CYP3A4 genotypes.\n",
    "source": "DPWG"
  },
  "trastuzumab": {
    "gene": "ERBB2, ERCC1, SLC28A3, HLA-DQA1, FCGR2B, ABCB1, ENOSF1, MTHFR, GSTT1, BARD1, PIK3CA, HLA-DQB1, FCGR3A, DPYD, ESR2, TYMP, PPCDC, ERCC2, ERBB3, RNF8, CDA, GSTM1, CYP3A4, PGR, HLA-DRB1, RARG, RAC2, FCGR2A, CYP3A5, UGT1A6, NCF4, TYMS, GSTP1, CBR3, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aspirin": {
    "gene": "HPGD, EFR3A, JMJD8, CYP2C9, IL6, HLA-DQA1, SLC6A12, SLC30A9, ABCB1, CDH15, AGAP3, PLA2G4A, GNB3, CYP2D6, TGFB1, ITGA2, PON1, TMEM196, TAPBP, P2RY1, CYP2C19, PTGS2, IL23R, KRTAP10-4, PAFAH1B2, HLA-DQB1, TSPEAR, G6PD, LPA, ALOX15, PTGIR, CYP4F2, GP1BA, HNMT, UGT1A9, P2RY12, ZBTB22, WDR24, LTC4S, GP6, MYOM2, PTGER3, CEP68, IL4, F2R, TBXA2R, TNFRSF11A, NECAB1, IL1A, CES1, B4GALT2, PTGER2, COL26A1, ZDHHC3, EYA1, ODC1, TBXAS1, AGT, IRS1, FCER1G, F13A1, ECHS1, CYP24A1, HLA-DRB1, PLCG1, TNF, HLA-DPB1, CHIA, ADORA1, CDH13, CYP2C8, FCER1A, HLA-DPB2, TSC1, TLR3, PTGS1, CYP3A5, IL1B, CYP4F11, THRA, NAT2, UGT1A6, NTRK1, NCF4, ACE, ITGB3, CYP1A2, FSIP1, IKBKB, PPARG, GSTP1, NOS3, PEAR1",
    "advice": "There is no reason to avoid aspirin at doses of ≤1g/day in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), aspirin ≤1g/day should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. CPIC gives a 'no recommendation' for the use of G6PD genotype for prescribing aspirin at doses &gt;1g/day. In summary, CPIC either does not provide, or recommend changing, prescribing actions based on G6PD genotype for aspirin at any dose.\n",
    "source": "CPIC"
  },
  "selective serotonin reuptake inhibitors": {
    "gene": "REPS1, RND1, DRD2, ABCB1, HTR1A, TPH1, PTCHD1, CYP2D6, ADRA2A, GRIK4, DEAF1, MTCL1, STMN2, CYP2C19, BDNF, TXNRD2, SLC6A3, FKBP5, GAL, OSMR, BRD2, ATF3, SLC6A4, HTR7, BCR, CSMD2, ANGPT2, HTR2A, GABRP, GRIA1, TPH2, APOE, MIR7-2, PHACTR1, AFAP1L1, PLCB1, TH, SLC6A2, DGCR5, CAP2, MTMR12, GRIA3, GABRA6, COMT, SLC1A1, LINC00478",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thiazides, plain": {
    "gene": "ADRB3, NELFCD, CSK, ZNF652, GNB3, HS3ST4, MTHFR, ERCC6L2, CSMD3, CLCN6, ADD1, SH2B3, PLCD3, AGTR1, PRKCA, SLC12A3, ACBD4, SLCO2A1, CNTNAP2, ACE, CABCOCO1, FGF5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "atenolol": {
    "gene": "ADRB3, LDLR, EDN1, STN1, CYP2C9, ADRB1, ABCB1, NEDD4L, PLA2G4A, GNB3, PPARA, CYP2D6, ADRA2A, PTGS2, SLC4A1, CYP11B2, MOV10, ACE2, SNX9, CAPZA1, XIRP2, PRKCB, NR1H3, PLEKHH2, RRP1B, GALNT2, HFE, CACNA1C, ARAP1, LRRC15, AGT, ADD1, OR10P1, CHIC2, AGTR1, ADRB2, GRK5, KCNH2, ALDH1A2, ACY3, ADRA2C, PROX1, PAH, SLCO2B1, TBX2, FTO, ZMAT4, DPYS, ACE, SLC25A31, GRK4, FGF5",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC"
  },
  "metoprolol": {
    "gene": "ADRB3, ADRB1, GNB3, PPARA, CYP2D6, CYP2C19, SLC4A1, SNX9, LRRC15, OR10P1, ADRB2, GRK5, ADRA2C, SEPTIN3, UGT1A1, ZMAT4, SLC25A31, GRK4",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC"
  },
  "fremanezumab": {
    "gene": "CALCR, CRCP, CALCRL, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "galcanezumab": {
    "gene": "CALCR, CRCP, CALCRL, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "erenumab": {
    "gene": "CALCR, RAMP1, CRCP, CALCRL, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clopidogrel": {
    "gene": "EFR3A, ABCC3, POR, JMJD8, CYP2C9, TLN1, KDR, ABCB1, CDH15, CD80, AGAP3, PPARA, MIR6076, CYP2B6, CYP2D6, ITGA2, CYP1A1, PON1, ITGA2B, P2RY1, ATP10A, CYP2C19, PIK3CA, KRTAP10-4, CYP2C18, TSPEAR, CES1P1, RASGRP2, CYP4F2, GP1BA, P2RY12, APBB1IP, WDR24, GP6, MYOM2, FMO3, F2R, SLC14A2, UGT2B7, NECAB1, CES1, ABCC2, B4GALT2, ZDHHC3, ARNT, THSD7A, IRS1, CYP3A4, F13A1, ECHS1, N6AMT1, NOC3L, UCP2, CDH13, CYP2C8, SELP, PTGS1, CYP3A5, ABCA1, MED12L, ZNF335, ITGB3, CYP1A2, NOS3, PEAR1",
    "advice": "The American Heart Association has a statement of CYP2C19 and clopidogrel and testing before oral P2Y12 inhibitors are prescribed in patients with acute coronary syndromes or percutaneous coronary intervention.\n",
    "source": "AHA"
  },
  "sodium oxybate": {
    "gene": "ALDH5A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levetiracetam": {
    "gene": "ALDH5A1, HLA-DQB1, HLA-A, SCN1A, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methadone": {
    "gene": "ALDH5A1, POR, NPY5R, CYP2C9, KCNE1, SLC22A1, DAO, DRD2, ABCB1, TPH1, NR3C1, GNB3, KCNE2, NGF, CYP2B6, CYP2D6, CRY1, ADRA2A, PNOC, OPRD1, DRD1, PDYN, MYOCD, OPRM1, CYP2C19, CCL11, NPY1R, BDNF, TXNRD2, SLC6A3, OPRK1, GRIN3B, KCNJ6, ARRB2, SLC6A4, DDC, HTR2A, BDNF-AS, UGT2B7, GAD1, CRHBP, TPH2, CNR1, ANKK1, CYP2A7P1, CYP3A4, TH, DBH, OPRL1, H2AX, GRIN3A, CYP3A5, CDH2, GRM6, NTRK2, NECTIN4, GABRD, CYP1A2, GAD2, COMT",
    "advice": "CPIC does not currently provide CYP2B6 genotype-based prescribing recommendations for methadone.\n",
    "source": "CPIC"
  },
  "phenytoin": {
    "gene": "ALDH5A1, CYP2C9, GABRB2, DRD2, ABCB1, HTR2C, PSORS1C3, CYP2B6, CYP2D6, MTHFR, CYP1A1, CFHR4, CYP2C19, UGT1A4, G6PD, POU5F1, UGT1A9, GABRG2, PSORS1C1, SLC6A4, HLA-A, HTR2A, EPHX1, SCN2A, CYCSP5, CYP3A4, HLA-B, SCN1A, HLA-DRB1, UGT2B15, GABRA1, GABRA3, HLA-C, CYP3A5, NAT2, POLG, UGT1A6, GABRA6, CYP1A2",
    "advice": "Phenytoin should be avoided if possible in patients with the HLA-B*15:02 allele.\n",
    "source": "DPWG"
  },
  "rosuvastatin": {
    "gene": "LDLR, CYP2C9, HNF4A, SCARB1, CYP2D6, CYP2C19, SCAP, SLC10A1, LPA, CETP, APOA5, NR1H4, TPMT, HNF1A, FMO3, CRP, ABCC2, APOE, NR1I2, ABCG2, ABCB11, CYP3A4, HLA-DRB1, RYR2, KIF6, CACNA1S, CYP3A5, ABCA1, SLCO2B1, FOXA3, HMGCR, SLCO1B1, NAT2, RXRA, GATM, COQ2, LPL, USP24",
    "advice": "Keep the rosuvastatin dose as low as possible (e.g. by adding ezetimibe) for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.\n",
    "source": "DPWG"
  },
  "pitavastatin": {
    "gene": "LDLR, CYP2C9, APOB, ABCC2, ABCG2, PCSK9, CYP3A4, HLA-DRB1, RYR2, CYP3A5, HMGCR, SLCO1B1, GATM",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC"
  },
  "peginterferon alfa-2a": {
    "gene": "LDLR, SCARB1, IL6, IL18, ABCB1, CTLA4, EGFR, ITPA, OAS1, APOH, METTL1, NT5C2, CYP27B1, HLA-A, IDO1, IFNL4, ZHX2, VDR, HLA-B, SOCS3, DNAAF9, CXCL10, MICB, DPP4, IFNL3, SLC29A1",
    "advice": "IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\n",
    "source": "CPIC"
  },
  "peginterferon alfa-2b": {
    "gene": "LDLR, IL6, IL18, CARD16, CTLA4, EGFR, ITPA, OAS1, APOH, TUT7, IL21R, IFIT1, OASL, CYP27B1, SLC6A4, HLA-A, IDO1, IFNL4, HLA-DPA1, VDR, KIR2DS2, HLA-B, SOCS3, DNAAF9, CXCL10, KLRK1, HLA-C, MICB, UGT1A1, CYP2R1, DPP4, SLC28A2, IFNL3, CASP1, SLC29A1",
    "advice": "IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\n",
    "source": "CPIC"
  },
  "lomitapide": {
    "gene": "LDLR, APOB, PCSK9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mipomersen": {
    "gene": "LDLR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alirocumab": {
    "gene": "LDLR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "evinacumab": {
    "gene": "LDLR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "inclisiran": {
    "gene": "LDLR, APOB, PCSK9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "atorvastatin": {
    "gene": "LDLR, POR, CAT, LEPR, APOC3, UGT1A10, CYP2C9, FDPS, SCARB1, MTTP, LPP, ABCB1, UGT1A3, RYR1, HTR2C, MYLIP, PPARA, CYP2D6, MTHFR, PON1, CYP2C19, SCAP, UGT1A4, LPA, PRDM16, HTR1D, CETP, APOA5, UGT1A9, SLC6A4, HTR7, UGT1A8, UGT1A5, HTR2A, IFNL4, ABCC2, APOE, ABCG2, AGT, PCSK9, HTR6, CYP3A4, AGTR1, CLMN, BDKRB2, HLA-DRB1, TNF, RYR2, HTR3A, CYP7A1, HTR5A, KIF6, SREBF1, UGT1A1, CACNA1S, CYP3A5, ABCA1, SLCO2B1, HMGCR, SLCO1B1, UGT1A6, DRD3, GATM, UGT1A7, COQ2, HTR3B, ACE, IFNL3, LPL, CYP3A7, NOS3, ABCG8, ESR1",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC"
  },
  "fluvastatin": {
    "gene": "LDLR, CYP2C9, ABCB1, CYP2D6, SCAP, CETP, LIPC, APOE, ABCG2, CYP3A4, HLA-DRB1, RYR2, SREBF1, CYP3A5, HMGCR, SLCO1B1, GATM, COQ2, ACE",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC"
  },
  "lovastatin": {
    "gene": "LDLR, PPARA, CYP2D6, CETP, APOA5, APOE, ABCG2, CYP3A4, CYP3A5, HMGCR, SLCO1B1",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC"
  },
  "pravastatin": {
    "gene": "LDLR, MTTP, ABCB1, HTR2C, DLGAP1, RHOA, NLRP8, MTHFR, FCAR, IL12B, SLC10A1, NPC1L1, HTR1D, CETP, KYNU, PPP1R1C, ADAMTS14, APOA1, SLCO1B3, SLC6A4, HTR7, LIPC, IP6K2, HTR2A, ABCC2, ITGBL1, APOE, ABCG2, RNFT2, ADAM12, HTR6, CYP3A4, TLR4, CLMN, ANKRD55, PPFIA1, HLA-DRB1, PDCD1LG2, CMKLR2, ADAMTS1, PDE4C, RYR2, HTR3A, MMP3, HTR5A, KIF6, CACNA1S, CYP3A5, ABCA1, IL1B, HMGCR, SLCO1B1, ITGA9, GATM, COQ2, HTR3B, ACE, LPL, APBB1, PPP2R5E",
    "advice": "There are currently no recommendations for pravastatin dosing based on SLCO1B1 genotypes.\n",
    "source": "DPWG"
  },
  "ribavirin": {
    "gene": "LDLR, SCARB1, IL6, IL18, CARD16, CTLA4, EGFR, ITPA, OAS1, APOH, TUT7, IL21R, IFIT1, OASL, CYP27B1, SLC6A4, BCL2, HLA-A, IFNL4, VDR, HLA-B, SOCS3, DNAAF9, KLRK1, HLA-C, MICB, UGT1A1, CYP2R1, FTO, SLC28A2, IFNL3, CASP1, SLC29A1",
    "advice": "IFNL3 (IL28B) variation (rs12979860) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (rs12979860 CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\n",
    "source": "CPIC"
  },
  "methylphenidate": {
    "gene": "SPSB2, GRIN2A, DRD2, CMTM8, ABCB1, HTR1B, ZNF565, CYP2D6, ADRA2A, DRD1, CHURC1, ETFDH, ZDHHC7, TRIB3, ADGRL3, BDNF, PEBP4, OPCML, SLC6A3, GRIN2B, CORO7, CDH23, PURA, MIR4278, ARHGAP12, SLC6A4, RRP7A, FXR2, GRM7, CES1, TPH2, CHRNA4, GGH, FARP2, ZNF211, STRBP, NFIB, SNAP25, DRD4, TH, SENP3, DBH, ESYT2, PYROXD2, SLC6A2, ELP5, PDIA2, ARHGEF28, PIGM, SYT1, ARSA, DRD3, HTT, COMT, ALDH1L1, ZNF134",
    "advice": "There are currently no dosing recommendations for methylphenidate based on COMT genotype.\n",
    "source": "DPWG"
  },
  "morphine-3-glucuronide": {
    "gene": "ABCC3, UGT2B7, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "busulfan": {
    "gene": "ABCC3, CYP2C9, GSTA1, CYP2B6, MTHFR, CYP2C19, SLC7A8, BCR, SLC22A4, GSTM1, GSTA5, CYP3A4, CTH, ABL1, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fentanyl": {
    "gene": "ABCC3, IL6, LAMB3, ABCB1, LY96, STAT6, P2RX7, CYP2D6, TGFB1, OPRD1, DRD1, CACNA1E, OPRM1, CYP2C19, SLC9A9, SERP2, PGAP6, BDNF, IL6R, CALCA, KCNJ6, ARRB2, MYD88, RHBDF2, TLR2, UGT2B7, CYP3A4, ADRB2, TNF, IL10, CASP5, UGT1A1, IL2, CYP3A5, CPPED1, ASTN2, CASP1, ATF2, ABCC1, COMT",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "lamivudine": {
    "gene": "ABCC3, ABCC4, NT5C, SLC22A1, CHPT1, ABCB1, CYP2B6, DCK, SLC22A2, PGK1, ABCC2, PCYT2, ABCG2, SLCO3A1, CYP3A4, HLA-B, PCYT1A, SLC22A3, UGT1A1, CMPK1, NME1, CYP2A6, ABCC1, NME2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "morphine": {
    "gene": "ABCC3, UGT1A10, ARVCF, SLC22A1, DRD2, IL6, ABCB1, UGT1A3, CYP2D6, OPRD1, OPRM1, CYP2C19, UGT1A4, CCL11, BDNF, TXNRD2, METTL21A, IL6R, OPRK1, UGT1A9, KCNJ6, SLC6A4, UGT1A8, RHBDF2, UGT1A5, HTR2A, TLR2, UGT2B7, SULT1A4, FAAH, IL16, UGT1A1, IL2, IL1B, TAOK3, UGT1A6, UGT1A7, SULT1A3, COMT, ESR1",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "vincristine": {
    "gene": "ABCC3, MIR202, SLC28A3, SNU13, FGD4, GSTA1, CAPG, NKAIN3, MIR146A, ABCB1, MCM3AP, CYBA, GATA3, NDRG1, MIR6076, CYP2B6, CEP72, MIR4481, MTHFR, CYP1A1, TUBB1, ASNS, TNRC6B, FCGR3A, RAB7A, BMP7, NRG3, MIR423, MIR577, SYNE2, MRPL47, CXCL12, TPMT, PNPLA3, BCR, BCL2, MIR411, MIR449B, XRCC1, GEMIN4, PAPPA, MIR2053, ABCC2, SLC5A7, XPO5, BPHL, ATP5F1E, METTL8, SPDYA, MTR, ATF5, NFIB, CYP3A4, C18orf56, ACTG1, SULF2, MIR1206, MIR1307, CPT1A, RALBP1, METTL3, MIR3117, TNRC6A, MIR4268, RAC2, MIR604, MTNR1B, GARS1, AGO1, DOK5, BAHD1, IL10, LINC00251, ARHGAP5, MIR492, UGT1A1, MIR300, CYP3A5, C5orf22, FBN2, LRRTM3, COCH, KANSL1, MAPT, VTI1A, ABCC10, DDX20, ABL1, MIR618, PDE4D, ABCC1, TYMS, IGHMBP2, CNOT1, STIM1, ZFAND3, ACTN1, GSTP1, DROSHA, TUBB3, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "morphine-6-glucuronide": {
    "gene": "ABCC3, OPRM1, UGT2B7, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "voriconazole": {
    "gene": "POR, CYP2C9, ABCB1, CYP2C19, CYP2C18, SLCO1B3, FMO3, ABCC2, NR1I2, ABCG2, CYP3A4, CYP3A5, SLCO2B1",
    "advice": "An alternative antifungal agent should be considered instead of voriconazole in patients who are known to be CYP2C19 ultrarapid metabolizers. CYP2C19 genotyping and use of an alternative antifungal agent is also recommended in patients with subtherapeutic voriconazole serum concentrations despite two dose adjustments.\n",
    "source": "AusNZ"
  },
  "clobazam": {
    "gene": "POR, CYP2C19, SCN1A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sunitinib": {
    "gene": "POR, ABCC4, KIT, KDR, ABCB1, MET, CYP1A1, CYP4F2, IL4R, SLCO1B3, FLT3, PDGFRB, GLP1R, VEGFA, PDGFRA, NR1I2, ABCG2, IL13, CYP3A4, FLT4, IL8, FLT1, CYP3A5, SLC22A5, RET, FGFR2, ZSCAN25, NR1I3, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rivaroxaban": {
    "gene": "POR, CYP2J2, PRF1, BRD3, GOT2, ABCB1, F5, CYP2C19, MMP13, APOB, CES1, ABCG2, SUSD3, CYP3A4, NCMAP, PRKAG2, CYP3A5, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dolutegravir": {
    "gene": "POR, ABCB1, SLC22A2, AADAC, NR1I2, ABCG2, CYP3A4, UGT1A1, CYP3A5, NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "edoxaban": {
    "gene": "POR, ABCB1, APOB, CES1, CYP3A5, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alectinib": {
    "gene": "POR, PPARA, ALK, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "apixaban": {
    "gene": "POR, SLC22A1, ABCB1, CYP4F2, APOB, CES1, ABCC2, APOE, ABCG2, CYP3A4, SLC6A2, CYP3A5, ZSCAN25",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cyclosporine": {
    "gene": "POR, IL6, TSPYL1, ABCB1, CTLA4, PPARA, CALM1, TGFB1, MTHFR, ATIC, CRTC2, UMOD, IMPDH2, TPMT, UGT1A8, NFATC1, ABCC2, NR1I2, SLC19A1, TCF7L2, PPP3R1, LEP, CYP3A4, DHFR, NFATC2, TNF, CYP2C8, NOD2, IL10, IMPDH1, IL2, CYP3A5, ABCC1, CYP3A7, SLC29A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "donepezil": {
    "gene": "POR, KCNE1, ABCB1, KCNE2, CYP2D6, CHAT, PRKCE, SLC5A7, APOE, NR1I2, ACHE, CYP3A4, BCHE, CYP3A5, CHRNA7, CYP3A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "galantamine": {
    "gene": "POR, ABCB1, CYP2D6, CHAT, PRKCE, SLC5A7, APOE, ACHE, CYP3A4, CYP3A5, CHRNA7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "glimepiride": {
    "gene": "POR, CYP2C9, G6PD, ABCC8, CDKAL1, TCF7L2, KCNJ11, IRS1, NOS1AP, KCNQ1",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "glipizide": {
    "gene": "POR, CYP2C9, G6PD, ABCC8, CDKAL1, TCF7L2, KCNJ11, IRS1, NOS1AP, KCNQ1",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "glyburide": {
    "gene": "POR, CYP2C9, FMO2, SCNN1B, G6PD, ABCC8, MAPK1, SPINK5, CDKAL1, CYP51A1, CHST13, TCF7L2, KCNJ11, IRS1, ABCB11, ABCC5, BDKRB2, UGT2B15, NOS1AP, SLCO2B1, KCNQ1, ESR1",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "midazolam": {
    "gene": "POR, ABCB1, CYP2C19, UGT1A4, NR1I2, VDR, CYP3A4, UGT1A1, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sirolimus": {
    "gene": "POR, ABCB1, PPARA, UGT1A8, NR1I2, TCF7L2, CYP3A4, TNF, IL10, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tacrolimus": {
    "gene": "POR, CYP2J2, IL6, IL3, IL18, ABCB1, CTLA4, CCDC22, PPARA, CYP2B6, TGFB1, CYP2C19, SLC7A8, FOXP3, UGT1A4, CRTC2, ABCC8, IL6R, C6, SLCO1B3, MYD88, UGT1A8, FMO3, TLR2, CRP, DUX1, ABCC2, NR1I2, ABCG2, TCF7L2, KCNJ11, LEP, SULT1E1, SLC2A2, CYP2A7P1, GSTM3, CYP2E1, VDR, CYP3A4, TLR4, SUMO4, CYP2C8, PPP3CA, NFATC4, NOD2, IL10, IMPDH1, IL2, CYP3A5, IL1B, SLCO1B1, CAPN10, KCNQ1, ACE, HSD11B1, CASP1, ZSCAN25, COMT, CYP3A7, NR1I3",
    "advice": "Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day.\n",
    "source": "RNPGx"
  },
  "zidovudine": {
    "gene": "POR, ABCC4, SLC28A1, SLC28A3, CYP2C9, SLC22A1, ABCB1, CYP2B6, SLC22A8, TK1, UGT2B7, ABCG2, SLC22A11, ABCC5, SLCO3A1, CYP2E1, CYP3A4, SLC22A6, UGT1A1, NME1, DTYMK, CYP2A6, SLC22A7, ABCC1, NME2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acenocoumarol": {
    "gene": "POR, CYP2C9, ABCB1, STX4, CYP2C19, CYP2C18, CYP4F2, VKORC1, APOE, GATA4, CYP3A4, CALU, GGCX",
    "advice": "Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.\n",
    "source": "RNPGx"
  },
  "diuretics": {
    "gene": "NELFCD, KCNE1, ADRB1, NEDD4L, GNB3, HS3ST4, ERCC6L2, CSMD3, CACNA1C, USP5, CDCA3, ADD1, ADRB2, PRKCA, ADRA2C, NOS1AP, CYP4A11, CNTNAP2, ACE, PDE4D, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "adefovir dipivoxil": {
    "gene": "ABCC4, SLC26A8, ABCC2, SLC22A6, AK2, NME1, AK4, NME2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tenofovir": {
    "gene": "ABCC4, UGT1A10, SLC26A8, GIMAP6, ABCB1, UGT1A3, LST1, CYP2B6, MTHFR, ATIC, FCGR3A, UGT1A4, DPYD, UGT1A9, CCDC12, FARP1, RPE, SLCO1B3, UGT1A8, UGT1A5, STK24, IFNL4, VKORC1, ABCC2, APOE, CLCN6, SLC19A1, ABCG2, PRSS53, SLC22A11, CYP2A7P1, LRIG3, APOC1, ADRB2, SLC22A6, OCRL, AK2, TNF, LTA, C1QTNF7, KIF6, UGT1A1, NME1, UGT1A6, ABCC10, SLC28A2, UGT1A7, IFNL3, AK4, NME2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "valganciclovir": {
    "gene": "ABCC4, SLC28A3, SLC22A1, ABCB1, ABCG2, SLC28A2, SLC29A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bisphosphonates": {
    "gene": "ABCC4, FDPS, PHB2, TAFA5, CSRNP3, TBC1D32, RBMS3, SFRP5, KCNT2, MARCHF1, IGFBP7, ALDH1A2, CYP2C8, IL1B, PKLR, MEX3C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "latanoprost": {
    "gene": "ABCC4, PTGFR, PTGS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "glucarpidase": {
    "gene": "ABCC4, GATA3, SLCO1B1, NTRK1, ARID5B, INSRR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tenofovir disoproxil fumarate": {
    "gene": "ABCC4, HNF4A, ABCB1, CYP27B1, ABCC2, VDR, SLC22A6, CYP24A1, ABCC10, SLC28A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "17beta-estradiol glucuronide": {
    "gene": "ABCC4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "azathioprine": {
    "gene": "ABCC4, HLA-DQA1, ABCB1, AOX1, ITPA, MTHFR, GSTT1, IL23R, IMPDH2, ADK, UGT1A9, CASP9, SLCO1B3, TPMT, UGT1A8, SUCLA2, ABCC2, PTPN2, GSTM1, XDH, C18orf56, DHFR, MOCOS, HLA-DRB1, GMPS, DDRGK1, PACSIN2, IMPDH1, RAC1, SLCO1B1, FTO, NUDT15, MSH3, ABCC1, RRM1, TYMS, GSTP1, SLC29A1",
    "advice": "Testing for TPMT genotype and phenotype is recommended for patients who are receiving azathioprine as an immunosuppressant. A dose reduction should be considered for patients with intermediate TPMT activity, while a greater dose reduction or selection of an alternate drug should be considered for patients with low TPMT activity.\n",
    "source": "RNPGx"
  },
  "efavirenz": {
    "gene": "ABCC4, HNF4A, SLC22A1, ABCB1, CYP2B6, CYP2C19, HTR2A, UGT2B7, ABCC2, TPH2, ABCC9, NR1I2, ABCG2, SLCO3A1, CYP2A7P1, CYP3A4, HLA-DRB1, HLA-C, IL10, UGT1A1, CYP3A5, SLCO1B1, NAT2, CYP2A6, CYP1A2, NR1I3",
    "advice": "Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the CYP2B6 IM phenotype, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed.\n",
    "source": "DPWG"
  },
  "furosemide": {
    "gene": "ABCC4, GNB3, CYP11B2, SLC22A11, ADD1, SLC12A3, SCNN1G, SLCO1B1, ACE, NPPA-AS1, SLC2A9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "indinavir": {
    "gene": "ABCC4, CYP3A4, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "irinotecan": {
    "gene": "ABCC4, ERCC1, UGT1A10, HNF4A, TDP1, IL6, SMARCAD1, ABCB1, SYNE3, NR3C1, PPARA, EGFR, AREG, ADCY2, TGFB1, CSPG4, TGFBR2, KRAS, CES1P1, STAT3, DPYD, DCBLD1, UGT1A9, PPARD, MTRR, SHMT1, SLCO1B3, UGT1A8, XRCC1, PDGFRB, VEGFA, CES1, VKORC1, ABCC2, NR1I2, SLC25A13, SLC19A1, ABCG2, ABCG1, NFKB1, GSTM1, ABCC5, PLCB1, KCNQ5, KLC1, VDR, CYP3A4, C18orf56, ALOX5, UGT1A, RXRG, HLA-B, RGS5, XRCC3, C8orf34, HLA-DRB1, RALBP1, TNF, BCHE, CES2, TOP1, UGT1A1, CYP3A5, PIN1, TOMM40L, SLCO1B1, NAT2, SEMA3C, UGT1A6, CYP2A6, PDZRN3, UBE2I, ETFRF1, SMAD7, IFNG, UGT1A7, KCNQ1, ABCC1, TYMS, HLA-DQB3, SLC1A1, NR1I3, PPARG, GSTP1",
    "advice": "An Italian working group comprising the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) has published recommendations for the use of UGT1A1*28 (TA7 repeats) genotype when prescribing irinotecan.\n",
    "source": "AIOM"
  },
  "mercaptopurine": {
    "gene": "ABCC4, SLC28A3, SLC22A1, HLA-DQA1, MIR146A, AOX1, CNNM2, GATA3, ITPA, MTHFR, MED4, CYP1A1, TNRC6B, FOLH1, IMPDH2, MIR423, MIR577, NT5C2, SHMT1, TPMT, PNPLA3, GNAQ, MIR449B, XRCC1, GEMIN4, CYP2A7, MIR2053, SUCLA2, XPO5, SLC19A1, PTPN2, MTR, XDH, C18orf56, DHFR, MIR1206, MIR1307, CPT1A, HLA-DRB1, TNRC6A, GMPS, MIR604, AGO1, PACSIN2, IL10, MIR492, UGT1A1, MIR300, IMPDH1, C5orf22, SLCO1B1, FTO, POLG, DDX20, NUDT15, MIR618, SLC28A2, MSH3, GNMT, TYMS, IGHMBP2, CNOT1, COMT, GSTP1, DROSHA, SLC29A1",
    "advice": "The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for TPMT.\n",
    "source": "RNPGx"
  },
  "misoprostol": {
    "gene": "ABCC4, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thioguanine": {
    "gene": "ABCC4, SLC28A3, GATA3, NAT1, BMP7, TPMT, PNPLA3, XDH, CPT1A, DOK5, LINC00251, UGT1A1, IMPDH1, NUDT15, IGHMBP2",
    "advice": "Select an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.\n",
    "source": "DPWG"
  },
  "purine analogues": {
    "gene": "ABCC4, FSTL5, ITPA, IL6ST, TPMT, PACSIN2, RAC1, NUDT15",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "platinum": {
    "gene": "STMN1, ERCC1, CD74, ABCB1, KLC3, AQP2, POU2F2, AQP9, SLC2A1, ERCC2, HNF1B, XRCC1, RICTOR, ERCC5, TMEM205, C18orf56, LRP1, TYMS, GSTP1, XRCC5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vinorelbine": {
    "gene": "STMN1, MTHFR, MTR, CYP3A5, CASP7, TYMS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "palonosetron": {
    "gene": "ERCC1, ABCB1, CYP2D6, ABCG2, HTR3D, TACR1, HTR3C, HTR3B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bevacizumab": {
    "gene": "ERCC1, EDN1, BAD, KDR, FHIT, ENOSF1, MTHFR, IL7, EGLN3, CSPG4, GSTT1, MAPK14, C3, VEGFB, DPYD, GC, CCT3, ARMS2, FZD4, HTRA1, EPO, TYMP, HSP90AB1, ERCC2, CXCL12, SHMT1, APOBEC2, ANGPT2, FGF2, PDGFRB, VEGFA, INHBA, CDA, ANGPT1, SLC19A1, ARHGEF4, KCNAB1, MMP9, CXCR2, GGH, GSTM1, CYP3A4, RGS5, PRKCA, HLA-DRB1, SERPING1, RALBP1, IL8, YBX1, FLT1, UGT1A1, CFH, CYP3A5, MGAT4A, CXCR4, PROM1, ANXA11, VEGFC, TYMS, EPAS1, CRHR1, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "radiotherapy": {
    "gene": "ERCC1, HLA-DQA1, KDR, AREG, ERCC4, TGFB1, GSTT1, APEX1, OGG1, HLA-DQB1, ATM, OSMR, ERCC2, CDK1, XRCC1, EPHX1, PRKCE, WRN, FEN1, TP53, ERCC5, NFKB1, GSTM1, RAD51, CACNA2D3, XPC, XRCC3, HLA-DRB1, TNF, MUTYH, IL8, ATG10, OSGEP, TMEM167A, TANC1, MSH2, CDH2, XRCC4, NEIL1, MEG3, MSH3, GSTP1, RIGI",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bleomycin": {
    "gene": "ERCC1, ABCB1, GSTT1, BLMH, ERCC2, GSTM1, CYP3A4, UGT1A1, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dexamethasone": {
    "gene": "ERCC1, CHRM3, KDR, ABCB1, CTLA4, NR3C1, GATA3, LRP5, MTHFR, GSTT1, CRISPLD2, PTGDR, BMP7, POLR1G, PPP1R13L, SERPINE1, F2RL1, PTH1R, VEGFA, VDR, CYP3A4, ACP5, CYP2C8, PTH, DOK5, LINC00251, UGT1A1, BCL2L11, BGLAP, PYGL, CTNNB1, GSTP1, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "diphenhydramine": {
    "gene": "ERCC1, ABCB1, GSTT1, POLR1G, PPP1R13L, CYP2C8, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "gemcitabine": {
    "gene": "ERCC1, SLC28A1, ATAT1, CAMK4, HELB, SLC28A3, NT5C, NT5C1A, ABCB1, KLC3, ACSS2, OR4D6, NRAS, DDX53, ALOX5AP, MTHFR, TENT4A, DAPK1, CTDP1, DCK, SPARC, BTRC, POLR1G, DCP1B, PPP1R13L, C6orf15, ESR2, FKBP5, DOCK8, POLR2A, PDE4B, MSH5, PPCDC, ERCC2, NT5C2, PSORS1C1, IL17F, XYLT2, XRCC1, MS4A2, SH2D5, BAZ2B, RAF1, CDA, ABCC2, ABCG2, WWOX, MUCL3, PRB2, SLC29A2, GSTM1, MTR, POLA2, FHL2, CYP3A4, C18orf56, HCP5, CDSN, HLA-DRB1, CDC5L, TNF, PPP1R18, NT5C3A, CDH4, PRRC2A, DCTD, HIF1A, CYP2C8, ALG10, HLA-C, CYP1B1, UBASH3B, SLC29A3, CMPK1, CYP3A5, SLCO1B1, ETS2, SERPINC1, SLC28A2, GPX5, CASP7, RRM1, TYMS, STIM1, SERPINA5, GSTP1, SLC29A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "granisetron": {
    "gene": "ERCC1, ABCB1, CYP2D6, CYP1A1, ABCG2, HTR3D, TACR1, HTR3A, HTR3C, NOS1AP, CYP3A5, HTR3B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "leucovorin": {
    "gene": "ERCC1, HNF4A, IL6, ABCB1, GATA3, PPARA, EGFR, MTHFR, CSPG4, SPARC, STAT3, DPYD, FASTKD3, MSH6, ERCC2, PPARD, MTRR, SHMT1, XRCC1, PDGFRB, VEGFA, SELE, UGT2B7, ABCC2, NR1I2, SLC19A1, ABCG2, ABCG1, NFKB1, UMPS, ABCC5, KLC1, VDR, C18orf56, RXRG, RGS5, XRCC3, HLA-DRB1, RALBP1, TNF, UGT1A1, SLCO1B1, IFNG, AGXT, ABCC1, TYMS, NR1I3, PPARG, GSTP1, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ranitidine": {
    "gene": "ERCC1, SLC22A1, ABCB1, GSTT1, SLC22A2, POLR1G, PPP1R13L, CYP2C8, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thalidomide": {
    "gene": "ERCC1, RPL13, ATP7A, GSTT1, CYP2C19, SPG7, SNORD68, PPARD, SULT1C4, FGF2, SLC10A2, VEGFA, CHST3, CYP4B1, ABCC6, NAT2, CTNNB1, XRCC5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trans 4-hydroxypraziquantel": {
    "gene": "CYP2J2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ebastine": {
    "gene": "CYP2J2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "daunorubicin": {
    "gene": "CYP2J2, SLC28A1, SETD4, SLC28A3, GPX3, AKR7A2, MIR146A, ABCB1, GATA3, MTHFR, GSTT1, TNRC6B, DCK, SLC22A2, ETFB, G6PD, BMP7, CYP4F2, SPG7, COL1A2, MIR423, HNMT, MIR577, SLC22A17, AKR1C3, RAD50, TPMT, CBR1, PNPLA3, MIR449B, GPR35, SLCO6A1, FMO3, GEMIN4, SLC10A2, HFE, SOD2, MIR2053, CDA, ABCC2, ABCC9, XPO5, ADH7, SERPINA6, GSTM1, GSTA2, ABCB11, ABCC5, XDH, GSTM3, ATF5, C18orf56, MIR1206, MIR1307, CPT1A, RARG, MIR3117, SZRD1, SLC13A3, TNRC6A, MIR4268, ATP7B, MIR604, AGO1, DOK5, AKR1C4, LINC00251, SULT2B1, MIR492, UGT1A1, MIR300, C5orf22, NRP2, ABCA1, SLCO1B1, UGT1A6, ABCC10, DDX20, SLC22A7, ABCB4, MIR618, MAN1B1, ABCC1, TYMS, IGHMBP2, CNOT1, GSTP1, DROSHA, SLCO4C1, NOS3, CBR3, SLC15A1",
    "advice": "The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of RARG , SLC28A3 , and UGT1A6 when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6 *4 (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).\n",
    "source": "CPNDS"
  },
  "terfenadine": {
    "gene": "CYP2J2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pegaspargase": {
    "gene": "ARHGAP28, APOC3, HLA-DQA1, GATA3, MYBBP1A, RGS6, HLA-DQB1, BMP7, CNOT3, APOA5, TPMT, PNPLA3, GRIA1, CCHCR1, ULK2, SPINK1, RFXAP, CPT1A, HLA-DRB1, NFATC2, DOK5, LINC00251, UGT1A1, IGHMBP2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "irbesartan": {
    "gene": "EDN1, CYP2C9, CYP11B2, APOB, AGT, AGTR1, KCNH2, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ara-ctp": {
    "gene": "SLC28A1, SLC28A3, CTPS1, DCK, CDA, DCTD, RRM1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "stavudine": {
    "gene": "SLC28A1, RRM2B, CYP2B6, MTHFR, APOE, SAMHD1, HLA-B, TNF",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydroxyurea": {
    "gene": "CAT, SLC14A1, MAP3K5, CYP2D6, HBG2, IFNL4, SIN3A, KLF4, ASS1, BCL11A, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fenofibrate": {
    "gene": "APOA4, APOC3, SCARB1, IL6, FABP1, PPARA, CETP, APOA5, APOB, APOA1, HLA-A, CRP, GCKR, APOE, ABCA1, SLCO1B1, LPL",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "candesartan": {
    "gene": "KCNK3, SULT1C3, CYP11B2, PLEKHJ1, GPR83, SH2B3, AGTR1, KCNH2, ACE, DOT1L",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sevoflurane": {
    "gene": "KCNK3, KCNE1, ABCB1, RYR1, FASTKD3, GRIN2B, MTRR, KCNK2, DUX1, CYP2E1, ADRB2, CACNA1S, GABRA2, GSTP1",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "hmg-coa reductase inhibitors": {
    "gene": "ATP2B1, CYP2C9, SUGCT, STAT4, ABCB1, UGT1A3, RYR1, GNB3, PPARA, TOMM40, CYP2D6, LILRB5, CYP2C19, NPC1L1, LPA, PRDM16, CETP, CHRNA1, SLC22A8, SIK3, SLCO1B3, HTR7, CXCL5, UGT2B7, ABCC2, SORT1, APOE, ABCG2, CFAP44, PCSK9, ABCB11, APOC1, CYP19A1, CYP3A4, SLCO1A2, SLC22A6, DMPK, HLA-DRB1, ADAMTS1, RYR2, CDH13, CYP2C8, EYS, KIF6, SREBF1, UGT1A1, CYP3A5, SLCO2B1, HMGCR, SLCO1B1, COQ3, GATM, COQ2, COQ5, CELSR2, NOS3, HLA-G, SLC15A1",
    "advice": "Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause.\n",
    "source": "RNPGx"
  },
  "antihypertensives": {
    "gene": "ATP2B1, ADRB1, NEDD4L, PTPRD, MMP9, AGT, ADD1, NAMPT, GRK5, CYP3A5, ADIPOQ, ZSCAN25, CLNK, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "celecoxib": {
    "gene": "CACNA2D1, CYP2C9, CACNA1G, CYP2D6, CDKN1B, CACNA1E, CDKN1A, CYP2C19, PTGS2, IL23R, CACNA2D2, DDIT3, CA12, KCNQ4, CASP9, PTGER4, PTGES, CACNA1I, CA9, CACNB1, VEGFA, PDK1, CACNA1C, KCNQ3, CACNA1H, KCNQ2, MMP9, CACNA1F, CACNA2D3, KCNQ5, CYP3A4, BCAR1, CACNB2, CACNA1D, CACNB3, CACNA2D4, CACNA1B, ATP2A3, CYP2C8, ATP2A1, CASP3, ATP2A2, CACNA1S, PTGS1, IGFBP3, CACNB4, CTNNB1, KCNQ1, CACNA1A, ALOX12, PPARG",
    "advice": "The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of\nthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "apremilast": {
    "gene": "LEPR, ILF3, P2RY11, DOCK6, PPAN-P2RY11, CDKN2B-AS1, TMEM130, PDE4B, TSPAN16, CYP3A4, CDKN2B, LEPROT, EIF3G, PDE4D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "setmelanotide": {
    "gene": "LEPR, PCSK1, POMC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "simvastatin": {
    "gene": "LEPR, CYP2C9, ABCB1, RYR1, HTR2C, RHOA, CYBA, PPARA, CYP2D6, ZNF542P, PON1, SCAP, LPA, PRDM16, HTR1D, CETP, APOA5, UGT1A9, SLC6A4, HTR7, LIPC, HTR2A, SREBF2, ABCC2, APOE, ABCG2, HTR6, CYP3A4, CLMN, HLA-DRB1, RYR2, HTR3A, CYP2C8, F3, HTR5A, KIF6, SREBF1, CACNA1S, CYP3A5, ABCA1, SLCO2B1, HMGCR, SLCO1B1, GATM, COQ2, HTR3B, LPL, HLA-G, ABCG8",
    "advice": "There are currently no recommendations for atorvastatin, lovastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin and simvastatin dosing based on HMGCR, CYP3A4 or CYP3A5 genotypes.\n",
    "source": "CPIC"
  },
  "acetylcysteine": {
    "gene": "MUC5B, EPHX1, TOLLIP",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "adalimumab": {
    "gene": "TANK, IL6, HLA-DQA1, IL2RB, FCGR2B, TNFRSF10A, STAT4, REV3L, REL, CTLA4, TLR9, TGFB1, MACO1, ALPL, CCL21, TAGAP, IL23R, CR1L, HLA-E, IL12B, TNFAIP3, FCGR3A, ERAP1, KLRC1, EYA4, TNFRSF1B, IL6R, CASP9, RSRP1, BLK, ATG16L1, PTGER4, CD40, PSORS1C1, IL17F, CERS6, CD40LG, ATG5, TLR2, SLCO1C1, VEGFA, CRP, HFE, MAP3K14, PTPN22, NFKBIA, PTPRC, NR1I2, PTPN2, KLRD1, ATP5F1E, IL13, TRAF1, ZNF816, VDR, SH3BP2, CR1, TLR4, NCR3, HLA-DRB1, NFATC2, TNF, KCNH7, CD28, EMSY, FCGR2A, LTA, PRKCQ, IL2RA, GAPDHP64, IL27, CCNY, IL2, PRDM1, TNFRSF1A, TRAF3IP2, SLC9A8, CD84, TF, IVL",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desflurane": {
    "gene": "ATP8B3, RYR1, CACNA1S",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "propofol": {
    "gene": "ATP8B3, CYP2C9, KCNE1, DRD2, ABCB1, RYR1, KCNE2, CYP2B6, SCN9A, UGT1A9, HTR2A, ADRB2, GABRA1, GABRA2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "emapalumab": {
    "gene": "PRF1, RAB27A, STX11, SH2D1A, STXBP2, XIAP, UNC13D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bezafibrate": {
    "gene": "APOC3, APOE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antivirals for treatment of hiv infections, combinations": {
    "gene": "APOC3, ABCB1, TOMM40, CYP2B6, GSTT1, APOA5, SIK3, APOE, GSTM1, APOC1, UGT1A1, NAT2, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "protease inhibitors": {
    "gene": "APOC3, ITPA, SLC28A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ritonavir": {
    "gene": "APOC3, SLC22A1, ABCB1, UGT1A3, TOMM40, CYP2B6, CYP2D6, ABCC2, APOE, NR1I2, APOC1, CYP3A4, SLC22A6, UGT1A1, CYP3A5, SLCO1B1, UGT1A7, ABCC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pazopanib": {
    "gene": "SCGB3A1, KDR, VEGFA, HFE, NR1I2, ABCG2, CYP3A4, HLA-B, FLT4, IL8, HIF1A, CYP2C8, UGT1A1, FGFR2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ace inhibitors, plain": {
    "gene": "MME, ADRB1, SH2B1, F5, GABRG2, KCNMA1, MBOAT1, PTGER3, CES1, AGT, CLASP1, AGTR1, ADRB2, PRKCA, BDKRB2, KCNIP4, XPNPEP2, ADRA2C, PRKCQ, RBFOX3, CYP4A11, ETV6, ACE, ABO, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "metformin": {
    "gene": "PPARGC1A, HNF4A, SLC22A1, NBEA, PRKAG1, PPARA, PRKAB2, PPARGC1B, GCK, AMHR2, PRKAB1, FMO5, SLC47A2, C11orf65, SLC29A4, SLC22A2, MEF2A, FKBP1A, BDNF, PRKAA2, ALDH3A2, PCK1, ABCC8, MEF2D, ATM, SLC30A8, HNF1B, HNF1A, SLC22A4, CPA6, FMO1, PRKAA1, NR1I2, SNORA59B, TCF7L2, KCNJ11, GCG, PRPF31, SLC2A2, CBARP, CSMD1, SRR, PRKAG3, SLC19A3, SLC22A3, PRKAG2, IL1B, STK11, SP1, CAPN10, ITLN2, ADIPOR2, SLC47A1, PKLR, PPARG, ARFGEF3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rosiglitazone": {
    "gene": "PPARGC1A, CYP2C9, PAX4, PLIN1, LPIN1, CYP2C8, SLCO1B1, PPARG",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zoledronate": {
    "gene": "MMP2, FDPS, PPCDC, TNFRSF11A, COL1A1, TNFRSF11B, VDR, SPP1, CYP2C8, SIRT1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ulinastatin": {
    "gene": "MMP2, MMP9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pamidronate": {
    "gene": "MMP2, TNFRSF11A, COL1A1, TNFRSF11B, SPP1, CYP2C8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lithium": {
    "gene": "CACNG2, CLOCK, DRD2, ABCB1, HTR2C, TPH1, SH2B1, OR52E2, HTR1B, GADL1, ADCY2, CRY1, DRD1, FYN, SCN8A, EPHX2, LECT2, NR1D1, BDNF, GSK3B, OR52J2P, FAM178B, GRIN2B, BMAL1, FKBP5, IMPA2, CREB1, ASIC2, BCR, GRAMD1B, NBAS, HTR2A, BDNF-AS, CNKSR3, TMCC1, ZNF804A, MMP9, ANKK1, MYO1H, ADCY1, PER3, THRA, OR52J3, NTRK2, DRD3, PDLIM5, FAM177A1, COMT, DGKH, RABEP1, PER2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "benazepril": {
    "gene": "PRCP, MTHFR, CYP11B2, AGT, ADD1, MTR, SPTA1, AGTR1, ADRB2, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluticasone / salmeterol": {
    "gene": "ZNF432, CHRM2, IL10, IL17A, CRHR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "budesonide": {
    "gene": "ZNF432, FCER2, GLCCI1, ADRB2, SUMF1, IL10, CYP3A5, IL17A, CRHR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluticasone propionate": {
    "gene": "ZNF432, CD14, GLCCI1, CA10, ORMDL3, TMCO6, CYP3A4, ADRB2, CYP3A5, CRHR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aripiprazole": {
    "gene": "CYP3A43, CYP2C9, DRD2, DTNBP1, ABCB1, HTR2C, SH2B1, CYP2B6, CYP2D6, MC4R, CYP2C19, UGT1A4, SLC6A4, RELN, HLA-A, HTR2A, APOE, CNR1, DAOA, AGT, ANKK1, FAAH, CYP3A4, HLA-B, CYP3A5, POLG, TAAR6, FAT1, DRD3, ACE, CYP1A2, RABEP1",
    "advice": "The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.\n",
    "source": "DPWG"
  },
  "ticagrelor": {
    "gene": "CYP3A43, CYP2C9, NUP153, ABCB1, CYP2B6, CYP2C19, CYP4F2, P2RY12, UGT2B7, SVEP1, CYP3A4, CYP3A5, SLCO1B1, PEAR1",
    "advice": "There are currently no dosing recommendations for ticagrelor based on CYP2C19 genotypes.\n",
    "source": "DPWG"
  },
  "haloperidol": {
    "gene": "CYP3A43, GRIN2A, KCNE1, DRD2, DTNBP1, ABCB1, RYR1, HTR2C, KCNE2, CYP2D6, HTR3E, MTHFR, GRIK4, DRD1, MC4R, IL1RN, SLC6A5, PLEKHA6, SLC6A3, GRIN2B, AKAP13, SLC6A4, HOMER1, DPP6, EPM2A, ABCB5, GRIA1, CACNA1C, UGT2B7, TOR1A, NKX6-1, CNR1, GRIN1, ANKK1, FAAH, CYP3A4, ZIC4, RTKN2, EIF2AK4, HTR3A, HSPG2, CYP3A5, RGS2, NTS, ARID5B, CYP1A2, COMT",
    "advice": "The recommendation for CYP2D6 poor metabolizers is to use 60% of the normal dose of haloperidol and for CYP2D6 ultrarapid metabolizers to use 1.5 times the normal dose or to choose an alternative to haloperidol.\n",
    "source": "DPWG"
  },
  "ziprasidone": {
    "gene": "CYP3A43, CYP2C9, DRD2, HTR2C, RGS4, CYP2B6, CYP2D6, MC4R, CYP2C19, UGT1A4, SV2C, SLC6A4, NALCN, HLA-A, HTR2A, APOE, LYN, AGT, CYP3A4, EHF, HLA-B, EIF2AK4, CDH4, CYP3A5, POLG, CNTN4, ACE, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mycophenolic acid": {
    "gene": "UGT1A10, HPRT1, IMPDH2, UGT1A9, SLCO1B3, UGT1A8, NFATC1, UGT2B7, CES1, ABCC2, CYP3A4, CES2, CYP2C8, UGT1A1, IMPDH1, CYP3A5, SLCO1B1, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "axitinib": {
    "gene": "UGT1A10, KDR, ABCB1, CYP2C19, UGT1A9, UGT1A8, OR2B11, ABCG2, HIF1A, FLT1, UGT1A1, CYP3A5, SLCO1B1, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sn-38": {
    "gene": "UGT1A10, ABCB1, UGT1A3, UGT1A4, UGT1A9, UGT1A8, CES1, ABCC2, ABCG2, BCHE, CES2, TOP1, UGT1A1, SLCO1B1, UGT1A6, ABCC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fesoterodine": {
    "gene": "UGT1A10, UGT1A3, CYP2D6, UGT1A4, UGT1A9, UGT1A8, UGT1A5, CES1, CYP3A4, UGT1A1, UGT1A6, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "febuxostat": {
    "gene": "UGT1A10, AOX1, UGT1A3, UGT1A4, UGT1A9, UGT1A8, UGT1A5, XDH, UGT1A1, UGT1A6, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetaminophen glucuronide": {
    "gene": "UGT1A10, UGT1A3, UGT1A4, UGT1A9, UGT1A8, UGT1A5, MROH2A, UGT1A, UGT1A1, UGT1A6, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "n-desmethylclozapine": {
    "gene": "UGT1A10, ABCB1, CYP2D6, CYP1A1, CYP2C19, UGT1A4, UGT1A9, SLC6A4, UGT1A8, UGT1A5, UGT2B7, CYP3A4, SLCO1B1, UGT1A6, UGT1A7, CYP1A2, UGT2B10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "folfiri": {
    "gene": "UGT1A10, ABCB1, MTHFR, CES1P1, DPYD, UGT1A8, CES1, ABCC2, ABCG2, BRAF, UGT1A1, DPYS, ABCC1, TYMS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetaminophen": {
    "gene": "UGT1A10, SULT1A1, UGT1A3, PLA2G4A, CD44, SULT2A1, CYP2D6, OPRD1, OPRM1, HLA-DQB1, UGT1A4, G6PD, UGT1A9, UGT1A8, HLA-A, UGT1A5, TNFRSF11A, SULT1A4, ABCG2, SULT1E1, CYP2E1, CYP3A4, UGT1A, HLA-B, TLR4, HLA-DRB1, PLCG1, UGT2B15, HLA-C, TRPV1, UGT1A1, CYP3A5, UGT1A6, CYP2A6, NPIPB8, UGT1A7, SULT1A3, CYP1A2, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "allopurinol": {
    "gene": "UGT1A10, AOX1, UGT1A3, PDZK1, PSORS1C3, TBL1XR1, HLA-DQB1, UGT1A4, POU5F1, SLC17A1, GREM2, UGT1A9, NTNG1, PSORS1C1, UGT1A8, HLA-A, UGT1A5, CCHCR1, ABCG2, SLC22A11, CYCSP5, XDH, HLA-B, MOCOS, PKD2, TRIB2, HLA-DRB1, TSHZ2, HLA-C, MYT1L, UGT1A1, UGT1A6, CFLAR, NOTCH4, PSORS1C2, SLC22A12, UGT1A7, SLC2A9",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has established national guidelines around testing for HLA-B*58:01 prior to prescription of allopurinol to avoid severe cutaneous adverse reactions (SCARs).\n",
    "source": "RNPGx"
  },
  "ketamine": {
    "gene": "UGT1A10, UGT1A3, CYP2B6, OPRM1, UGT1A4, GRIN2B, UGT1A9, UGT1A8, UGT1A5, UGT1A1, UGT1A6, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ondansetron": {
    "gene": "UGT1A10, KCNE1, ABCB1, UGT1A3, KCNE2, CYP2D6, UGT1A4, UGT1A9, SLC6A4, UGT1A8, UGT1A5, CYP3A4, UGT1A1, CYP3A5, UGT1A6, UGT1A7",
    "advice": "The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "oxcarbazepine": {
    "gene": "UGT1A10, CYP2C9, HNF4A, DRD2, ABCB1, HTR2C, CYP2B6, CYP2D6, CYP2C19, UGT1A4, UGT1A9, SLC6A4, UGT1A8, HLA-A, HTR2A, UGT2B7, ABCC2, SCN2A, CYP3A4, HLA-B, SCN1A, HLA-DRB1, UGT2B15, GABRA1, GABRA3, CYP3A5, POLG, UGT1A6, UGT1A7, CYP1A2",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has guidance about carbamazepine and oxcarbazepine toxicity and HLA-B*15:02 and HLA-A*31:01.\n",
    "source": "RNPGx"
  },
  "topiramate": {
    "gene": "UGT1A10, ABCB1, UGT1A3, CYP2D6, GRIK1-AS2, OPRM1, CYP2C19, GRIK1, UGT1A4, CA12, UGT1A9, UGT1A8, UGT1A5, SCN2A, GABRA1, GABRA3, UGT1A1, UGT1A6, INSR, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "salbutamol": {
    "gene": "THRB, SPATS2L, CLOCK, PRKG1, COL22A1, IGF2R, NCOA3, PAPPA2, SLC24A4, COL2A1, ADCY9, DUSP1, VEGFA, CRHR2, ADRB2, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "gemcitabine triphosphate": {
    "gene": "SLC28A3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "prednisolone": {
    "gene": "SLC28A3, TSPYL1, ABCB1, CYBA, GATA3, MTHFR, FCGR3A, CD40, PNPLA3, DSE, TLR4, RAC2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "midostaurin": {
    "gene": "KIT, FLT3, NPM1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "avapritinib": {
    "gene": "KIT, PDGFRA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sorafenib": {
    "gene": "KIT, CYP2C9, SLC22A1, MAPK11, KDR, ABCB1, EGFR, CYP2B6, MAPK3, MAPK12, ADAMTS18, MAPK14, VEGFB, GALNT14, FGFR1, PIK3R5, UGT1A9, MAPK1, FLT3, SLC15A2, PDGFRB, VEGFA, PRKCE, RAF1, ABCC2, NR1I2, ABCG2, WWOX, CYP3A4, BRAF, FLT4, TNF, MAPK7, MAPK9, CDH13, HIF1A, CYP2C8, MAP2K6, FLT1, MAPK10, UGT1A1, CYP3A5, ARAF, MAPK8, SLCO1B1, MAPK4, RET, MAPK13, MAPK6, EPAS1, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nintedanib": {
    "gene": "DSP, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fosdenopterin": {
    "gene": "MOCS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bosentan": {
    "gene": "CYP2C9, SLCO1B3, ABCB11, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "duloxetine": {
    "gene": "CYP2C9, TEX10, DRD2, IL6, HTR2C, CYP2B6, CYP2D6, ATP10A, CYP2C19, UGT1A4, ANO2, FCN2, BDNF, KMT2E, SLC6A4, HTR7, ZNF385D, HLA-A, HTR2A, MIEF2, NCAM1, TREML4, NRXN1, CYP3A4, HLA-B, INVS, CYP3A5, POLG, DRD3, CYP1A2, COMT, SKIC3",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "escitalopram": {
    "gene": "CYP2C9, KCNE1, DRD2, ABCB1, HTR1A, TSPAN5, HTR2C, TPH1, GNB3, KCNE2, HTR1B, CYP2B6, CYP2D6, IL11, CYP2C19, CYP2C18, UGT1A4, SLITRK5, ERICH3, RFK, BDNF, FKBP5, SLC6A4, HTR7, HLA-A, HTR2A, BDNF-AS, FAIM2, CYP3A4, HLA-B, GRK5, KCNH2, BMP5, RPP30, CYP3A5, POLG, CYP1A2, COMT, GLDC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "sulfonamides, urea derivatives": {
    "gene": "CYP2C9, SLC22A1, CYP2C19, SLC22A2, ABCC8, CDKAL1, TCF7L2, KCNJ11, IRS1, CYP2C8, NOS1AP, SLC47A1, KCNQ1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfamethoxazole / trimethoprim": {
    "gene": "CYP2C9, KCNE1, CYB5R3, G6PD, HLA-A, GSTM1, CYB5A, HLA-B, HLA-C, NAT2",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "gliclazide": {
    "gene": "CYP2C9, CYP2C19, G6PD, ABCC8, KCNJ11, KCNQ1",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "tenoxicam": {
    "gene": "CYP2C9",
    "advice": "The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "benzbromarone": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "prasugrel": {
    "gene": "CYP2C9, CYP2B6, CYP2C19, P2RY12, CYP3A4, CYP3A5, ABCA1, NTRK1, ZNF335, CYP1A2, PEAR1",
    "advice": "There are currently no dosing recommendations for prasugrel based on CYP2C19 genotypes.\n",
    "source": "DPWG"
  },
  "antiinflammatory agents, non-steroids": {
    "gene": "CYP2C9, IL22RA2, DRD2, CTLA4, OPRD1, HRH2, OPRM1, PTGS2, CDKN2B-AS1, MMP10, MMP1, ALOX15, BDNF, HLA-A, IL4, HTR2A, CRP, VKORC1, AGT, HLA-B, DBH, HRH1, HLA-DRB1, CYP2C8, IL10, PTGS1, HRH4, COMT, KL",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin k and analogues": {
    "gene": "CYP2C9, G6PD, CYP4F2, VKORC1, AIFM2",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "vitamin k antagonists": {
    "gene": "CYP2C9, CYP4F2, VKORC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "gliquidone": {
    "gene": "CYP2C9, ABCC8, KCNJ11",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fosphenytoin": {
    "gene": "CYP2C9, HLA-B",
    "advice": "Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (&quot;HLA-B*15:02-positive&quot;) due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin.\n",
    "source": "CPIC"
  },
  "sitagliptin": {
    "gene": "CYP2C9, IL6, WFS1, CTRB1, CDKAL1, GLP1R, GIPR, TCF7L2, KCNJ11, PRKD1, CTRB2, HLA-DRB1, DPP4, KCNQ1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "praziquantel": {
    "gene": "CYP2C9, CYP2D6, CYP2C19, CYP3A4, CYP3A5, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lumiracoxib": {
    "gene": "CYP2C9, HLA-DQA1, HLA-DQB1, HLA-DRB1",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC"
  },
  "divalproex sodium": {
    "gene": "CYP2C9, DRD2, HTR2C, CYP2B6, CYP2D6, CYP2C19, UGT1A4, SLC6A4, HLA-A, HTR2A, CYP3A4, HLA-B, CYP3A5, POLG, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ethambutol": {
    "gene": "CYP2C9, IL6, UGT1A3, CYP2B6, CYP2D6, CYP1A1, GSTT1, CYP2C19, STAT3, ALAS1, HSPA1L, NR1I2, GSTM1, CYP2E1, CYP3A4, TNF, ATP7B, FECH, UGT1A1, SLCO1B1, NAT2, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dabigatran": {
    "gene": "CYP2C9, SLC22A1, ABCB1, CYP2B6, CYP2D6, CYP2C19, CYP4F2, APOB, CES1, ABCC2, CYP3A4, CYP2C8, UGT1A1, CYP3A5, SLCO1B1, CYP2A6, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "noscapine": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydroxyphenytoin": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lornoxicam": {
    "gene": "CYP2C9",
    "advice": "The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of\nthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "fluindione": {
    "gene": "CYP2C9, CYP4F2, EPHX1, VKORC1",
    "advice": "Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.\n",
    "source": "RNPGx"
  },
  "aceclofenac": {
    "gene": "CYP2C9",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC"
  },
  "endoxifen": {
    "gene": "CYP2C9, SULT1A2, CYP2D6, CYP2C19, TCF20, SREBF2, NDUFA6, CYP3A4, SEPTIN3, CYP3A5, WBP2NL, CYP2D7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "n-desmethyltamoxifen": {
    "gene": "CYP2C9, CYP2D6, CYP2C19, SMIM45, TCF20, SREBF2, CENPM, ABCG2, CYP3A4, SEPTIN3, CYP3A5, WBP2NL",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-hydroxytamoxifen": {
    "gene": "CYP2C9, SULT1A2, CYP2D6, CYP2C19, CYP3A4, CYP3A5, WBP2NL",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dipyrone": {
    "gene": "CYP2C9, CYP2C19, NAT2",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC"
  },
  "losartan e-3174": {
    "gene": "CYP2C9, ZNF703, FBXW12, SLC17A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "7-hydroxy r-warfarin": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "7-hydroxy s-warfarin": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carboxycelecoxib": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "osimertinib": {
    "gene": "CYP2C9, IL6, ABCB1, EGFR, F5, STAT3, LZTR1, ABCG2, HLA-B, CYP2A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flibanserin": {
    "gene": "CYP2C9, CYP2D6, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "brivaracetam": {
    "gene": "CYP2C9, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lesinurad": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ar-c124910xx": {
    "gene": "CYP2C9, CYP2B6, CYP2C19, UGT2B7, CYP3A4, CYP3A5, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "uric acid": {
    "gene": "CYP2C9, PADI4, BRINP3, VEGFC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "avatrombopag": {
    "gene": "CYP2C9, ABCB1, CTLA4, F5, F2, PROC, CYP3A5, PROS1, SERPINC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "erdafitinib": {
    "gene": "CYP2C9, FGFR3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "siponimod": {
    "gene": "CYP2C9",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes or CYP2C9 intermediate metabolizer (not including *2 and *3) and to avoid siponimod for the CYP2C9 *3/*3 genotype or CYP2C9 poor metabolizer (two alleles with no/decreased enzyme activity, of which at least one other than *2 or *3).\n",
    "source": "DPWG"
  },
  "ospemifene": {
    "gene": "CYP2C9, CYP2B6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rimegepant": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "macitentan": {
    "gene": "CYP2C9, CYP3A4, CYP2C8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "abrocitinib": {
    "gene": "CYP2C9, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "selexipag": {
    "gene": "CYP2C9, CYP2C8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "apatinib": {
    "gene": "CYP2C9, KDR, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "apatinib metabolite m1-1": {
    "gene": "CYP2C9, CYP2D6, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "apatinib metabolite m1-2": {
    "gene": "CYP2C9, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "etrasimod": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "deuruxolitinib": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "seladelpar": {
    "gene": "CYP2C9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dimolegin": {
    "gene": "CYP2C9, ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amitriptyline": {
    "gene": "CYP2C9, DRD2, ABCB1, HTR2C, CYP2B6, CYP2D6, CYP2C19, UGT1A4, BDNF, SLC6A4, HLA-A, HTR2A, CYP3A4, HLA-B, CYP3A5, POLG, CYP1A2",
    "advice": "There are currently no dosing recommendations for amitriptyline based on CYP2C19 genotype.\n",
    "source": "DPWG"
  },
  "anastrozole": {
    "gene": "CYP2C9, PRKG1, ABCB1, DLGAP1, TNFSF11, MAP4K4, DLG2, TUBB1, SLC37A1, DGKI, UGT1A4, ESR2, CCDC148, FLT3, ZNF613, TNFRSF11A, PPP1R14C, CLDN11, CYP19A1, TNFRSF11B, CYP3A4, DNAH12, PGR, CSMD1, DOCK4, TCL1A, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "buprenorphine": {
    "gene": "CYP2C9, DRD2, ABCB1, CYP2B6, CYP2D6, ADRA2A, PNOC, OPRD1, OPRM1, CYP2C19, SLC6A3, OPRK1, ARRB2, SLC6A4, HTR2A, UGT2B7, SLC39A10, CYP3A4, ADAMTSL2, CYP1A2, COMT",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "buspirone": {
    "gene": "CYP2C9, DRD2, HTR2C, CYP2B6, CYP2D6, CYP2C19, UGT1A4, SLC6A4, HLA-A, HTR2A, CYP3A4, HLA-B, CYP3A5, POLG, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carbamazepine": {
    "gene": "CYP2C9, GABRB2, HNF4A, DRD2, HLA-DQA1, ABCB1, HTR2C, PSORS1C3, CYP2B6, CYP2D6, MICA, CYP1A1, CYP2C19, HLA-DQB1, UGT1A4, POU5F1, GABRG2, HSPA1L, PSORS1C1, SLC6A4, MLN, HLA-A, HTR2A, ALK, EPHX1, UGT2B7, ABCC2, NR1I2, BAG6, SCN2A, CYCSP5, CYP3A4, HLA-B, SCN1A, HLA-DRB1, RALBP1, TNF, HSPA1A, GABRA1, PRRC2A, CYP2C8, GABRA3, LTA, HLA-C, ZNRD1-AS1, CYP3A5, POLG, UGT1A6, GABRA6, CYP1A2, NR1I3",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has guidance about carbamazepine and oxcarbazepine toxicity and HLA-B*15:02 and HLA-A*31:01.\n",
    "source": "RNPGx"
  },
  "carvedilol": {
    "gene": "CYP2C9, ADRB1, PPARA, CYP2D6, CYP2C19, UGT2B7, ADRB2, GRK5, ADRA2C, UGT1A1, SLCO1B1, GRK4",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC"
  },
  "citalopram": {
    "gene": "CYP2C9, KCNE1, DRD2, ADRB1, DTNBP1, ABCB1, HTR1A, DISP1, TSPAN5, HTR2C, TPH1, NEDD4L, KCNE2, HTR1B, CYP2B6, CYP2D6, GRIK4, IL11, PAPLN, REEP5, CYP2C19, UGT1A4, SRP19, SLITRK5, ERICH3, RFK, BDNF, GSK3B, METTL21A, FKBP5, CREB1, SLC6A4, HLA-A, SERPINE1, HTR2A, BDNF-AS, FAIM2, CACNA1C, TPH2, RORA, COL26A1, ABCG1, CRHR2, HES6, HTR6, CYP3A4, HLA-B, GRK5, GRIK2, ABCB6, CYP3A5, SLC18A2, POLG, GRIA3, CYP1A2, GLDC",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "dapsone": {
    "gene": "CYP2C9, CYB5R3, G6PD, HLA-A, HLA-B, HLA-DRB1, NAT2",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "diazepam": {
    "gene": "CYP2C9, DRD2, ABCB1, HTR2C, CYP2B6, CYP2D6, CYP2C19, UGT1A4, SLC6A4, HLA-A, HTR2A, ABCG2, CYP3A4, HLA-B, CYP3A5, NAT2, POLG, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "diclofenac": {
    "gene": "CYP2C9, IL6, PLA2G4A, LST1, UGT2B7, TNFRSF11A, IL1A, ABCC2, PLCG1, TNF, CYP2C8, LTA, IL1B, UGT2B17, SLC22A7, PPARG",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC"
  },
  "doxepin": {
    "gene": "CYP2C9, CYP2D6, CYP2C19, CYP3A4, CYP1A2",
    "advice": "There are currently no dosing recommendations for doxepin based on CYP2C19 genotype.\n",
    "source": "DPWG"
  },
  "dronabinol": {
    "gene": "CYP2C9, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluconazole": {
    "gene": "CYP2C9, KCNE1, KCNE2, CYP2C19, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluoxetine": {
    "gene": "CYP2C9, DRD2, ABCB1, HTR1A, DISP1, HTR2C, TPH1, HTR1B, CYP2B6, CYP2D6, REEP5, CYP2C19, UGT1A4, SRP19, SLITRK5, BDNF, GSK3B, FKBP5, SLC6A4, HTR7, HLA-A, SERPINE1, HTR2A, FAIM2, TPH2, ABCG1, HES6, HTR6, CYP3A4, HLA-B, ABCB6, CYP3A5, SLCO1B1, POLG, PDLIM5, ACE, CYP1A2, COMT, CRHR1",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "flurbiprofen": {
    "gene": "CYP2C9, UGT2B7, UGT1A1",
    "advice": "The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of\nthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "ibuprofen": {
    "gene": "CYP2C9, IL6, UGT1A3, LST1, CYP2B6, CYP2D6, NOS2, CYP2C19, NOS1, PTGS2, UGT1A9, UGT2B4, UGT2B7, IL1A, FAAH, CYP2A7P1, CYP3A4, TNF, AMACR, CYP2C8, LTA, PTGS1, CYP3A5, IL1B, UGT2B17, COMT, NOS3",
    "advice": "There are currently no recommendations for NSAIDs dosing based on CYP2C8 genotypes.\n",
    "source": "CPIC"
  },
  "indomethacin": {
    "gene": "CYP2C9, IL6, LST1, IL1A, TFAP2B, TNF, LTA, IL1B, EPAS1",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC"
  },
  "isoniazid": {
    "gene": "CYP2C9, IL6, HLA-DQA1, ABCB1, UGT1A3, CYP2B6, CYP2D6, NOS2, CYP1A1, GSTT1, CYP2C19, HLA-DQB1, STAT3, G6PD, HSPA1L, HLA-A, XPO1, SOD2, DUX1, CES1, NR1I2, GSTM1, CYP2E1, HLA-B, TNF, HLA-DPB1, BACH1, UGT1A1, SLCO1B1, NAT2, ASTN2, MAFK, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ketoprofen": {
    "gene": "CYP2C9, CYP2D6, PTGS2, PTGS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ketorolac": {
    "gene": "CYP2C9, IL6, LST1, CYP2D6, IL1A, TNF, LTA, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lamotrigine": {
    "gene": "CYP2C9, HNF4A, SLC22A1, DRD2, ABCB1, HTR2C, CYP2B6, CYP2D6, CYP2C19, HLA-DQB1, UGT1A4, SLC6A4, HLA-A, HTR2A, UGT2B7, ABCC2, CACNA1H, NR1I2, ABCG2, SCN2A, CYP3A4, HLA-B, SCN1A, HLA-DRB1, UGT2B15, GABRA1, GABRA3, HLA-C, CYP3A5, POLG, CYP1A2",
    "advice": "Avoid lamotrigine in patients with HLA-B*15:02 if an alternative is available. If avoidance is not possible, advise to report any rash immediately.\n",
    "source": "DPWG"
  },
  "losartan": {
    "gene": "CYP2C9, ABCB1, ZNF703, STK39, CAMK1D, FBXW12, NPHS1, UGT2B7, AGT, CYP3A4, AGTR1, UGT1A1, KIRREL2, SLC17A4, SLC22A12, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "meloxicam": {
    "gene": "CYP2C9, CYB5R3, G6PD",
    "advice": "The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "mirtazapine": {
    "gene": "CYP2C9, DRD2, HTR2C, SH2B1, CYP2B6, CYP2D6, CYP2C19, UGT1A4, BDNF, FKBP5, GAL, SLC6A4, HLA-A, HTR2A, TPH2, CYP3A4, HLA-B, CYP3A5, POLG, CYP1A2, RABEP1",
    "advice": "There are currently no dosing recommendations for mirtazapine based on CYP2C19 genotypes.\n",
    "source": "DPWG"
  },
  "modafinil": {
    "gene": "CYP2C9, DRD2, ABCB1, HTR2C, CYP2B6, CYP2D6, OPRM1, CYP2C19, UGT1A4, BDNF, SLC6A4, HLA-A, HTR2A, CYP3A4, HLA-B, CYP3A5, POLG, CYP1A2, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nabumetone": {
    "gene": "CYP2C9",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC"
  },
  "naproxen": {
    "gene": "CYP2C9, IL6, ABCB1, LST1, IL1A, TNF, LTA, IL1B",
    "advice": "There are currently no recommendations for dosing of aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen based on CYP2C9 genotypes.\n",
    "source": "CPIC"
  },
  "nateglinide": {
    "gene": "CYP2C9, CYP3A4, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nevirapine": {
    "gene": "CYP2C9, SLC22A1, ABCB1, CYP2B6, CYP2D6, CYP2B7P1, GSTT1, CYP2C19, HLA-DQB1, PSORS1C1, TCF19, HLA-A, NR1I2, CCHCR1, CYCSP5, GSTM1, SLCO3A1, POLR3G, CYP3A4, HLA-B, HCP5, HLA-DRB1, HLA-C, CYP3A5, NAT2, CYP2A6, ABCC10, TRAF3IP2, CYP1A2, NR1I3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nortriptyline": {
    "gene": "CYP2C9, KCNE1, DRD2, ABCB1, HTR2C, GNB3, CYP2B6, CYP2D6, ADRA2A, OPRM1, CYP2C19, UGT1A4, BDNF, SLC6A4, HTR7, HLA-A, HTR2A, UST, PPM1A, CYP3A4, HLA-B, SLC39A14, CYP3A5, POLG, CYP1A2, NOS3",
    "advice": "The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "paroxetine": {
    "gene": "CYP2C9, DRD2, ABCB1, HTR1A, GDNF, DISP1, HTR2C, TPH1, HTR1B, CYP2B6, CYP2D6, REEP5, CYP2C19, UGT1A4, SRP19, SLITRK5, BDNF, FKBP5, SLC6A4, HTR7, HLA-A, HTR2A, FAIM2, TPH2, ABCG1, MDGA2, HES6, HTR6, CYP3A4, HLA-B, ADM, HTR3A, ABCB6, RPP30, CYP3A5, POLG, DRD3, HTR3B, CYP1A2, COMT",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "phenprocoumon": {
    "gene": "CYP2C9, STX4, PPARA, CYP2C19, CYP4F2, EPHX1, VKORC1, GATA4, CYP3A4, CALU, PROC, CYP3A5, F7, GGCX",
    "advice": "There are currently no recommendations for phenprocoumon dosing based on CYP2C9 genotypes.\n",
    "source": "DPWG"
  },
  "pioglitazone": {
    "gene": "CYP2C9, CYP2D6, G6PD, PTPRD, CYP2C8, CYP3A5, SLCO1B1, ADIPOQ, LPL, PPARG",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "piroxicam": {
    "gene": "CYP2C9, CYP2C8",
    "advice": "The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "primidone": {
    "gene": "CYP2C9, CYP2D6, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "progesterone": {
    "gene": "CYP2C9, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pyrazinamide": {
    "gene": "CYP2C9, IL6, HLA-DQA1, ABCB1, AOX1, UGT1A3, CYP2B6, CYP2D6, CYP1A1, GSTT1, CYP2C19, HLA-DQB1, STAT3, HSPA1L, GSTM1, CYP2E1, TNF, UGT1A1, SLCO1B1, NAT2, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rifampin": {
    "gene": "CYP2C9, IL6, HLA-DQA1, ABCB1, UGT1A3, CYP2B6, CYP2D6, NOS2, CYP1A1, GSTT1, CYP2C19, HLA-DQB1, STAT3, AADAC, HSPA1L, CUX2, CYP27B1, HLA-A, XPO1, RIPOR2, DUX1, NR1I2, GSTM1, CYP2E1, VDR, CYP3A4, AGBL4, TNF, HLA-DPB1, BACH1, UGT1A1, SLCO1B1, NAT2, MAFK, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sertraline": {
    "gene": "CYP2C9, DRD2, ABCB1, HTR1A, DISP1, HTR2C, GNB3, HTR1B, CYP2B6, CYP2D6, REEP5, CYP2C19, CYP2C18, UGT1A4, SRP19, SLITRK5, P3H3, BDNF, SLC6A4, HLA-A, HTR2A, BDNF-AS, FAIM2, ABCG1, CYP3A4, HLA-B, ABCB6, CYP3A5, POLG, DRD3, ACE, CYP1A2",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "sildenafil": {
    "gene": "CYP2C9, GNB3, ARG1, VEGFA, ARG2, CYP3A4, CYP3A5, ACE, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfamethoxazole": {
    "gene": "CYP2C9, GCLC, G6PD, HLA-B, NAT2",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "tamoxifen": {
    "gene": "CYP2C9, SULT1A1, HLA-DQA1, ZNF423, LPP, ABCB1, IGF1, CYP2B6, CYP2D6, C1QTNF6, LRMDA, F5, NCOA1, CYP2C19, HLA-DQB1, UGT1A4, ESR2, ZNF613, FMO3, FMO1, UGT2B7, ABCC2, E2F7, IRS1, HS6ST3, CYP19A1, IGF1R, CYP3A4, SLCO1A2, PGR, RRAS2, HLA-DRB1, F2, UGT2B15, CCNA2, CYP3A5, SLCO2B1, SLCO1B1, IGFBP3, WBP2NL, CYP1A2, ESR1",
    "advice": "The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that there is no recommendation\nfor genotyping CYP2D6 in all patients starting a tamoxifen regimen.\n",
    "source": "RNPGx"
  },
  "tolbutamide": {
    "gene": "CYP2C9, CYP2C19, G6PD, KCNJ11",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "trazodone": {
    "gene": "CYP2C9, DRD2, ABCB1, HTR2C, CYP2B6, CYP2D6, CYP2C19, UGT1A4, SLC6A4, HLA-A, HTR2A, CYP3A4, HLA-B, CYP3A5, POLG, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trimipramine": {
    "gene": "CYP2C9, ABCB1, CYP2D6, CYP2C19",
    "advice": "Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "venlafaxine": {
    "gene": "CYP2C9, KCNE1, DRD2, ABCB1, HTR1A, HTR2C, TPH1, HTR1B, CYP2B6, CYP2D6, GRIK4, OPRM1, CYP2C19, UGT1A4, BDNF, SLC6A3, FKBP5, SLC6A4, HTR7, HLA-A, HTR2A, GABRP, TPH2, CYP3A4, HLA-B, SLC6A2, CYP3A5, GABRQ, POLG, GRIA3, GABRA6, CYP1A2, COMT",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "zafirlukast": {
    "gene": "CYP2C9, CYSLTR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hormonal contraceptives for systemic use": {
    "gene": "CYP2C9, SUGCT, MTHFR, FGG, F5, PROCR, F2, F11, KNG1, ABO",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "arsenic trioxide": {
    "gene": "MT1A, PML, AS3MT, RARA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desloratadine": {
    "gene": "HDC, ORAI1, HRH1, FCER1A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "phenobarbital": {
    "gene": "GABRB2, ABCB1, MTHFR, CYP1A1, CYP2C19, UGT1A9, GABRG2, HLA-A, SCN2A, HLA-B, HLA-DRB1, UGT2B15, GABRA1, UGT1A6, GABRA6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "corticosteroids for systemic use": {
    "gene": "HDAC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "o-desmethyltramadol": {
    "gene": "HCN1, SLC22A1, ABCB1, CYP2D6, ICA1, UGT1A8, RFPL4B, ABCC2, RGL4, SULT1A3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tramadol": {
    "gene": "HCN1, SLC22A1, ABCB1, CYP2B6, CYP2D6, OPRD1, ICA1, OPRM1, ARRB2, RFPL4B, UGT2B7, CYP2A7P1, CYP3A4, CYP1B1, SEPTIN3, CYP3A5, WBP2NL, RGL4, SULT1A3, COMT",
    "advice": "Alternate non-codeine analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific dose of tramadol is warranted for CYP2D6 normal and intermediate metabolizers.\n",
    "source": "CPIC"
  },
  "qt-prolonging drugs": {
    "gene": "KCNE1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dronedarone": {
    "gene": "KCNE1, KCNE2, CYP2D6, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "papaverine": {
    "gene": "KCNE1, KCNE2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cilostazol": {
    "gene": "KCNE1, KCNE2, CYP2C19, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydroxychloroquine": {
    "gene": "KCNE1, KCNE2, CYP2D6, MTHFR, ATIC, HLA-DQB1, G6PD, SHMT1, HLA-A, SLC19A1, MTR, CYP3A4, C18orf56, DHFR, HLA-B, HLA-DRB1, CYP2C8, HLA-C, CYP3A5, TYMS",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "amiodarone": {
    "gene": "KCNE1, KCNE2, CYP2D6, CACNA1C, CYP3A4, HLA-DRB1, KCNH2, NOS1AP",
    "advice": "There are currently no dosing recommendations for amiodarone based on CYP2D6 genotype.\n",
    "source": "DPWG"
  },
  "azithromycin": {
    "gene": "KCNE1, ABCB1, KCNE2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chlorpromazine": {
    "gene": "KCNE1, DRD2, KCNE2, MTHFR, EPM2A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ciprofloxacin": {
    "gene": "KCNE1, KCNE2, CYP2D6, G6PD, UGT2B7, HLA-B, CYP1A2",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "clarithromycin": {
    "gene": "KCNE1, KCNE2, CYP2C19, VDR, CYP3A4, KCNH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dofetilide": {
    "gene": "KCNE1, KCNE2, KCNH2, C18orf21",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "erythromycin": {
    "gene": "KCNE1, ABCB1, KCNE2, ABCC2, CYP3A4, CYP3A5, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flecainide": {
    "gene": "KCNE1, ADRB1, KCNE2, CYP2D6, SCN4A, CYP3A5, CYP1A2",
    "advice": "Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.\n",
    "source": "DPWG"
  },
  "hydroxyzine": {
    "gene": "KCNE1, KCNH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levofloxacin": {
    "gene": "KCNE1, ABCB1, KCNE2, ABCG2, HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "metoclopramide": {
    "gene": "KCNE1, CYB5R3, CYP2D6, CYB5R4, G6PD, CYB5R2, CYB5R1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "moxifloxacin": {
    "gene": "KCNE1, ABCB1, KCNE2, G6PD, HLA-B, UGT1A1, SLCO1B1",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "pentamidine": {
    "gene": "KCNE1, KCNE2, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "procainamide": {
    "gene": "KCNE1, KCNE2, NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "prochlorperazine": {
    "gene": "KCNE1, DRD2, CYP2D6, OPRM1, ANKK1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "promethazine": {
    "gene": "KCNE1, CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "quinidine": {
    "gene": "KCNE1, KCNE2, CYP2D6, CACNA1C, CYP3A4, KCNH2, C18orf21",
    "advice": "There are currently no dosing recommendations for quinidine based on CYP2D6 genotypes.\n",
    "source": "DPWG"
  },
  "sotalol": {
    "gene": "KCNE1, ADRB1, KCNE2, CYP2D6, CACNA1C, ADRB2, GRK5, ADRA2C, C18orf21, NOS1AP, GRK4",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC"
  },
  "tizanidine": {
    "gene": "KCNE1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trifluoperazine": {
    "gene": "KCNE1, EPM2A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antiarrhythmics, class i and iii": {
    "gene": "KCNE1, KCNH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "abt-751": {
    "gene": "SULT1A2, SULT1A1, UGT1A4, UGT1A8, UGT2B7, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "brostallicin": {
    "gene": "GSTA1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "prednisone": {
    "gene": "GSTA1, RAPGEF5, MIR146A, ABCB1, CTLA4, NR3C1, CYBA, GATA3, CYP1A1, ASNS, TNRC6B, BMP7, MIR423, MIR577, CXCL12, TPMT, MIR449B, XRCC1, NFATC1, GEMIN4, MIR2053, CCHCR1, XPO5, SLC19A1, ATF5, C18orf56, RFXAP, MIR1206, MIR1307, EDNRA, MIR3117, TNRC6A, MIR4268, MIR604, AGO1, DOK5, LINC00251, MIR492, MIR300, CYP3A5, C5orf22, DDX20, MIR618, TYMS, CNOT1, GSTP1, DROSHA, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rituximab": {
    "gene": "GSTA1, IL6, TNFRSF10A, STAT4, ABCB1, CTLA4, CYBA, TGFB1, NOS1, TNFAIP3, FCGR3A, CXCL13, TNFRSF1B, CXCL12, MS4A1, PTPN22, ABCC2, ABCG2, TRAF1, TNFSF10, HLA-B, TNF, CIDEA, FCGR2A, LTA, IL10, IL2, SLC35F4, NCF4, CBR3, OXNAD1, TNIP3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cladribine": {
    "gene": "NT5C1A, RRM2B, RRM2, RRM1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bortezomib": {
    "gene": "PKNOX1, CTLA4, CBS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fenoterol": {
    "gene": "SLC22A1, ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tropisetron": {
    "gene": "SLC22A1, CYP2D6",
    "advice": "The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "anticholinergics": {
    "gene": "SLC22A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antiemetics and antinauseants": {
    "gene": "SLC22A1, SLC6A3, SDK1, HTR3A, HTR3B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dopamine agonists": {
    "gene": "SLC22A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "olmesartan": {
    "gene": "SLC22A1, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rasagiline": {
    "gene": "SLC22A1, DRD2, ABCB1, ABCC2, CYP1A2, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cycloguanil": {
    "gene": "SLC22A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "berberine": {
    "gene": "SLC22A1, CYP2D6, SLC6A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nilotinib": {
    "gene": "SLC22A1, ABCB1, CYP1A1, BCR, ABCG2, CYP3A4, UGT1A1, ABL1, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "n-desmethyltramadol": {
    "gene": "SLC22A1, CYP2D6, UGT1A8, ABCC2, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amantadine": {
    "gene": "SLC22A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "codeine": {
    "gene": "SLC22A1, ABCB1, CYP2D6, OPRM1, UGT2B7, CYP1B1, SEPTIN3, WBP2NL, COMT",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "levodopa": {
    "gene": "SLC22A1, DRD2, DRD1, MAOB, G6PD, SLC6A3, ADORA2A, HOMER1, DBH, DRD3, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lopinavir": {
    "gene": "SLC22A1, ABCB1, CYP2B6, ABCC2, CYP3A4, SLC22A6, CYP3A5, SLCO1B1, ABCC1, ZSCAN25",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "naratriptan": {
    "gene": "SLC22A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "proguanil": {
    "gene": "SLC22A1, CYP2C19, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rizatriptan": {
    "gene": "SLC22A1, DRD2, IL6, HTR1B, MAOA, SLC6A4, GRIA1, IL1A, TNF, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "selegiline": {
    "gene": "SLC22A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sumatriptan": {
    "gene": "SLC22A1, DRD2, IL6, GNB3, HTR1B, OPRM1, BDNF, HTR2A, GRIA1, IL1A, DBH, TNF, IL1B, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zolmitriptan": {
    "gene": "SLC22A1, IL6, GRIA1, IL1A, TNF, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nemonapride": {
    "gene": "DRD2, ANKK1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "analgesics": {
    "gene": "DRD2, OPRM1, BDNF, KCNJ6, HTR2A, DBH, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ergot alkaloids": {
    "gene": "DRD2, OPRM1, BDNF, HTR2A, DBH, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "botulinum toxin type a": {
    "gene": "DRD2, WFS1, KCNS1, HTR2C, P2RX7, SCN9A, MEF2D, TRPV3, CALCA, TRPM8, SLC1A2, GABRE, GRIK3, LRP1, GABRA3, TRPV1, GABRQ",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bromperidol": {
    "gene": "DRD2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amphetamine": {
    "gene": "DRD2, CYP2D6, OPRM1, SLC6A3, KAT2B, CDH13",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "caffeine": {
    "gene": "DRD2, RYR1, AHR, CYP1A1, SPECC1L, ADORA2A, CYP2E1, ACTR3B, CYP3A4, ADORA1, CACNA1S, NAT2, CYP2A6, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "disulfiram": {
    "gene": "DRD2, ADRA1A, MTHFR, OPRD1, SLC6A3, SLC6A4, TPH2, ANKK1, DBH, ALDH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methamphetamine": {
    "gene": "DRD2, DTNBP1, HTR1A, CYP2D6, OPRM1, NRG1, BDNF, SLC6A9, ARRB2, ANKS1B, GRIN1, AKT1, DAOA, ANKK1, FAAH, DRD4, CSNK1E, PICK1, DRD3, GAD2, COMT, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "naltrexone": {
    "gene": "DRD2, OPRD1, GRIK1-AS2, OPRM1, GRIK1, ADH1B, OPRK1, ANKK1, DBH, AKR1C4, COMT, ADH1C, ALDH2",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "oxycodone": {
    "gene": "DRD2, ABCB1, CYP2D6, OPRD1, OPRM1, CYP2C19, OPRK1, KCNJ6, RHBDF2, UGT2B7, FAAH, MACROD2, CYP3A4, SEPTIN3, CYP3A5, WBP2NL, COMT",
    "advice": "There are currently no recommendations for dosing of methadone or oxycodone based on CYP2D6, OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "perphenazine": {
    "gene": "DRD2, RGS4, CYP2D6, MCPH1, RELN, PRKCE, MAML3, CDH13, SKOR2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "opioids": {
    "gene": "DRD2, IL6, ABCB1, HTR1A, GNAZ, GNB3, STAT6, CYP2B6, CYP2D6, HTR3E, ADRA2A, OPRD1, PDYN, PDE3A, OPRM1, CYP2C19, CLCC1, SCN9A, BDNF, TXNRD2, TNFRSF1B, OPRK1, GAL, KCNJ6, ARRB2, RSPH14, ENPP2, TACR3, ZNF165, GPR98, HNF1A, MUC16, MCOLN1, RHBDF2, HTR2A, BDNF-AS, CNIH3, UGT2B7, TGFB2, EXOC4, CNR1, ZNF804A, KAT2B, HTR3D, RGS19, ANKK1, GCH1, TACR1, CRYBG2, FAAH, CYP2A7P1, CYP3A4, SLCO1A2, TH, TLR5, DBH, HRH1, GABRB3, HINT1, TNF, MC1R, HTR3A, POM121L2, OPRL1, HTR4, GABBR2, HTR3C, IL2, CYP3A5, IL1B, TAOK3, SLCO1B1, SLC18A2, IL17A, GRK3, ZNF568, DRD3, HTR3B, LKAAEAR1, CYP1A2, ZSCAN25, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "heroin": {
    "gene": "DRD2, GRM3, OPRD1, OPRM1, BDNF, SLC6A3, OPRK1, GAL, ANKS1B, DDC, BDNF-AS, SOD2, CES1, ANKK1, XPC, TH, DBH, CSNK1E, DRD3, HTR3B, ALDH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "telbivudine": {
    "gene": "RRM2B, TK2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ranibizumab": {
    "gene": "SCARB1, BAD, KDR, SYN3, FHIT, LRP5, C2, MAPK14, C3, ANO2, CCT3, ARMS2, FZD4, HTRA1, CFI, VEGFA, INHBA, APOE, SERPINF1, SKIC2, RGS5, CFB, IL8, YBX1, NRP1, FLT1, CFH, EPAS1, CRHR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "beta blocking agents": {
    "gene": "CSK, ADRB1, ZNF652, GNB3, PPARA, CYP2D6, MTHFR, CLCN6, USP5, SH2B3, PLCD3, ADRB2, PRKCA, GRK5, ACBD4, ADRA2C, CYP4A11, ACE, CABCOCO1, KL, NOS3, FGF5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "diltiazem": {
    "gene": "CSK, ADRB1, NEDD4L, ZNF652, MTHFR, CLCN6, SH2B3, PLCD3, SLCO1B1, CABCOCO1, FGF5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "repaglinide": {
    "gene": "PAX4, NEUROD1, SLC30A8, NR1I2, TCF7L2, KCNJ11, IGF2BP2, CYP3A4, CYP2C8, NOS1AP, SLCO1B1, KCNQ1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "exemestane": {
    "gene": "PRKG1, AKR7A2, DLGAP1, MAP4K4, CYP1A1, TUBB1, SLC37A1, DGKI, ESR2, CCDC148, AKR1C3, FLT3, PPP1R14C, CYP19A1, CYP3A4, DNAH12, PGR, DOCK4, AKR1C4, CYP1B1, CYP4A11, UGT2B17, TCL1A, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "abacavir": {
    "gene": "LSM2, LST1, LTB, HLA-DQB1, ADH1B, ADK, DDX39B, HSPA1L, HLA-B, HCP5, HLA-DRB1, TNF, HSPA1A, LTA, ADH1A, ADH1C",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has established national guidelines and requires mandatory HLA testing prior to prescribing abacavir and abacavir is contraindicated in patients where the HLA-B*57:01 is present.\n",
    "source": "RNPGx"
  },
  "antidepressants": {
    "gene": "RAPGEF5, NBEA, ABCB1, HTR1A, FHIT, TPH1, NR3C1, GNB3, CYP2D6, GRIK4, CTNNA3, TGFBR3, OPRM1, CYP2C19, ERICH3, BDNF, METTL21A, MAPK1, FKBP5, GAL, CUX1, MAOA, MTRF1L, NGFR, CREB1, SLC6A4, HTR7, SERPINE1, HTR2A, BDNF-AS, ADCY9, GABRP, PON2, TPH2, NAV2, CRH, RGS17, HTR6, SLC6A2, SLC22A3, ACSS3, RPP30, CHL1, GRIA3, GABRA6, NTRK2, ACE, CYP1A2, CACNA1A, COMT, CRHR1, PARP11",
    "advice": "The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends CYP2D6 and CYP2C19 genotyping before initiating an antidepressant treatment, especially in patients with a high risk of toxicity.\n",
    "source": "RNPGx"
  },
  "almotriptan": {
    "gene": "IL6, GRIA1, IL1A, TNF, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eletriptan": {
    "gene": "IL6, CYP2D6, GRIA1, IL1A, TNF, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dipeptidyl peptidase 4 (dpp-4) inhibitors": {
    "gene": "IL6, HLA-DQA1, ABCB1, HLA-DQB1, PNPLA3, CTRB1, CDKAL1, GLP1R, TCF7L2, KCNJ11, PRKD1, CTRB2, NAT2, DPP4, KCNQ1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tumor necrosis factor alpha (tnf-alpha) inhibitors": {
    "gene": "IL6, IL18, HLA-DQA1, IL2RB, FCGR2B, TAP1, TNFRSF10A, STAT4, PGLYRP4, REL, CTLA4, TLR9, IL9, MAFB, LY96, CST5, MICA, PON1, ALPL, CTNNA2, CCL21, MAP3K1, CD14, TAGAP, IL23R, IL12B, TNFAIP3, FCGR3A, IL1RN, IL5, EYA4, IFNGR2, TNFRSF1B, IL6R, BLK, CD40, KLRC4, SLC12A8, MOB3B, CERS6, IFNGR1, TLR2, CDKAL1, SLCO1C1, PTPN22, PADI4, CSRP3, C9orf72, PTPRC, TRAF1, FBXL19, NLRP3, ZNF816, SH3BP2, TLR4, TLR5, NCR3, GBP6, TNF, CD28, FCGR2A, IL17RA, PRKCQ, HLA-C, IL2RA, CNPY4, GAPDHP64, IL2, PRDM1, IL1B, CNTN5, CHUK, IL17A, TNFRSF1A, ARAP2, IFNG, TBX21, JAK2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "frovatriptan": {
    "gene": "IL6, GRIA1, IL1A, TNF, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tocilizumab": {
    "gene": "IL6, FCGR3A, IL6R, GALNT18, KCNMB1, CD69, CLEC2D, HLA-DRB1, FCGR2A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vildagliptin": {
    "gene": "IL6, WFS1, CTRB1, GLP1R, GIPR, TCF7L2, KCNJ11, PRKD1, CTRB2, DPP4, KCNQ1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "teneligliptin": {
    "gene": "IL6, FMO3, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "linagliptin": {
    "gene": "IL6, WFS1, GLP1R, TCF7L2, KCNJ11, PRKD1, DPP4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alogliptin": {
    "gene": "IL6, PNPLA3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "etanercept": {
    "gene": "IL6, IL2RB, FCGR2B, TNFRSF10A, STAT4, REV3L, REL, CTLA4, TLR9, TGFB1, MACO1, ALPL, CCL21, MAP3K1, TAGAP, IL23R, CR1L, PTTG1, HLA-E, IL12B, TNFAIP3, FCGR3A, ERAP1, KLRC1, EYA4, TNFRSF1B, IL6R, RSRP1, BLK, CD40, PSORS1C1, IL17F, CERS6, SLCO1C1, PTPN22, NFKBIA, PTPRC, PTPN2, KLRD1, ATP5F1E, TRAF1, NLRP3, NFKB1, ZNF816, VDR, SH3BP2, CR1, HLA-B, NCR3, GBP6, HLA-DRB1, NFATC2, TNF, KCNH7, CD28, FCGR2A, LTA, PRKCQ, IL10, IL2RA, GAPDHP64, IL2, PRDM1, TNFRSF1A, CARD8, TRAF3IP2, CD84",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "streptomycin": {
    "gene": "IL6, MT-RNR1, CYP1A1, GSTT1, STAT3, G6PD, HSPA1L, GSTM1, CYP2E1, NAT2, GSTP1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "infliximab": {
    "gene": "IL6, HLA-DQA1, IL2RB, FCGR2B, TNFRSF10A, STAT4, REL, CTLA4, TLR9, TGFB1, MACO1, ALPL, CCL21, TAGAP, IL23R, CR1L, HLA-E, IL12B, HLA-DQB1, FCGR3A, KLRC1, EYA4, TNFRSF1B, IL6R, RSRP1, BLK, CD40, IL17F, CERS6, TLR2, SLCO1C1, MAP3K14, PTPN22, NFKBIA, PTPRC, KLRD1, ATP5F1E, TRAF1, NLRP3, ZNF816, VDR, SH3BP2, CR1, HLA-B, TLR4, NCR3, HLA-DRB1, NFATC2, TNF, HLA-DPB1, CD28, FCGR2A, ADAM17, LTA, PRKCQ, HLA-C, IL2RA, GAPDHP64, IL2, PRDM1, IL1B, TNFRSF1A, CARD8, SLC9A8, IVL",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rasburicase": {
    "gene": "CYB5R3, CYB5R4, G6PD, CYB5R2, CYB5R1",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "bupivacaine": {
    "gene": "CYB5R3, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sodium nitrite": {
    "gene": "CYB5R3, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lidocaine / prilocaine": {
    "gene": "CYB5R3, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lidocaine and tetracaine": {
    "gene": "CYB5R3, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "articaine / epinephrine": {
    "gene": "CYB5R3, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "oxymetazoline and tetracaine": {
    "gene": "CYB5R3, G6PD, BCHE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ceftriaxone": {
    "gene": "CYB5R3, ABCB1, G6PD, HLA-A, ABCC2, ABCG2, ABCB11, SLCO1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chloroprocaine": {
    "gene": "CYB5R3, G6PD, BCHE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "isosorbide dinitrate": {
    "gene": "CYB5R3, CYB5R4, CYB5R2, CYB5R1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "isosorbide mononitrate": {
    "gene": "CYB5R3, CYB5R4, CYB5R2, CYB5R1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "primaquine": {
    "gene": "CYB5R3, CYP2D6, CYB5R4, G6PD, CYB5R2, MAOA, SLCO2B1, CYB5R1, IKBKG",
    "advice": "Primaquine should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA) in most cases, with some exceptions for G6PD deficient patients without CNSHA. In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "ropivacaine": {
    "gene": "CYB5R3, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "regadenoson": {
    "gene": "AMPD1, ADORA2A, ADORA2A-AS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "folic acid": {
    "gene": "AMPD1, ABCB1, ITPA, MTHFR, MTHFD1, ATIC, MTRR, SHMT1, SLC19A1, MTR, C18orf56, DHFR, TLR4, TYMS",
    "advice": "There are currently no recommendations for folic acid dosing based on MTHFR rs1801133 genotypes.\n",
    "source": "DPWG"
  },
  "conjugated estrogens": {
    "gene": "SULT1A1, VDR, SLCO1B1, ABCC1, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desmethylnaproxen": {
    "gene": "SULT1A1, NPIPB8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tapentadol": {
    "gene": "SULT1A1, OPRM1, NPIPB8, SULT1A3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "interferon alfa-2a, recombinant": {
    "gene": "IL18, TLR7, IDO1, IFNL4, HLA-B, FTO, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "interferon alfa-2b, recombinant": {
    "gene": "IL18, ITPA, IFNL4, FTO, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "interferons": {
    "gene": "IL18, STAT3, BCL2, IFNL4, VDR, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "catecholamines": {
    "gene": "ADRB1, SLC22A3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nebivolol": {
    "gene": "ADRB1, CYP2D6, CYP2C19, GRK5, ADRA2C, GRK4",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC"
  },
  "angiotensin ii antagonists": {
    "gene": "ADRB1, CYP2D6, F5, ADRB2, PRKCA, ADRA2C, CYP4A11, MMP16, ACE, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "beta blocking agents, non-selective": {
    "gene": "ADRB1, ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "beta blocking agents, selective": {
    "gene": "ADRB1, NEDD4L, BST1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "labetalol": {
    "gene": "ADRB1, ABCB1, CYP2D6, CYP2C19, UGT2B7, ADRB2, GRK5, ADRA2C, UGT1A1, GRK4",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC"
  },
  "bucindolol": {
    "gene": "ADRB1, ADRA2C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acebutolol": {
    "gene": "ADRB1, CYP2D6, GRK5, ADRA2C, GRK4",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC"
  },
  "betaxolol": {
    "gene": "ADRB1, CYP2D6, GRK5, ADRA2C, GRK4",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC"
  },
  "bisoprolol": {
    "gene": "ADRB1, CYP2D6, GRK5, KCNH2, ACY3, ADRA2C, CYP3A5, GRK4",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC"
  },
  "digoxin": {
    "gene": "ADRB1, ABCB1, ADRB2, ADRA2C, NOS1AP, CYP4A11, ACE, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dobutamine": {
    "gene": "ADRB1, GNAS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "esmolol": {
    "gene": "ADRB1, GRK5, ADRA2C, GRK4",
    "advice": "There are currently no recommendations for dosing of orally administered beta-blockers based on ADRB1, ADRA2C, GRK4 and/or GRK5 genotypes.\n",
    "source": "CPIC"
  },
  "isoproterenol": {
    "gene": "ADRB1, ADRA1A, ADRA2A, ADRA1B, ADRA2B, ADRB2, ADRA2C, ADRA1D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nadolol": {
    "gene": "ADRB1, SLCO1A2, ADRB2, GRK5, ADRA2C, SLCO2B1, GRK4",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC"
  },
  "pindolol": {
    "gene": "ADRB1, CYP2D6, SLC6A4, ADRB2, GRK5, ADRA2C, GRK4",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC"
  },
  "propranolol": {
    "gene": "ADRB1, ABCB1, HTR1B, CYP2D6, CYP2C19, ADRB2, GRK5, ADRA2C, CYP1A2, COMT, GRK4",
    "advice": "There are currently no recommendations for dosing of carvedilol, labetalol, nadolol, pindolol, propranolol or sotalol based on ADRB2 genotypes.\n",
    "source": "CPIC"
  },
  "spironolactone": {
    "gene": "ADRB1, CYP11B2, ADD1, ADRB2, ADRA2C, CYP4A11, ACE, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sufentanil": {
    "gene": "ADRB1, ABCB1, REL, CYP2D6, OPRM1, IL1RN, IL1A, NFKBIA, NFKB1, CYP3A4, TNF, IL8, IL10, CYP3A5, IL1B, COMT",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "timolol": {
    "gene": "ADRB1, CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "verapamil": {
    "gene": "ADRB1, ABCB1, PCDHB8, ITGAL, PTPRD, NR1H3, PLEKHH2, CACNA1C, KCNMB1, ADD1, CYP3A4, CACNB2, GRK5, KCNIP1, PCDHB6, NOS1AP, CYP3A5, ACE, GRK4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "measles vaccines": {
    "gene": "HLA-DQA1, HLA-B, HLA-DRB1, TLR3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flucloxacillin": {
    "gene": "HLA-DQA1, HLA-DQB1, HLA-A, NR1I2, HLA-DRA, HLA-B, HLA-DRB1, HLA-C, ST6GAL1",
    "advice": "Monitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*57:01.\n",
    "source": "DPWG"
  },
  "ustekinumab": {
    "gene": "HLA-DQA1, STAT4, REV3L, IL23R, IL12B, TNFAIP3, ERAP1, TNFRSF1B, IL12A, IL17F, SLC22A4, HTR2A, NFKBIA, C9orf72, IL13, IL23A, ZNF816, TLR5, AGBL4, ADAM33, KCNH7, HLA-C, IL1B, CHUK, TIRAP, CD84",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mepolizumab": {
    "gene": "HLA-DQA1, FIP1L1, PDGFRA, ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "letrozole": {
    "gene": "HLA-DQA1, TNFSF11, ESR2, CCDC148, ZNF613, TNFRSF11A, PPP1R14C, CYP19A1, TNFRSF11B, PGR, CYP2A6, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "abiraterone": {
    "gene": "TSPYL1, CYP17A1, AKR1C3, DSE, SRD5A2, YBX1, SLCO2B1, HSD3B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "raloxifene": {
    "gene": "ZNF423, CYP2D6, ESR2, UGT1A8, VDR, UGT1A1, COMT, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lenalidomide": {
    "gene": "KDR, ABCB1, FGF2, VEGFA, CTNNB1, NCF4, CRBN, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "brivanib": {
    "gene": "KDR, FGFR3P1, FGFR3, FGFR1, FGFR4, FGFR1OP2, FGFR2, FGFRL1, CEP43",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "regorafenib": {
    "gene": "KDR, KRAS, CYP3A4, HLA-B, HLA-C, RORC, IL12RB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "motesanib": {
    "gene": "KDR, FLT1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vandetanib": {
    "gene": "KDR, CYP3A4, RET",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carfilzomib": {
    "gene": "KDR, VEGFA, TMSB10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "anlotinib": {
    "gene": "KDR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pranlukast": {
    "gene": "CYSLTR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "montelukast": {
    "gene": "CYSLTR1, UGT1A3, LTA4H, LTC4S, CA10, ABCC9, GALNT17, ALOX5, ADRB2, CYP2C8, SLCO2B1, MLLT3, ABCC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levothyroxine": {
    "gene": "DIO1, TBL1X, NOX3, PAX8, MROH2A, DIO2, UGT1A, SLCO1B1, IRS4, TSHB, NKX2-5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "atorvastatin lactone": {
    "gene": "LPP, CYP3A4, UGT1A1, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "2-hydroxyatorvastatin": {
    "gene": "LPP, UGT1A3, NR3C1, PPARA, CYP3A4, PGRMC2, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-hydroxyatorvastatin": {
    "gene": "LPP, UGT1A3, SLCO2B1, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methotrexate polyglutamate": {
    "gene": "FSTL5, CEP72, ATG16L1, SLCO1B3, IMPDH1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pirtobrutinib": {
    "gene": "IGH, BTK, TP53",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "curcumin": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "genistein": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "roflumilast": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ivacaftor": {
    "gene": "CFTR, HTR2C, SLC26A9",
    "advice": "Ivacaftor is suggested for some cystic fibrosis patients with specific CFTR gating mutations, including the R117H or G551D variants.\nNote that the guideline also suggests that ivacaftor should not be used in patients with at least one R117H mutation who are aged under 6 years or aged 12-17 years and with ppFEV1 greater than 90% predicted.\n",
    "source": "CFF"
  },
  "lumacaftor": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ataluren": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ivacaftor / lumacaftor": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "latonduine a": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "corr-4a": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nppb": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cavosonstat": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tezacaftor": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ivacaftor / tezacaftor": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "elexacaftor": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "elexacaftor / tezacaftor / ivacaftor": {
    "gene": "CFTR, SERPINA1, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vanzacaftor / tezacaftor / deutivacaftor": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cysteamine": {
    "gene": "CFTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "asparaginase": {
    "gene": "MIR146A, GATA3, MYBBP1A, MTHFR, CYP1A1, F5, ASNS, TNRC6B, CPA2, MIR423, MIR577, PNPLA3, MIR449B, XRCC1, GEMIN4, GRIA1, SOD2, MIR2053, CCHCR1, XPO5, ATL2, ATF5, SPINK1, C18orf56, RFXAP, MIR1206, MIR1307, HLA-DRB1, NFATC2, MIR3117, TNRC6A, MIR4268, MIR604, AGO1, IL10, IL16, MIR492, MIR300, C5orf22, PYGL, DDX20, MIR618, TYMS, CNOT1, GSTP1, DROSHA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "esomeprazole": {
    "gene": "ABCB1, STAT6, CYP2C19",
    "advice": "The CPIC Dosing Guideline for CYP2C19 and Proton Pump Inhibitor Dosing states that inconsistent findings regarding the effect of CYP2C19 genotype on the pharmacokinetics and therapeutic response to esomeprazole and rabeprazole preclude making recommendations for these proton pump inhibitors.\n",
    "source": "CPIC"
  },
  "vindesine": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "atazanavir": {
    "gene": "ABCB1, UGT1A3, CYP2C19, G6PD, ABCC2, TPH2, NR1I2, CYP3A4, SLC22A6, SORCS2, UGT1A1, CYP3A5, SLCO1B1, UGT1A7",
    "advice": "For patients who are UGT1A1 *28/*28, avoidance of atazanavir is recommended if there is a suitable alternative.\n",
    "source": "DPWG"
  },
  "ezetimibe": {
    "gene": "ABCB1, ABCG5, ABCC2, SLCO1B1, ABCG8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cannabinoids": {
    "gene": "ABCB1, OPRM1, UGT2B7, KAT2B, FAAH, TRPV1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "calcein": {
    "gene": "ABCB1, ABCC2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desmethylcitalopram": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aliskiren": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bisantrene": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "forskolin": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "talinolol": {
    "gene": "ABCB1, ABCB5, ABCC2, ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "taxanes": {
    "gene": "ABCB1, EGLN3, SCN10A, GSR, CYP4X1, VEGFA, UGT2B7, NR1I2, GSTM1, ATP7B, FLT1, EPAS1, NR1I3, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dactinomycin": {
    "gene": "ABCB1, CYP2B6, MTHFR, MTR, C18orf56, TYMS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "posaconazole": {
    "gene": "ABCB1, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "paliperidone": {
    "gene": "ABCB1, HTR2C, SH2B1, CYP2D6, MC4R, NFIB, ERBB4, RABEP1, ADCK1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "melatonin receptor agonists": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "proton pump inhibitors": {
    "gene": "ABCB1, STAT6, CYP2C19, TRPM6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ranolazine": {
    "gene": "ABCB1, CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mitotane": {
    "gene": "ABCB1, CYP2B6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "temsirolimus": {
    "gene": "ABCB1, NR1I2, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dicloxacillin": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rocuronium": {
    "gene": "ABCB1, RYR1, CYP2D6, IAPP, CYP3A4, SLCO1A2, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "daptomycin": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "l-asparagine": {
    "gene": "ABCB1, ASNS, CNOT3, GRIA1, NFATC2, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "liothyronine": {
    "gene": "ABCB1, HTR1B, FKBP5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rifapentine": {
    "gene": "ABCB1, NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "raltegravir": {
    "gene": "ABCB1, UGT1A9, ABCC2, SLCO1A2, HLA-B, SLC22A6, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "celiprolol": {
    "gene": "ABCB1, CYP2D6, SLCO1A2, KCNH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rhodamine 123": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tipifarnib": {
    "gene": "ABCB1, CYP3A4, UGT1A1, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lumefantrine": {
    "gene": "ABCB1, CYP2B6, ABCC2, CYP3A4, CYP3A5, ZSCAN25",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "crizotinib": {
    "gene": "ABCB1, MET, ROS1, ALK",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vemurafenib": {
    "gene": "ABCB1, NRAS, HRAS, KRAS, CYP3A4, BRAF, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "boceprevir": {
    "gene": "ABCB1, ITPA, APOH, IFNL4, VDR, SLC28A2, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trabectedin": {
    "gene": "ABCB1, ABCC2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "agomelatine": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cabazitaxel": {
    "gene": "ABCB1, TUBB1, CYP3A4, CYP2C8, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dexlansoprazole": {
    "gene": "ABCB1, CYP2C19",
    "advice": "The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "bilirubin": {
    "gene": "ABCB1, SLCO1B7, SLCO1B3, SOD2, UGT1A, UGT1A1, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "silibinin": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clopidogrel thiol metabolite h4": {
    "gene": "ABCB1, CYP2C19, RAD18, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "venetoclax": {
    "gene": "ABCB1, CYP2C19, SLCO1B3, FLT3, IDH1, ABCG2, TP53, CYP3A4, CYP3A5, SLCO1B1, NPM1, IDH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "romidepsin": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dehydroaripiprazole": {
    "gene": "ABCB1, CYP2D6, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dihydrocodeine": {
    "gene": "ABCB1, CYP2D6, OPRM1, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "highly active antiretroviral therapy (haart)": {
    "gene": "ABCB1, OPRM1, IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "s-eddp": {
    "gene": "ABCB1, CYP2B6, CYP2D6, CYP2C19, UGT2B7, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "iguratimod": {
    "gene": "ABCB1, CYP2C19, ABCG2, NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clopidogrel carboxylic acid": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "folfox": {
    "gene": "ABCB1, MTHFR, CDX2, DPYD, BRAF, DPYS, SMAD7, TYMS, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "xelox": {
    "gene": "ABCB1, MTHFR, DPYD, ABCG5, BRAF, ABCA2, TYMS, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "piritramide": {
    "gene": "ABCB1, OPRM1, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tilidine": {
    "gene": "ABCB1, OPRM1, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levomethadone": {
    "gene": "ABCB1, CYP2B6, CYP2D6, OPRM1, UGT2B7, COMT, NR1I3",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "tenofovir alafenamide": {
    "gene": "ABCB1, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amlodipine": {
    "gene": "ABCB1, NPPA, GNB3, RYR3, CACNA1C, AGT, CYP3A4, CACNA1D, NOS1AP, CYP3A5, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clomipramine": {
    "gene": "ABCB1, DISP1, HTR1B, CYP2D6, CYP2C19, SLITRK5, BDNF, FKBP5, SLC6A4, HTR2A, CYP3A4, SLC6A2, CYP3A5, CYP1A2",
    "advice": "The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.\n",
    "source": "DPWG"
  },
  "colchicine": {
    "gene": "ABCB1, CYP2D6, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dexrazoxane": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fexofenadine": {
    "gene": "ABCB1, SLCO2B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluvoxamine": {
    "gene": "ABCB1, HTR1A, DISP1, HTR1B, CYP2D6, CYP2C19, SLITRK5, BDNF, SLC6A4, FGF2, HTR2A, FAIM2, MDGA2, HTR3A, HTR3B, CYP1A2, COMT",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "hydromorphone": {
    "gene": "ABCB1, CYP2D6, OPRM1, CYP2C19, UGT2B7, COMT",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "ifosfamide": {
    "gene": "ABCB1, KLC3, ALDH1A1, ERCC2, ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ivermectin": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lansoprazole": {
    "gene": "ABCB1, CYP2C19, CYP2C18, SLC22A8, SLC22A6, TNF, IL1B, SLCO1B1",
    "advice": "The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "loperamide": {
    "gene": "ABCB1, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methylprednisolone": {
    "gene": "ABCB1, SERPINE1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mitoxantrone": {
    "gene": "ABCB1, MECP2, C10orf67, DCK, GALNT14, WWOX, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mycophenolate mofetil": {
    "gene": "ABCB1, TGFB1, HUS1, IMPDH2, UGT1A9, IL12A, SLCO1B3, UGT1A8, UGT2B7, CES1, ABCC2, CYP3A4, TNF, CES2, CYP2C8, IL10, IMPDH1, IL2, CYP3A5, SLCO1B1, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nefazodone": {
    "gene": "ABCB1, HTR1B, CYP2D6, FKBP5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nelfinavir": {
    "gene": "ABCB1, CYP2C19, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nimodipine": {
    "gene": "ABCB1, CACNA1C, CACNA1B, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "omeprazole": {
    "gene": "ABCB1, AHR, CYP2C19, SLC22A8, VDR, SLC22A6, TNF, IL1B",
    "advice": "The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "oseltamivir": {
    "gene": "ABCB1, NEU2, CES1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pantoprazole": {
    "gene": "ABCB1, CYP2C19, CYP2C18, SLC22A8, CYP3A4, SLC22A6, IL1B",
    "advice": "The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (&gt;12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "prazosin": {
    "gene": "ABCB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "probenecid": {
    "gene": "ABCB1, G6PD",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "remifentanil": {
    "gene": "ABCB1, ADRA2A, OPRM1, CACNA2D2, SLC9A9, PGAP6, KCNJ6, ADRB2, COMT",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "temozolomide": {
    "gene": "ABCB1, HDAC4, MGMT, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vinblastine": {
    "gene": "ABCB1, GSTT1, GSTM1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "glucocorticoids": {
    "gene": "ABCB1, NR3C1, NLRP1, HLA-E, KLRC1, FKBP5, CYP17A1, GLCCI1, KLRD1, ATP5F1E, TNF, CDH2, HSD3B1, CRHR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mecasermin": {
    "gene": "GH1, IGF1, GHR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chlorthalidone": {
    "gene": "NPPA, AGT, MMP3, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "milnacipran": {
    "gene": "HTR1A, ADRA2A, BDNF, SLC6A4, HTR2A, MDGA2",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "lurasidone": {
    "gene": "HTR1A, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "xk469": {
    "gene": "AOX1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "deferasirox": {
    "gene": "UGT1A3, CYP2D6, CYP1A1, GC, CYP27B1, ABCC2, ABCG2, VDR, CYP24A1, UGT1A1, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fiboflapon": {
    "gene": "UGT1A3, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mirabegron": {
    "gene": "UGT1A3, CYP2D6, UGT1A4, SLC19A1, CYP3A4, SLC6A2, SLCO1B1, NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "telmisartan": {
    "gene": "UGT1A3, GNB3, SLCO1B3, ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "glp-1 receptor agonists": {
    "gene": "WFS1, ARRB1, GLP1R, CNR1, TCF7L2, SORCS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "darapladib": {
    "gene": "FHIT, HEATR4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "calcium": {
    "gene": "RYR1, VDR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "anesthetics": {
    "gene": "RYR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chlorocresol": {
    "gene": "RYR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "volatile anesthetics": {
    "gene": "RYR1, OPRM1, ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ryanodine": {
    "gene": "RYR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "remimazolam": {
    "gene": "RYR1, CES1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "enflurane": {
    "gene": "RYR1, CACNA1S",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "halothane": {
    "gene": "RYR1, CACNA1S",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "isoflurane": {
    "gene": "RYR1, CYP2E1, MC1R, CACNA1S",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "methoxyflurane": {
    "gene": "RYR1, CACNA1S",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "succinylcholine": {
    "gene": "RYR1, BCHE, CACNA1S",
    "advice": "The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "serotonin": {
    "gene": "TSPAN5, MAOB, ERICH3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "enalapril": {
    "gene": "PCGF3, VEGFA, CES1, NR3C2, CLASP1, ADRB2, BDKRB2, SLCO1B1, PNPT1, ACE, ABO, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "iloperidone": {
    "gene": "HTR2C, CYP2D6, CERKL, NRG3, ZFP91-CNTF, NUBPL, CELF4, CNTF",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydroxymethyl ivacaftor": {
    "gene": "HTR2C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "atrasentan": {
    "gene": "ORM2, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eltrombopag": {
    "gene": "CTLA4, F5, ABCG2, UGT1A1, SERPINC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "glatiramer acetate": {
    "gene": "CTLA4, TGFB1, PVT1, CLEC16A, EOMES, HLA-DRB1, CCR5, IFNAR1, IFNG, IFNB1, IL7R",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "melphalan": {
    "gene": "CTLA4, SLC7A5, POLR1G",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chlorothiazide": {
    "gene": "HMGCS2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "timbetasin": {
    "gene": "TMSB4X",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "afatinib": {
    "gene": "UHRF1, EGFR, ARF1, NUP62, DVL2, NR1I2, AKT1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "l-ornithine": {
    "gene": "NPC2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "arimoclomol": {
    "gene": "NPC2, NPC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levacetylleucine": {
    "gene": "NPC2, NPC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cysteine-s-sulfate": {
    "gene": "NPC2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "1,7-dimethylxanthine": {
    "gene": "AHR, CYP1A1, ACTR3B, CYP2A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "xenobiotics": {
    "gene": "AHR, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cholic acid": {
    "gene": "DHCR7, HSD3B7, HSD3B2, AMACR, CYP7A1, AKR1D1, CYP27A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aldosterone antagonists": {
    "gene": "NEDD4L",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amiloride": {
    "gene": "NEDD4L, SCNN1B, SCNN1A, SCNN1G, CYP4A11",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thiazolidinediones": {
    "gene": "AQP2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carglumic acid": {
    "gene": "NAGS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sodium benzoate / sodium phenylacetate": {
    "gene": "NAGS, ARG1, ASL, CPS1, OTC, ASS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "glycerol phenylbutyrate": {
    "gene": "NAGS, ARG1, ASL, CPS1, OTC, ASS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trofinetide": {
    "gene": "MECP2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cetuximab": {
    "gene": "NRG2, NRAS, EGFR, AREG, EREG, PTGS2, WWTR1, KRAS, NRG1, FCGR3A, GC, NRG3, APOBEC2, EGF, VEGFA, RASSF1, ARHGEF4, CCND1, TGFA, HBEGF, BRAF, IL8, FCGR2A, BTC, MGAT4A, LATS2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "panitumumab": {
    "gene": "NRG2, NRAS, EGFR, AREG, EREG, PTGS2, KRAS, NRG1, FCGR3A, NRG3, EGF, VEGFA, CCND1, TGFA, HBEGF, IL8, FCGR2A, BTC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pyrazolones": {
    "gene": "PLA2G4A, TNFRSF11A, PLCG1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "propionic acid derivatives": {
    "gene": "PLA2G4A, TNFRSF11A, PLCG1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "leukotriene receptor antagonists": {
    "gene": "CYSLTR2, LTA4H, LTC4S, ALOX5, ADRB2, SLCO2B1, PRORP, MLLT3, ABCC1, GLT1D1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "low density lipoprotein": {
    "gene": "SH2B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dabrafenib": {
    "gene": "NRAS, HRAS, KRAS, G6PD, BRAF, HLA-DRB1",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "trametinib": {
    "gene": "NRAS, HRAS, KRAS, G6PD, BRAF",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "encorafenib": {
    "gene": "NRAS, HRAS, KRAS, BRAF",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "azacitidine": {
    "gene": "NRAS, MTHFR, KRAS, PTPN11, XRCC1, CDA, CBL, TYMS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vancomycin": {
    "gene": "GJA1, G6PD, MIA3, HLA-A, PLEKHN1, AIDA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydralazine / isosorbide dinitrate": {
    "gene": "GNB3, CYP11B2, NAT2, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bumetanide": {
    "gene": "GNB3, SLC17A3, ADD1, SLC12A3, SCNN1G, ACE, NPPA-AS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clonidine": {
    "gene": "GNB3, CYP2D6, ADRA2A, ADRA2B, ADRA2C",
    "advice": "There are currently no dosing recommendations for clonidine based on CYP2D6 genotype and DPWG suggest clonidine as possible alternative for atomoxetine in variant CYP2D6 metabolisers.\n",
    "source": "DPWG"
  },
  "sibutramine": {
    "gene": "GNB3, CYP2B6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "torasemide": {
    "gene": "GNB3, ADD1, SLC12A3, SCNN1G, ACE, NPPA-AS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "risedronate": {
    "gene": "LRP5, SIRT1, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "teniposide": {
    "gene": "NUP50, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "migalastat": {
    "gene": "GLA, HNRNPH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lovastatin acid": {
    "gene": "PPARA, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chiglitazar": {
    "gene": "PPARA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ketanserin": {
    "gene": "HTR1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dihydroergotamine": {
    "gene": "HTR1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methysergide": {
    "gene": "HTR1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "topoisomerase i inhibitors": {
    "gene": "EGFR, SLFN11",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "geldanamycin": {
    "gene": "EGFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "egfr inhibitors": {
    "gene": "EGFR, PIK3CA, HLA-A, PIK3R1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alkylating agents": {
    "gene": "EGFR, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "atezolizumab": {
    "gene": "EGFR, IL7, SMAD3, SEMA5A, HLA-A, ALK, GABRP, BRAF, CD274, SLCO1B1, EDIL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "durvalumab": {
    "gene": "EGFR, PDCD1, SMAD3, SEMA5A, HLA-A, ALK, GABRP, CD274, SLCO1B1, EDIL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dacomitinib": {
    "gene": "EGFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ipilimumab": {
    "gene": "EGFR, IL7, SMAD3, KRAS, SEMA5A, HLA-A, ALK, GABRP, CD274, SLCO1B1, EDIL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ramucirumab": {
    "gene": "EGFR, KRAS, ALK",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tepotinib": {
    "gene": "EGFR, MET, ALK",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cemiplimab-rwlc": {
    "gene": "EGFR, ROS1, ALK, CD274",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mobocertinib": {
    "gene": "EGFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tremelimumab": {
    "gene": "EGFR, ALK, CD274",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lazertinib": {
    "gene": "EGFR, GSTM1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amivantamab": {
    "gene": "EGFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tegafur": {
    "gene": "EGFR, CDX2, DPYD, FASTKD3, MTRR, CDA, UMPS, C18orf56, CYP2A6, SMAD7, TYMS",
    "advice": "An Italian working group comprising the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) has published recommendations for the use of DPYD genotype when prescribing fluoropyrimidines (5-fluorouracil, capecitabine and tegafur).\n",
    "source": "AIOM"
  },
  "cannabidiol": {
    "gene": "AOC1, ABCC5, SLC15A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "protein kinase inhibitors": {
    "gene": "STAT6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "3,4-methylenedioxymethamphetamine": {
    "gene": "CYP2B6, CYP2D6, OPRM1, CYP2C19, SLC6A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "non-nucleoside reverse transcriptase inhibitors": {
    "gene": "CYP2B6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "artemisinin": {
    "gene": "CYP2B6, G6PD, CYP3A4, CYP2A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "artemether": {
    "gene": "CYP2B6, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "arteether": {
    "gene": "CYP2B6, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dihydroartemisinin": {
    "gene": "CYP2B6, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "efavirenz / emtricitabine / tenofovir disoproxil": {
    "gene": "CYP2B6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "s-methadone": {
    "gene": "CYP2B6, CYP2D6, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydroxybupropion": {
    "gene": "CYP2B6, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "r-eddp": {
    "gene": "CYP2B6, CYP2D6, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desbutyl lumefantrine": {
    "gene": "CYP2B6, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chlorambucil": {
    "gene": "CYP2B6, CXCL12",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fludarabine": {
    "gene": "CYP2B6, CXCL12, CYP2E1, SULT2B1, SLCO1B1, SLC22A12, ADH1A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levonorgestrel": {
    "gene": "CYP2B6, ADAMTS10, TP53, UGT1A1, NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "medroxyprogesterone": {
    "gene": "CYP2B6, ESR2, VDR, NAT2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eplerenone": {
    "gene": "ATP1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "capmatinib": {
    "gene": "MET",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alpha-adrenoreceptor antagonists": {
    "gene": "ADRA1A, ADRA1B, ADRA1D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dihydropyridine derivatives": {
    "gene": "ADRA1A, RYR3, APCDD1, NUMA1, NOS1AP, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dopamine": {
    "gene": "ADRA1A, ADRA2A, ADRA1B, ADRA2B, ADRA2C, ADRA1D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "epinephrine": {
    "gene": "ADRA1A, ADRA2A, ADRA1B, ADRA2B, ADRB2, ADRA2C, ADRA1D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methoxamine": {
    "gene": "ADRA1A, ADRA1B, ADRA1D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nifedipine": {
    "gene": "ADRA1A, ACE2, SLC14A2, CACNA1C, MMP9, CYP3A4, ADRB2, NOS1AP, CYP3A5, ADIPOQ, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "norepinephrine": {
    "gene": "ADRA1A, ADRA2A, ADRA1B, ADRA2B, ADRA2C, ACE, ADRA1D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "phenylephrine": {
    "gene": "ADRA1A, ADRA1B, ADRB2, ADRA1D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dextromethorphan": {
    "gene": "PHETA2, CYP2D6, TCF20, SMDT1, IP6K2, NFIB, CYP3A4, SEPTIN3, WBP2NL, CYP2D7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eteplirsen": {
    "gene": "DMD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "golodirsen": {
    "gene": "DMD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "viltolarsen": {
    "gene": "DMD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "casimersen": {
    "gene": "DMD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bromazepam": {
    "gene": "CYP2D6, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flupenthixol": {
    "gene": "CYP2D6, NFKB1",
    "advice": "There are currently no dosing recommendations for flupenthixol based on CYP2D6 genotype.\n",
    "source": "DPWG"
  },
  "oxprenolol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "formoterol": {
    "gene": "CYP2D6, CYP2C19, ADRB2, IL10, IL17A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mianserin": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levomepromazine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "atomoxetine": {
    "gene": "CYP2D6, CYP2C19, HTR7, SLC6A2",
    "advice": "The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "tetrabenazine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "opipramol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "anticholinergic agents": {
    "gene": "CYP2D6, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "enzyme inhibitors": {
    "gene": "CYP2D6, CYP19A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "opium derivatives and expectorants": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bevantolol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "arformoterol": {
    "gene": "CYP2D6, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lofexidine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tolterodine": {
    "gene": "CYP2D6, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lisdexamfetamine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "penbutolol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cevimeline": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bepridil": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pregabalin": {
    "gene": "CYP2D6, SLC7A5, NAT2, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tiotropium": {
    "gene": "CYP2D6, ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "darifenacin": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sertindole": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydroxyamitriptyline": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desvenlafaxine": {
    "gene": "CYP2D6, CYP2C19, SLC6A4, HTR7, HTR2A, UGT1A1",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "bufuralol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pridopidine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tafenoquine": {
    "gene": "CYP2D6, G6PD",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "ibrutinib": {
    "gene": "CYP2D6, BTK, MYD88, ABCG2, CYP3A4, KCNQ1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vortioxetine": {
    "gene": "CYP2D6, SLC6A4, HTR2A",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "eliglustat": {
    "gene": "CYP2D6",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for renal and hepatic impairment.\n",
    "source": "DPWG"
  },
  "casopitant": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "s-norfluoxetine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "noroxycodone": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "r-norfluoxetine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "n,n-didesmethyltramadol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "n,o-didesmethyltramadol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desmethyl clomipramine": {
    "gene": "CYP2D6, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "noroxymorphone": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dapoxetine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tolperisone": {
    "gene": "CYP2D6, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "coptisine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "brexpiprazole": {
    "gene": "CYP2D6, CYP3A4",
    "advice": "The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the normal dose of brexpiprazole for poor metabolizers of CYP2D6.\n",
    "source": "DPWG"
  },
  "aripiprazole lauroxil": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "paramethoxymethamphetamine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rucaparib": {
    "gene": "CYP2D6, BRCA1, BRCA2, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "2-hydroxymethyl olanzapine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "deutetrabenazine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "valbenazine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ritalinic acid": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dextromethorphan / quinidine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluoxetine / olanzapine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cariprazine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "umeclidinium": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alpha-hydroxymetoprolol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dextropropoxyphene": {
    "gene": "CYP2D6, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nordextropropoxyphene": {
    "gene": "CYP2D6, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetaminophen / codeine": {
    "gene": "CYP2D6, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vernakalant": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "umeclidinium / vilanterol": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "paracetamol, combinations excl. psycholeptics (vicks medinait sirup)": {
    "gene": "CYP2D6, G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mephedrone": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pitolisant": {
    "gene": "CYP2D6, HRH3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "upadacitinib": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desethyl hydroxychloroquine": {
    "gene": "CYP2D6, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desethylchloroquine": {
    "gene": "CYP2D6, CYP2C8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dihydromorphine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ethylmorphine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ketobemidone": {
    "gene": "CYP2D6, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "oliceridine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetaminophen / caffeine / dihydrocodeine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "beta-dihydrodeutetrabenazine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alpha-dihydrodeutetrabenazine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "viloxazine": {
    "gene": "CYP2D6, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "norquetiapine": {
    "gene": "CYP2D6, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dextromethorphan hydrobromide / bupropion hydrochloride": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "solanidine": {
    "gene": "CYP2D6, NFIB",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "apatinib-25-n-oxide": {
    "gene": "CYP2D6, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pyrantel": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ulotaront": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "primaquine 5,6-orthoquinone": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ibogaine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "xanomeline / trospium": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "iloperidone metabolite p88": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-hydroxysolanidine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amoxapine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cimetidine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desipramine": {
    "gene": "CYP2D6, CYP2C19, BDNF, CYP3A4, SLC6A2, MC1R, CYP1A2",
    "advice": "Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "dexmedetomidine": {
    "gene": "CYP2D6, ADRA2A, CACNA2D2, KCNMA1, PRKCB, ADRA2B, KCNMB1, ABCC9, NR1I2, ABCG2, KCNA3, ADRB2, CACNB2, CYP2A6, GABRA2, WBP2NL, CYP1A2, UGT2B10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "disopyramide": {
    "gene": "CYP2D6, KCNH2",
    "advice": "There are currently no dosing recommendations for disopyramide based on CYP2D6 genotype.\n",
    "source": "DPWG"
  },
  "dolasetron": {
    "gene": "CYP2D6, NOS1AP",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluphenazine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydrocodone": {
    "gene": "CYP2D6, OPRM1, MACROD2, SEPTIN3, WBP2NL, COMT",
    "advice": "CYP2D6 intermediate and poor metabolizers should initiate hydrocodone therapy using the label recommended age- or weight-specific dosing. However, if there is no response to hydrocodone in these patients, an alternative analgesic should be considered.\nThere is insufficient evidence to provide a dosing recommendation for hydrocodone in CYP2D6 ultrarapid metabolizers.\n",
    "source": "CPIC"
  },
  "imipramine": {
    "gene": "CYP2D6, CYP2C19, UGT1A4, BDNF, CYP3A4, CYP1A2",
    "advice": "Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered. The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "leuprolide": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "loratadine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "maprotiline": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "meclizine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mexiletine": {
    "gene": "CYP2D6, SCN4A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "oxymorphone": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pimozide": {
    "gene": "CYP2D6, CYP3A4",
    "advice": "Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.\n",
    "source": "DPWG"
  },
  "propafenone": {
    "gene": "CYP2D6, SCN4A, SCN5A",
    "advice": "Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor propafenone plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.\n",
    "source": "DPWG"
  },
  "protriptyline": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "quinine": {
    "gene": "CYP2D6, G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "sulfasalazine": {
    "gene": "CYP2D6, MTHFR, ATIC, HLA-DQB1, G6PD, SHMT1, HLA-A, SLC19A1, ABCG2, MTR, C18orf56, DHFR, HLA-B, HLA-DRB1, SLCO2B1, NAT2, TYMS",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "tamsulosin": {
    "gene": "CYP2D6, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "terbinafine": {
    "gene": "CYP2D6, HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thioridazine": {
    "gene": "CYP2D6, CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "toremifene": {
    "gene": "CYP2D6, ESR2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sparteine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "debrisoquine": {
    "gene": "CYP2D6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zuclopenthixol": {
    "gene": "CYP2D6",
    "advice": "For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose. For ultrarapid metabolizers, if the effectiveness is insufficient a dose increase not exceeding 1.5x normal dose is suggested.\n",
    "source": "DPWG"
  },
  "meperidine": {
    "gene": "FIP1L1, SERINC5, CYP2C19, UGT1A1, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "brimonidine": {
    "gene": "ADRA2A, ADRA2B, ADRA2C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "doxazosin": {
    "gene": "ADRA2A, ADRA1B, KCNH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "phenoxybenzamine": {
    "gene": "ADRA2A, ADRA1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "yohimbine": {
    "gene": "ADRA2A, ADRA2B, ADRA2C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amikacin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "netilmicin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "paromomycin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "plazomicin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "isepamicin": {
    "gene": "MT-RNR1, MT-ND1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "micronomicin": {
    "gene": "MT-RNR1, MT-ND1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hygromycin b": {
    "gene": "MT-RNR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dihydrostreptomycin": {
    "gene": "MT-RNR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dibekacin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "ribostamycin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "gentamicin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "kanamycin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "neomycin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "tobramycin": {
    "gene": "MT-RNR1",
    "advice": "Administration of aminoglycoside antibiotics should be avoided in patients carrying certain MT-RNR1 variants due to the increased risk of developing aminoglycoside-induced hearing loss (AIHL). The guideline has been updated since its original publication. Please see the guideline annotation for more information.\n",
    "source": "CPIC"
  },
  "aminoglycoside antibacterials": {
    "gene": "MT-RNR1, GSTT1, MT-ND1, GSTM1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mesalazine": {
    "gene": "NAT1, G6PD, TPMT",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "telaprevir": {
    "gene": "ITPA, APOH, IFNL4, CYP24A1, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "simeprevir": {
    "gene": "ITPA, IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sofosbuvir": {
    "gene": "ITPA, IFNL4, CES1, HINT1, NME1, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thioguanosine monophosphate": {
    "gene": "ITPA, TPMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thioguanosine diphosphate": {
    "gene": "ITPA, TPMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thioguanosine triphosphate": {
    "gene": "ITPA, TPMT, PACSIN2, NUDT15",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "iodine (131i) compounds": {
    "gene": "TGFB1, ATM, NFKB1, TNF, ATG10",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin b-complex, plain": {
    "gene": "MTHFR, MTRR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pyrimidine analogues": {
    "gene": "MTHFR, DPYD, MIR27A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin b-complex, incl. combinations": {
    "gene": "MTHFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aprepitant": {
    "gene": "MTHFR, UGT2B7, HTR3C, HTR3B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ethinyl estradiol / norelgestromin": {
    "gene": "MTHFR, F5, F2, PROC, PROS1, SERPINC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levomefolic acid": {
    "gene": "MTHFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "l-methylfolate": {
    "gene": "MTHFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "betaine": {
    "gene": "MTHFR, MMADHC, CBS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin b12 and folic acid": {
    "gene": "MTHFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nitrous oxide": {
    "gene": "MTHFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cyanocobalamin": {
    "gene": "MTHFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors": {
    "gene": "IL7, IL22RA1, FTO, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetaldehyde": {
    "gene": "SRPRB, ADH1B, PGM1, ADH1A, ALDH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nalmefene": {
    "gene": "OPRD1, OPRM1, OPRK1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "buprenorphine / naloxone": {
    "gene": "OPRD1, OPRM1, UGT2B7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "norbuprenorphine": {
    "gene": "OPRD1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "selective beta-2-adrenoreceptor agonists": {
    "gene": "ARG1, CRHR2, VDR, ADRB2, ADAM33",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bosutinib": {
    "gene": "CAMK2G, BCR, ABL1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "drotrecogin alfa": {
    "gene": "DRD1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dextroamphetamine": {
    "gene": "DRD1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "belimumab": {
    "gene": "ANO3, TNFSF13B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amodiaquine": {
    "gene": "CYP1A1, G6PD, CYP2C8, CYP1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dacarbazine": {
    "gene": "CYP1A1, GSTT1, GSTM1, EPM2AIP1, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "insulins and analogues": {
    "gene": "SCNN1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "insulin recombinant": {
    "gene": "SCNN1B, G6PD, SLC30A8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aldosterone": {
    "gene": "SCNN1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "farglitazar": {
    "gene": "SCNN1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "triamterene": {
    "gene": "SCNN1B, SCNN1A, SCNN1G",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "niraparib": {
    "gene": "BRCA1, BRCA2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "leflunomide": {
    "gene": "PON1, CYP2C19, DHODH, ESR2, PTPN22, ABCG2, CYB5A, CYP1A2, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "certolizumab pegol": {
    "gene": "ALPL, HLA-E, KLRC1, EYA4, CERS6, KLRD1, ATP5F1E, VDR, NCR3, TNF",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "givosiran": {
    "gene": "CPOX, PPOX, HMBS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "direct thrombin inhibitors": {
    "gene": "FGG, F2, FGA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "direct factor xa inhibitors": {
    "gene": "FGG, F2, FGA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "abciximab": {
    "gene": "FGG, ITGA2B, FGB, ITGB3, FGA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eptifibatide": {
    "gene": "FGG, ITGA2B, FGB, ITGB3, FGA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tirofiban": {
    "gene": "FGG, ITGA2B, FGB, ITGB3, FGA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "drospirenone / ethinyl estradiol": {
    "gene": "F5, CYP2C19, PROC, PROS1, SERPINC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lusutrombopag": {
    "gene": "F5, F2, PROC, PROS1, SERPINC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "relugolix / estradiol / norethindrone acetate": {
    "gene": "F5, PROC, PROS1, SERPINC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antithrombotic agents": {
    "gene": "F5, G6PD, F2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "immunosuppressants": {
    "gene": "GSTT1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "gabapentin": {
    "gene": "SLC7A5, GABRA1, GABRA3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alpha-msh": {
    "gene": "POMC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "5-hydroxyindole-3-acetic acid": {
    "gene": "MAOB",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flunitrazepam": {
    "gene": "GABRG1, CYP2C19, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "benzodiazepine derivatives": {
    "gene": "OPRM1, GAL",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "opioid anesthetics": {
    "gene": "OPRM1, ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "other general anesthetics": {
    "gene": "OPRM1, ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sympathomimetics": {
    "gene": "OPRM1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "butorphanol": {
    "gene": "OPRM1, OPRK1, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetaminophen / tramadol": {
    "gene": "OPRM1, G6PD, MIR23B, MIR107",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tianeptine": {
    "gene": "OPRM1, OPRK1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alfentanil": {
    "gene": "OPRM1, CYP3A5, COMT",
    "advice": "There are currently no recommendations for dosing of alfentanil, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levomethadone, naltrexone, remifentanil, sufentanil or tramadol based on OPRM1 or COMT genotypes.\n",
    "source": "CPIC"
  },
  "naloxone": {
    "gene": "OPRM1, UGT2B7, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thiotepa": {
    "gene": "ALDH1A1, ALDH3A1, GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "platelet aggregation inhibitors excl. heparin": {
    "gene": "CYP2C19, GP1BA, PEAR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "respiratory system": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ambrisentan": {
    "gene": "CYP2C19, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "etravirine": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lafutidine": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "icotinib": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ginkgo biloba extract": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "3-cyano-7-ethoxycoumarin": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "selumetinib": {
    "gene": "CYP2C19, ABCG2, BRAF, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lacosamide": {
    "gene": "CYP2C19, ABCC2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rilpivirine": {
    "gene": "CYP2C19, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "norclobazam": {
    "gene": "CYP2C19, GABRA2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "androstenedione": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "phenazepam": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "normeperidine": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "belzutifan": {
    "gene": "CYP2C19, VHL, UGT2B17",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mavacamten": {
    "gene": "CYP2C19",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for mavacamten recommends a lower dose for CYP2C19 poor metabolizers and to avoid mavacamten in CYP2C19 poor metabolizers with strong CYP3A4 inhibitor as co-medication.\n",
    "source": "DPWG"
  },
  "6beta-hydroxytestosterone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "16alpha-hydroxytestosterone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "11alpha-hydroxytestosterone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "16alpha-hydroxyprogesterone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "11a-hydroxyprogesterone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "6beta-hydroxyprogesterone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desoxycortone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dt-678": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulforidazine": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amoxicillin": {
    "gene": "CYP2C19, HLA-DQB1, ERAP1, HLA-DRB5, HLA-A, PTPN22, HLA-DRA, VDR, HLA-B, HLA-DRB1, ERAP2, HLA-DPB1, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carisoprodol": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "famotidine": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydroxyprogesterone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ketoconazole": {
    "gene": "CYP2C19, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mephenytoin": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methylphenobarbital": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mesoridazine": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "oxazepam": {
    "gene": "CYP2C19, UGT1A9, UGT2B7, CYP3A4, UGT2B15, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rabeprazole": {
    "gene": "CYP2C19, TNF, IL1B",
    "advice": "The CPIC Dosing Guideline for CYP2C19 and Proton Pump Inhibitor Dosing states that inconsistent findings regarding the effect of CYP2C19 genotype on the pharmacokinetics and therapeutic response to esomeprazole and rabeprazole preclude making recommendations for these proton pump inhibitors.\n",
    "source": "CPIC"
  },
  "temazepam": {
    "gene": "CYP2C19, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ticlopidine": {
    "gene": "CYP2C19, HLA-DQB1, P2RY12, HLA-A, HLA-B, HLA-DRB1, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tranylcypromine": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "troglitazone": {
    "gene": "CYP2C19",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "moclobemide": {
    "gene": "CYP2C19, HTR2A",
    "advice": "No action is needed for this gene-drug interaction.\n",
    "source": "DPWG"
  },
  "chop": {
    "gene": "NOS1, ABCC2, ABCG2, CIDEA, IL10, SLC35F4, NCF4, CBR3, OXNAD1, TNIP3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nimesulide": {
    "gene": "PTGS2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "coxibs": {
    "gene": "PTGS2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "omega-3 polyunsaturated fatty acids": {
    "gene": "PTGS2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rofecoxib": {
    "gene": "PTGS2, PTGS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "isatuximab": {
    "gene": "CD38",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "maralixibat": {
    "gene": "JAG1, MYO5B, ABCB11, ATP8B1, TJP2, ABCB4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "odevixibat": {
    "gene": "JAG1, NOTCH2, ABCB11, ATP8B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "epidermal growth factor receptor (egfr) tyrosine kinase inhibitors": {
    "gene": "KIR3DL2, CTBP2, HLA-DRB5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "laropiprant": {
    "gene": "PTGDR, NR1H3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "avelumab": {
    "gene": "SMAD3, SEMA5A, GABRP, CD274, SLCO1B1, EDIL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "indapamide": {
    "gene": "TRIB3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "perindopril": {
    "gene": "TRIB3, G6PD, BDKRB1, AGTR1, BDKRB2, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "adagrasib": {
    "gene": "KRAS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sotorasib": {
    "gene": "KRAS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fruquintinib": {
    "gene": "KRAS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aflibercept": {
    "gene": "VEGFB, ANO2, VEGFA, VEGFC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alendronate": {
    "gene": "MVK, ESR2, SOST, TNFRSF11A, VDR, DKK1, SIRT1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vegf/vegfr (vascular endothelial growth factor) inhibitors": {
    "gene": "TRIB1, VEGFA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acamprosate": {
    "gene": "CHDH, GRIN2B, GLRB, IL17RB",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "first-generation cephalosporins": {
    "gene": "HLA-DQB1, HLA-B, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fourth-generation cephalosporins": {
    "gene": "HLA-DQB1, HLA-B, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "influenza vaccines": {
    "gene": "HLA-DQB1, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "other cephalosporins": {
    "gene": "HLA-DQB1, HLA-B, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "third-generation cephalosporins": {
    "gene": "HLA-DQB1, HLA-B, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clavulanate": {
    "gene": "HLA-DQB1, ERAP1, HLA-DRB5, HLA-A, PTPN22, HLA-DRA, HLA-B, HLA-DRB1, ERAP2, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bucillamine": {
    "gene": "HLA-DQB1, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flupirtine": {
    "gene": "HLA-DQB1, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "beta-lactam antibacterials, penicillins": {
    "gene": "HLA-DQB1, HLA-A, HLA-DRB1, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "other beta-lactam antibacterials": {
    "gene": "HLA-DQB1, HLA-A, HLA-DRB1, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "imidapril": {
    "gene": "CYP11B2, AGT, BDKRB2, KCNH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zenocutuzumab": {
    "gene": "NRG1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tildrakizumab": {
    "gene": "TNFAIP3, ATG5, IL17RC, PDE4D",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "l-tryptophan": {
    "gene": "SLC22A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fampridine": {
    "gene": "SLC22A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tipiracil hydrochloride": {
    "gene": "SLC22A2, SLC47A1, SLC29A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trifluridine": {
    "gene": "SLC22A2, SLC47A1, SLC29A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trimethoprim": {
    "gene": "SLC22A2, G6PD, SLC47A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antithymocyte globulin": {
    "gene": "FCGR3A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tamoxifen-n-glucuronide": {
    "gene": "UGT1A4, UGT2B7, UGT2B15",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clozapine 5-n-glucuronide": {
    "gene": "UGT1A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desmethylclozapine glucuronide": {
    "gene": "UGT1A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pexidartinib": {
    "gene": "UGT1A4, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "testosterone": {
    "gene": "UGT1A4, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "leniolisib": {
    "gene": "PIK3CD, PIK3R1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lutetium (177lu) vipivotide tetraxetan": {
    "gene": "FOLH1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "anakinra": {
    "gene": "IL1RN, NLRP3, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "canakinumab": {
    "gene": "IL1RN, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "heparin": {
    "gene": "IL1RN, HLA-DRB3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "folfirinox": {
    "gene": "CES1P1, DPYD, ABCG2, UGT1A1, DPYS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trandolapril": {
    "gene": "CES1P1, PTPRD, CES1, GRK5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tegafur / gimeracil / oteracil": {
    "gene": "DPYD, HLA-DRB1, UGT1A1, UGT1A6, CYP2A6, UGT1A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluorouracil / salicylic acid": {
    "gene": "DPYD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "uracil": {
    "gene": "DPYD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "3-aminoisobutyrate": {
    "gene": "DPYD, AGXT2, UPB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flucytosine": {
    "gene": "DPYD",
    "advice": "The Dutch Pharmacogenetics Working Group Guideline for flucytosine states that patients with a DPYD activity score of 0 should avoid flucytosine. Patients with a DPYD activity score of 1 or 1.5 should be alert to the occurrence of severe side effects and flucytosine should be stopped if severe side effects occur.\n",
    "source": "DPWG"
  },
  "artemisinin and derivatives": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ascorbic acid (vitamin c), combinations": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ascorbic acid (vitamin c), plain": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "quinolone antibacterials": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin b-complex with vitamin c": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "quinacrine": {
    "gene": "G6PD",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "nalidixic acid": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "furazolidone": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "phenazopyridine": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "trihexyphenidyl": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfametopyrazine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mepivacaine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfisoxazole": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "nitrofurazone": {
    "gene": "G6PD",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "tolazamide": {
    "gene": "G6PD",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "artesunate": {
    "gene": "G6PD, CYP2C8, CYP2A6, IKBKG",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chlorproguanil": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dimercaprol": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "pegloticase": {
    "gene": "G6PD",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "mafenide": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "pamaquine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sitamaquine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "menadione sodium bisulfite": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "moviprep": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sodium ascorbate": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "erythromycin ethylsuccinate / sulfisoxazole acetyl": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amlodipine / atorvastatin / perindopril arginine": {
    "gene": "G6PD, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "metabutethamine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bisoprolol fumarate / perindopril arginine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carbasalate calcium": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nicorandil": {
    "gene": "G6PD",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "toluidine blue": {
    "gene": "G6PD",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "sodium nitrate": {
    "gene": "G6PD",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "carboxyprimaquine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "primaquine n-carbamoyl glucuronide": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aminosalicylic acid": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "atovaquone": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chloramphenicol": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "chloroquine": {
    "gene": "G6PD, SLCO2B1",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "chlorpropamide": {
    "gene": "G6PD",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "doxycycline": {
    "gene": "G6PD, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flutamide": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ganciclovir": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mefloquine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methylene blue": {
    "gene": "G6PD, BLVRB",
    "advice": "High risk drugs should be avoided in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "nitrofurantoin": {
    "gene": "G6PD",
    "advice": "Nitrofurantoin should be use with caution in G6PD deficient patients without chronic non-spherocytic hemolytic anemia (CNSHA) and completely avoided by G6PD deficient patients with CNSHA. In patients with a G6PD variable or indeterminate phenotype an enzyme activity test should be carried out before initiating drug therapy.\nThe G6PD gene is located on the X chromosome. Therefore, some patients will only have one copy, whereas others will have two copies. See full guideline for disclaimers, further details and supporting evidence.\n",
    "source": "CPIC"
  },
  "nitroglycerin": {
    "gene": "G6PD, ALDH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "norfloxacin": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "ofloxacin": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "phenylbutazone": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "prilocaine": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pyrimethamine": {
    "gene": "G6PD, IKBKG",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "succimer": {
    "gene": "G6PD",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfacetamide": {
    "gene": "G6PD",
    "advice": "There are currently no recommendations for dosing of chlorpropamide, dabrafenib, gliclazide, glimepiride, glipizide, mepacrine (aka quinacrine), mesalazine, moxifloxacin, nicorandil, nitrofural (aka nitrofurazone), probenecid, sodium nitrate, sulfacetamide, tolazamide or trametinib based on G6PD genotype.\n",
    "source": "CPIC"
  },
  "sulfadiazine": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "sulfadoxine": {
    "gene": "G6PD, IKBKG",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfamethazine": {
    "gene": "G6PD, NAT2",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "sulfanilamide": {
    "gene": "G6PD",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "vitamin c": {
    "gene": "G6PD, TXNRD1",
    "advice": "There is no reason to avoid low-to-no risk drugs in patients with the G6PD deficient or G6PD variable phenotypes. In patients who are G6PD deficient with chronic non-spherocytic hemolytic anemia (CNSHA), low-to-no risk drugs should be used with caution and close monitoring for acute exacerbation of chronic hemolysis is recommended. However, CPIC does not recommend changing prescribing actions based on G6PD genotype for low-to-no risk drugs.\n",
    "source": "CPIC"
  },
  "ritodrine": {
    "gene": "KCNMB2, PDE4B, CACNA1C, ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pemigatinib": {
    "gene": "FGFR1, FGFR2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "selective serotonin (5ht1) agonists": {
    "gene": "PRDM16, PHACTR1, LRP1, ASTN2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hdl cholesterol": {
    "gene": "CRTC2, CYP19A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "glucose": {
    "gene": "CRTC2, SLCO1B1, COMT, RABEP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vorinostat": {
    "gene": "CHD4, UGT2B17",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "calcineurin inhibitors": {
    "gene": "IMPDH2, CYP2C8, IMPDH1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "empagliflozin": {
    "gene": "BDNF, ATP2A2, SLC5A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "arachidonic acid": {
    "gene": "CYP4F2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin k1": {
    "gene": "CYP4F2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "brincidofovir": {
    "gene": "CYP4F2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin e": {
    "gene": "CYP4F2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methacholine": {
    "gene": "RUNX1, ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "photodynamic therapy": {
    "gene": "ARMS2, F13A1, CFH",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "somatropin recombinant": {
    "gene": "CDK4, COL1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hepatitis vaccines": {
    "gene": "IL4R, IL13, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pitrakinra": {
    "gene": "IL4R",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zonisamide": {
    "gene": "CA12, HLA-A, CYP3A4, HLA-B, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cefaclor": {
    "gene": "TPSAB1, HLA-DRB5, LIMD1, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "captopril": {
    "gene": "ACE2, AGT, AGTR1, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "goserelin": {
    "gene": "ESR2, PGR, SLCO1B1, ESR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alglucosidase alfa": {
    "gene": "GAA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sarilumab": {
    "gene": "IL6R",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "satralizumab": {
    "gene": "IL6R, AQP4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fructose": {
    "gene": "KHK",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "isoniazid / pyrazinamide / rifampin": {
    "gene": "ALAS1, NR1I2, CYP2E1, CYP3A4, ATP7B, FECH, NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "entacapone": {
    "gene": "UGT1A9, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mycophenolic acid glucuronide": {
    "gene": "UGT1A9, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cotinine glucuronide": {
    "gene": "UGT1A9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ertugliflozin": {
    "gene": "UGT1A9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "canagliflozin": {
    "gene": "UGT1A9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfinpyrazone": {
    "gene": "UGT1A9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tolcapone": {
    "gene": "UGT1A9, COMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cangrelor": {
    "gene": "P2RY12",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "inebilizumab": {
    "gene": "AQP4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "metreleptin": {
    "gene": "BSCL2, LEP, LMNB2, AGPAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "imiquimod": {
    "gene": "TLR7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methimazole": {
    "gene": "NOX3, KLRC4, HLA-B, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "propylthiouracil": {
    "gene": "NOX3, KLRC4, HLA-B, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "immunoglobulins": {
    "gene": "COQ8B, PRIMPOL, CASP3, ITPKC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "triheptanoin": {
    "gene": "HADHB, CPT2, ACADVL, HADHA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lorlatinib": {
    "gene": "ROS1, ALK",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "entrectinib": {
    "gene": "ROS1, NTRK2, NTRK1, NTRK3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "repotrectinib": {
    "gene": "ROS1, NTRK2, NTRK1, NTRK3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sodium phenylbutyrate": {
    "gene": "CPS1, OTC, ASS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methionine": {
    "gene": "CPS1, PSPH, CBS, GNMT, ALDH1L1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zinc acetate": {
    "gene": "SLC30A8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dichloroacetic acid": {
    "gene": "POMT2, GSTZ1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cefotaxime": {
    "gene": "SLC22A8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antiandrogens": {
    "gene": "AKR1C3, CYP19A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eslicarbazepine acetate": {
    "gene": "AADAC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "adenosine": {
    "gene": "ADORA2A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dextrorphan": {
    "gene": "TCF20, IP6K2, NFIB",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alemtuzumab": {
    "gene": "CXCL12",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ethosuximide": {
    "gene": "CACNA1I, CACNA1H, SCN1A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "didanosine": {
    "gene": "NT5C2, XDH",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lutetium (177lu) dotatate": {
    "gene": "SSTR3, SSTR5, SSTR1, SSTR4, SSTR2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "gilteritinib": {
    "gene": "FLT3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "quizartinib": {
    "gene": "FLT3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "evodiamine": {
    "gene": "SLC6A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vilazodone": {
    "gene": "SLC6A4, HTR2A, CYP3A4",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "levomilnacipran": {
    "gene": "SLC6A4, HTR2A",
    "advice": "There are currently no recommendations for dosing of escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, vilazodone, vortioxetine, levomilnacipran, or milnacipran based on SLC6A4 genotypes.\n",
    "source": "CPIC"
  },
  "clozapine n+ glucuronide": {
    "gene": "UGT2B@",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rivastigmine": {
    "gene": "CHAT, PRKCE, SLC5A7, APOE, ACHE, BCHE, CHRNA7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zanubrutinib": {
    "gene": "MYD88, TP53",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ivosidenib": {
    "gene": "IDH1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "olutasidenib": {
    "gene": "IDH1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vorasidenib": {
    "gene": "IDH1, IDH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "s-adenosylmethionine": {
    "gene": "TPMT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methylmercaptopurine": {
    "gene": "TPMT, XDH",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "deoxy-thioguanosine triphosphate": {
    "gene": "TPMT, PACSIN2, NUDT15",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carbidopa": {
    "gene": "DDC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "doxorubicinol": {
    "gene": "CBR1, SLC22A16, AKR1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dasatinib": {
    "gene": "BCR, ABCG2, ABL1, NQO2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ponatinib": {
    "gene": "BCR, ABL1, ABCC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "omacetaxine": {
    "gene": "BCR, ABL1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "blinatumomab": {
    "gene": "BCR, CD19, ABL1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "inotuzumab ozogamicin": {
    "gene": "BCR, ABL1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "asciminib": {
    "gene": "BCR, ABL1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "polatuzumab vedotin": {
    "gene": "BCL2, MYC, BCL6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "flunisolide": {
    "gene": "GLCCI1, TBXT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nedocromil": {
    "gene": "GLCCI1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "triamcinolone": {
    "gene": "GLCCI1, HCG22",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "colistimethate": {
    "gene": "SLC15A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "niacin": {
    "gene": "HCAR2, NR1H3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "creatine": {
    "gene": "MOBP, UNC13A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tretinoin": {
    "gene": "PML, RARA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bacampicillin": {
    "gene": "HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cefdinir": {
    "gene": "HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "benznidazole": {
    "gene": "HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tebentafusp": {
    "gene": "HLA-A",
    "advice": "The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) requires testing for HLA-A*02:01 to select patients with metastatic uveal melanoma suitable for treatment with tebentafusp.\n",
    "source": "RNPGx"
  },
  "bcr-abl tyrosine kinase inhibitors": {
    "gene": "HLA-A, HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ampicillin": {
    "gene": "HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cefazolin": {
    "gene": "HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cefuroxime": {
    "gene": "HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cephalexin": {
    "gene": "HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methazolamide": {
    "gene": "HLA-A, HLA-B, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tetanus antitoxin": {
    "gene": "HLA-A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "semaglutide": {
    "gene": "CTRB1, GLP1R, TCF7L2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "6-hydroxy s-warfarin": {
    "gene": "GRID2, PARP14",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "6-hydroxy r-warfarin": {
    "gene": "GRID2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bimatoprost": {
    "gene": "PTGFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "itopride": {
    "gene": "FMO3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "olanzapine 10-n-glucuronide": {
    "gene": "FMO3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulindac": {
    "gene": "FMO3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "5'-deoxy-5-fluorouridine": {
    "gene": "ABCG5, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ivacaftor carboxylate": {
    "gene": "HTR2A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dutasteride": {
    "gene": "SRD5A2, HSD3B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nivasorexant": {
    "gene": "HCRTR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "brentuximab vedotin": {
    "gene": "ALK, TNFRSF8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ceritinib": {
    "gene": "ALK",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "brigatinib": {
    "gene": "ALK",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ensartinib": {
    "gene": "ALK",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dalcetrapib": {
    "gene": "ADCY9",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "albiglutide": {
    "gene": "ARRB1, GLP1R",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dulaglutide": {
    "gene": "ARRB1, GLP1R, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "8-oxo-dgtp": {
    "gene": "NUDT1, NUDT15",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tositumomab": {
    "gene": "MS4A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ibritumomab": {
    "gene": "MS4A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ofatumumab": {
    "gene": "MS4A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "obinutuzumab": {
    "gene": "MS4A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "exenatide": {
    "gene": "GLP1R, TCF7L2, SORCS1, KCNQ1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "saxagliptin": {
    "gene": "GLP1R, PRKD1, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "liraglutide": {
    "gene": "GLP1R, CNR1, TCF7L2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "gemigliptin": {
    "gene": "GLP1R",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "topotecan": {
    "gene": "DDO, ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pegaptanib": {
    "gene": "VEGFA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "erythropoietin": {
    "gene": "HFE, ORAI1, STIM1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "iron": {
    "gene": "HFE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nirogacestat": {
    "gene": "APC, CTNNB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "olaratumab": {
    "gene": "PDGFRA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "gemtuzumab ozogamicin": {
    "gene": "CD33, CYP2E1, SULT2B1, SLCO1B1, SLC22A12, ADH1A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "calcium channel blockers": {
    "gene": "CACNA1C, PICALM, NUMA1, TANC2, KCNH2, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nitrendipine": {
    "gene": "CACNA1C, AGTR1, KCNH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lacidipine": {
    "gene": "CACNA1C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "felodipine": {
    "gene": "CACNA1C, ABCG2, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "silodosin": {
    "gene": "UGT2B7, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mycophenolic acid acyl glucuronide": {
    "gene": "UGT2B7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "diclofenac acyl glucuronide": {
    "gene": "UGT2B7, CYP2C8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "letrozole carbinol": {
    "gene": "UGT2B7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "letrozole carbinol glucuronide": {
    "gene": "UGT2B7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lorazepam": {
    "gene": "UGT2B7, UGT2B15, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ecallantide": {
    "gene": "KLKB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "interferon alfa-n1": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "deleobuvir": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "faldaprevir": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ledipasvir": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "daclatasvir": {
    "gene": "IFNL4, VDR, CYP24A1, HINT1, NME1, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "asunaprevir": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ombitasvir / paritaprevir / ritonavir": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "velpatasvir": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ledipasvir / sofosbuvir": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "elbasvir / grazoprevir": {
    "gene": "IFNL4, SLCO1B1, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "voxilaprevir": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "direct acting antivirals": {
    "gene": "IFNL4, IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pirfenidone": {
    "gene": "TOLLIP, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "2-oxo-clopidogrel": {
    "gene": "CES1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sacubitril": {
    "gene": "CES1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "quinapril": {
    "gene": "CES1, AGT, AGTR1, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "difluorodeoxyuridine": {
    "gene": "CDA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lonafarnib": {
    "gene": "ZMPSTE24, FNTB, CYP3A4, LMNA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "emtricitabine": {
    "gene": "ABCC2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "10-monohydroxy oxcarbazepine": {
    "gene": "ABCC2, INSR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cholesterol": {
    "gene": "APOE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lecanemab": {
    "gene": "APOE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aducanumab": {
    "gene": "APOE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "donanemab": {
    "gene": "APOE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acitretin": {
    "gene": "APOE, APOC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dinutuximab": {
    "gene": "MYCN",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eflornithine": {
    "gene": "MYCN",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "memantine": {
    "gene": "NR1I2, BCHE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "etonogestrel": {
    "gene": "NR1I2, PGR, CYP3A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "etidronic acid": {
    "gene": "COL1A1, VDR, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "diflomotecan": {
    "gene": "ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lenvatinib": {
    "gene": "ABCG2, CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "n-desethyl sunitinib": {
    "gene": "ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "letermovir": {
    "gene": "ABCG2, UGT1A1, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ezetimibe / rosuvastatin": {
    "gene": "ABCG2, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "resmetirom": {
    "gene": "ABCG2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ramipril": {
    "gene": "ABCG2, ADRB2, UGT1A1, SLCO1B1, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "crizanlizumab-tmca": {
    "gene": "HBB, SELP",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "voxelotor": {
    "gene": "HBB",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "luspatercept": {
    "gene": "HBB",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "drugs used in alcohol dependence": {
    "gene": "GATA4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sacrosidase": {
    "gene": "SI",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methyldopa": {
    "gene": "MMP9, ARG2, ADIPOQ",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydralazine": {
    "gene": "MMP9, HLA-DRB1, NAT2, ADIPOQ",
    "advice": "Consider a starting total daily dose of hydralazine of at least 75 mg. for patients who are NAT2 rapid metabolizers and NAT2 intermediate metabolizers and titrate up to 300 mg as tolerated. For patients who are NAT2 poor metabolizers, initiate therapy at a total daily dose of hydralazine of 40 to 75 mg and carefully titrate upwards; use caution with total daily hydralazine doses of 200 mg or more.\n",
    "source": "CPIC"
  },
  "lisinopril": {
    "gene": "AGT, BDKRB2, MMP3, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "valsartan": {
    "gene": "AGT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "drugs used in diabetes": {
    "gene": "IRS1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfonamides, plain": {
    "gene": "SLC12A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mirvetuximab soravtansine": {
    "gene": "FOLR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antineoplastic and immunomodulating agents": {
    "gene": "ABCC5, SLC22A6, ABCC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "darunavir": {
    "gene": "SLCO3A1, CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thioxanthine": {
    "gene": "XDH",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "triglycerides": {
    "gene": "CYP19A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hydrocortisone": {
    "gene": "ATF5, MIR3117, MIR4268",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nitric oxide": {
    "gene": "NAMPT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pyridoxal phosphate": {
    "gene": "CYP2E1, NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetaminophen sulfate": {
    "gene": "CYP2E1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "theophylline": {
    "gene": "CYP2E1, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clodronate": {
    "gene": "VDR, IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "golimumab": {
    "gene": "VDR, TNF",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "calcitriol": {
    "gene": "VDR, CYP24A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fosamprenavir": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "telithromycin": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tipranavir": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cabozantinib": {
    "gene": "CYP3A4, RET",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lurbinectedin": {
    "gene": "CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ruxolitinib": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ivabradine": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "1-hydroxymidazolam": {
    "gene": "CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clozapine n-oxide": {
    "gene": "CYP3A4, CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-beta-hydroxycholesterol": {
    "gene": "CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "norfentanyl": {
    "gene": "CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "umifenovir": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acalabrutinib": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "perampanel": {
    "gene": "CYP3A4, CYP3A5, ZSCAN25",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ripretinib": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "blonanserin": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "omaveloxolone": {
    "gene": "CYP3A4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "alprazolam": {
    "gene": "CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clindamycin": {
    "gene": "CYP3A4, HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lidocaine": {
    "gene": "CYP3A4, SCN5A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "triazolam": {
    "gene": "CYP3A4, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zileuton": {
    "gene": "ALOX5, PRORP",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cobimetinib": {
    "gene": "BRAF",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "binimetinib": {
    "gene": "BRAF, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nivolumab / relatlimab": {
    "gene": "BRAF, CD274, LAG3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tovorafenib": {
    "gene": "BRAF",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "multivitamins, plain": {
    "gene": "DHFR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "metyrosine": {
    "gene": "TH",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rubella vaccines": {
    "gene": "HLA-B, HLA-C",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfonamides and trimethoprim": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carbimazole": {
    "gene": "HLA-B, HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "penicillin v": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "trichloroethylene": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lamivudine / abacavir": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "zidovudine / lamivudine / abacavir": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dolutegravir / abacavir / lamivudine": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cabotegravir / rilpivirine": {
    "gene": "HLA-B, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetazolamide": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ceftazidime": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "minocycline": {
    "gene": "HLA-B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "penicillin g": {
    "gene": "HLA-B, HLA-DPB1, IFNG",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pertussis vaccines": {
    "gene": "TLR4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "angiotensin ii": {
    "gene": "AGTR1, ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "drugs for obstructive airway diseases": {
    "gene": "ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "indacaterol": {
    "gene": "ADRB2, UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ephedrine": {
    "gene": "ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "orciprenaline": {
    "gene": "ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "salmeterol": {
    "gene": "ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "terbutaline": {
    "gene": "ADRB2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "aminohippurate": {
    "gene": "SLC22A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cidofovir": {
    "gene": "SLC22A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thyrotropin alfa": {
    "gene": "FSHR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "menotropins": {
    "gene": "FSHR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "follitropin beta": {
    "gene": "FSHR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "chorionic gonadotropin": {
    "gene": "FSHR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "urofollitropin": {
    "gene": "FSHR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-ene valproic acid": {
    "gene": "CPT1A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "2-aminoheptanoate": {
    "gene": "ACAD11",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "2-hydroxylaurate": {
    "gene": "ACAD11",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "2-aminooctanoic acid": {
    "gene": "ACAD11",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bicalutamide": {
    "gene": "HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "abatacept": {
    "gene": "HLA-DRB1, FCGR2A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "rilonacept": {
    "gene": "HLA-DRB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nutlin-3": {
    "gene": "MDM2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "secukinumab": {
    "gene": "ERAP2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lomustine": {
    "gene": "METTL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cerivastatin": {
    "gene": "RYR2, CYP2C8, HMGCR, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tislelizumab": {
    "gene": "CD274",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cosibelimab": {
    "gene": "CD274",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cisapride": {
    "gene": "KCNH2, SCN5A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mivacurium": {
    "gene": "BCHE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sipoglitazar": {
    "gene": "UGT2B15",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dabigatran glucuronide": {
    "gene": "UGT2B15",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "revumenib": {
    "gene": "KMT2A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "arsenic compounds": {
    "gene": "AS3MT, CBS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nicardipine": {
    "gene": "CACNA1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "avacopan": {
    "gene": "C5AR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "coumarin": {
    "gene": "CYP2A13, CYP2A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ursodeoxycholic acid": {
    "gene": "MGAT5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "estradiol / progesterone": {
    "gene": "PROC, PROS1, SERPINC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "synthetic conjugated estrogens, a": {
    "gene": "PROC, PROS1, SERPINC1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "velaglucerase alfa": {
    "gene": "GBA1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "inotersen": {
    "gene": "TTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "patisiran": {
    "gene": "TTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tafamidis": {
    "gene": "TTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vutrisiran": {
    "gene": "TTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "eplontersen": {
    "gene": "TTR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "maraviroc": {
    "gene": "CCR5, CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ibandronate": {
    "gene": "SIRT1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "carbocisteine": {
    "gene": "PAH",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "l-phenylalanine": {
    "gene": "PAH",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ibutilide": {
    "gene": "C18orf21",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-hydroxyestradiol": {
    "gene": "CYP1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nusinersen": {
    "gene": "SMN2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "risdiplam": {
    "gene": "SMN2, SMN1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mizolastine": {
    "gene": "FCER1A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cerliponase alfa": {
    "gene": "TPP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "omalizumab": {
    "gene": "IL10, IL17A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "parathyroid hormones and analogues": {
    "gene": "CASR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cinacalcet": {
    "gene": "CASR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "denileukin diftitox": {
    "gene": "IL2RA",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pregnenolone": {
    "gene": "SULT2B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hmg coa reductase inhibitors, other combinations": {
    "gene": "EYS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "raltitrexed": {
    "gene": "UGT1A1, TYMS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tranilast": {
    "gene": "UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "belinostat": {
    "gene": "UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "atazanavir / ritonavir": {
    "gene": "UGT1A1, CYP3A5, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "raloxifene-4′-glucuronide": {
    "gene": "UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "raloxifene 6-glucuronide": {
    "gene": "UGT1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "2-hydroxyatorvastatin lactone": {
    "gene": "UGT1A1, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-hydroxyatorvastatin lactone": {
    "gene": "UGT1A1, SLCO2B1, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vardenafil": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "simvastatin acid": {
    "gene": "CYP3A5, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-hydroxycyclophosphamide": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "6beta-hydroxycortisol": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "fluticasone": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "3,4-dehydrocilostazol": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "naldemedine": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "beclomethasone dipropionate": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "isavuconazole": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amprenavir": {
    "gene": "CYP3A5, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "beclomethasone": {
    "gene": "CYP3A5, CRHR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "itraconazole": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mometasone": {
    "gene": "CYP3A5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "saquinavir": {
    "gene": "CYP3A5, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "calcidiol": {
    "gene": "CYP2R1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "anifrolumab": {
    "gene": "IFNAR1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tiludronate": {
    "gene": "IL1B",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "estrone sulfate": {
    "gene": "SLCO2B1, SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "grazoprevir": {
    "gene": "SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "elagolix": {
    "gene": "SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ezetimibe / simvastatin": {
    "gene": "SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pitavastatin lactone": {
    "gene": "SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "estrone": {
    "gene": "SLCO1B1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfapyridine": {
    "gene": "NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "daniquidone": {
    "gene": "NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetylisoniazid": {
    "gene": "NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "solithromycin": {
    "gene": "NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amifampridine phosphate": {
    "gene": "NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "amifampridine": {
    "gene": "NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "clonazepam": {
    "gene": "NAT2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "deferiprone": {
    "gene": "UGT1A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "3-hydroxycotinine glucuronide": {
    "gene": "CYP2A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "methoxsalen": {
    "gene": "CYP2A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "metronidazole": {
    "gene": "CYP2A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pilocarpine": {
    "gene": "CYP2A6",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "elosulfase alfa": {
    "gene": "GALNS",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mavorixafor": {
    "gene": "CXCR4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "procarbazine": {
    "gene": "EPM2AIP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "larotrectinib": {
    "gene": "NTRK2, NTRK1, NTRK3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "selpercatinib": {
    "gene": "RET",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pralsetinib": {
    "gene": "RET",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "mitapivat": {
    "gene": "PKLR",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "infigratinib": {
    "gene": "FGFR2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "futibatinib": {
    "gene": "FGFR2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pramipexole": {
    "gene": "DRD3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lumasiran": {
    "gene": "AGXT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nedosiran": {
    "gene": "AGXT",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "lasmiditan": {
    "gene": "HTR1F",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "estradiol": {
    "gene": "TCL1A, NFE2L2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "enzymes": {
    "gene": "A2M, F12",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "5,6-dihydrothymine": {
    "gene": "UPB1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bradykinin": {
    "gene": "ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "salvianolic acid b": {
    "gene": "ACE, NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "acetylcholine": {
    "gene": "ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nitroprusside": {
    "gene": "ACE",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dasabuvir / ombitasvir / paritaprevir / ritonavir": {
    "gene": "IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dasabuvir": {
    "gene": "IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sofosbuvir / velpatasvir": {
    "gene": "IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sofosbuvir / velpatasvir / voxilaprevir": {
    "gene": "IFNL3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "enfortumab vedotin": {
    "gene": "NECTIN4",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "daunorubicinol": {
    "gene": "AKR1A1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ropeginterferon alfa-2b": {
    "gene": "JAK2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desmethyl olanzapine": {
    "gene": "CYP1A2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "olezarsen": {
    "gene": "LPL",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "desmopressin": {
    "gene": "F8",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "enasidenib": {
    "gene": "IDH2",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "pilsicainide": {
    "gene": "SCN5A",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "tofersen": {
    "gene": "SOD1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "cortisone acetate": {
    "gene": "CYP3A7",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dimethyl fumarate": {
    "gene": "GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "levamisole": {
    "gene": "GSTP1",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ganaxolone": {
    "gene": "CDKL5",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antihypertensives and diuretics in combination": {
    "gene": "NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "l-arginine": {
    "gene": "NOS3",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "ace inhibitors": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "plain": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antivirals for treatment of hiv infections": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "combinations": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "sulfonamides": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "urea derivatives": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "interferon alfa-2a": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "recombinant": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "antiinflammatory agents": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "non-steroids": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "vitamin b-complex": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "thiazides": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "interferon alfa-2b": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "adrenergics": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "inhalants": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "nucleoside and nucleotide reverse transcriptase inhibitors": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "4-methylenedioxymethamphetamine": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "loxoprofen": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "salicylamide": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "hmg coa reductase inhibitors": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "other combinations": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "incl. combinations": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "selective": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "bempedoic acid / ezetimibe": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "evolocumab": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "teclistamab": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "estradiol valerate": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "dostarlimab": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "duvelisib": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  },
  "elranatamab": {
    "gene": "See CPIC",
    "advice": "Follow standard protocol.",
    "source": "General"
  }
}